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Polychlorinated biphenyls (PCBs) are persistent organic pollutants 
associated with non-alcoholic fatty liver disease (NAFLD) and diabetes. 
Based on their ability to activate the aryl hydrocarbon receptor (AhR), PCBs 
are subdivided into two classes: dioxin-like (DL) and non- dioxin-like (NDL) 
PCBs. This study not only evaluated the chronic effect of DL PCBs (PCB126), 
NDL PCBs (Aroclor1260 mainly contains NDL), and the DL/NDL PCB mixture 
(PCB126/Aroclor1260 mixture) on liver, but also explored the acute hepatic 
effects of DL PCB and potential mechanisms in NAFLD and the role of AhR in 
regulating hepatic proteome and lipid metabolism, and whether the process 
independent of PCB exposure. Additionally, the acute effects of different 
doses of Aroclor1260/PCB126 on pancreatic proteome in female mice model 
were evaluated. HFD fed male C57BL/6J mice were treated with same 
exposures above for 12 weeks; and chow diet fed male C57BL/6J and AhR-/- 
mice were exposed to PCB 126 (20 µg/kg) for 2 weeks. Besides, chow 
vi 
 
diet fed female C57BL/6J mice were treatd with low dose and high dose Aroclor 
1260/PCB 126 mixture for 2 weeks. Chronic exposure experiments revealed 
Aroclor1260 increased hepatic inflammation and promoted phosphoprotein 
signaling disruption; PCB126 altered cytoskeletal remodeling, metal 
homeostasis, and disruption of intermediary/xenobiotic metabolism. 
Aroclor1260+PCB126 exposure enriched multiple epigenetic processes. AhR-/- 
mice fed control diet had histological steatosis with higher levels of hepatic free 
fatty acids and triglycerides. AhR ablation upregulated lipogenic genes (Cd36, 
Perilipin-2) and downregulated lipolytic genes (Pnpla3). Pancreatic proteome in 
acute female mice showed transcription factors related to pancreas function were 
overconnected with low dose and high dose Aroclor 1260/PCB 126, including 
NEUROD5, HNF1-beta, HNF4-alpha, E2F1, FOXP3, HNF1-alpha. Processes 
associated with the insulin signal pathway were enriched by low dose or high 
dose Aroclor 1260/PCB126, including ‘insulin-like growth factor receptor 
signaling pathway’, ‘receptor tyrosine kinase signaling pathway’, ‘signal 
transduction_insulin signaling. In summary, PCB exposures differentially 
regulated the hepatic proteome and the histologic severity of diet induced 
NAFLD. AhR plays a pivotal role in maintenance of lipid metabolism and energy 
homeostasis and suggested AhR regulated the hepatic proteome and lipid 
metabolism independent of PCB exposure. Aroclor1260+PCB126 exposure was 
overconnected transcription factors related to pancreas function and enriched 
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Polychlorinated biphenyls (PCBs) 
Polychlorinated biphenyls (PCBs) are a group of persistent environmental 
toxicants that are detected in the serum of 100% American adults (1). PCB 
exposures are associated with fatty liver disease, diabetes, obesity and 
hypertension (1-6). PCBs are thermodynamically stable polyhalogenated 
aromatic hydrocarbons consisting of up to ten chlorine atoms attached to the 
biphenyl rings. The number of chlorine atoms and their location in the PCB 
molecule are associated with its physical and chemical properties (Fig, 1.1). 
PCBs were manufactured from 1929 until these chemicals were banned by 
the United States Congress in 1979 under the Toxic Substances Control Act 
(7) and globally by the Stockholm Convention in 2001 (8) due to a variety of 
toxicities such as causing fatty liver disease, diabetes, obesity, etc. (1-6).  
PCB congeners have been categorized into two major classes: coplanar and 
noncoplanar PCBs.  
Coplanar PCB congeners have none or only one chlorine atom attached 
to the ortho-position of biphenyl rings, called non-ortho and mono-ortho 
PCBs, respectively. There are 12 coplanar PCBs: PCB 77, PCB 81, PCB 126, 




PCB157, PCB118, PCB167, PCB123 and PCB189 are mono-ortho PCBs. 
Coplanar PCBs have dioxin-like toxicity, and they can activate the aryl 
hydrocarbon receptor (AhR), so they are also called dioxin-like (DL) PCBs. 
Non-coplanar PCB congeners have two or more chlorine atoms at the ortho-
position of biphenyl rings, and do not have dioxin-like properties, thus, these 
are known as non-dioxin-like (NDL) PCBs. 
Aroclor 1260 is a commercial mixture of PCBs containing an average of 
chlorine content of 60% -- it was manufactured by Monsanto, a well-known 
PCB manufacturer in Anniston, Alabama in North America. It consists of 
mainly pentachlorobiphenyls (43.35%) and hexa-chlorobiphenyls (38.54%) 
and also includes mono-, bi-, tri, tetra-, hexa-, octa- and nona-chlorinated 
homologs. Minimally chlorinated PCB congeners are easily metabolized and 
eliminated, and only PCB congeners with high-level chlorination are resistant 
to metabolism and have bioaccumulated in humans. The PCB profiles in 
Aroclor 1260 best mimic the PCBs present in human adipose tissue(2) (Fig. 
1.2). However, Aroclor1260 contains lower amounts of DL-PCBs, which 
cannot activate murine and human AhR; PCB126 (20µg/kg) was added in my 
project to make the PCB mixture (Aroclor1260/PCB126) more 
environmentally relevant, making a significant contribution by effect, while a 
small contribution by mass. 
PCBs interact with some xenobiotic receptors associated with non-
alcoholic fatty liver disease (NAFLD). The receptors include AhR, constitutive 




proliferator-activated receptors (PPARs), and liver-X-receptor(9, 10). AhR is a 
transcription factor that regulates gene expression of phase I and phase II 
xenobiotic metabolizing enzyme genes (such as the CYP1A1 gene). AhR is 
normally inactive and bound to several co-chaperones and can be activated 
by several exogenous ligands such as natural plant flavonoids, polyphenolics 
and indoles, but the majority of the identified high-affinity ligands are synthetic 
chemicals, including synthetic polycyclic aromatic hydrocarbons and dioxin-
like compounds. Upon binding to ligands such as 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD) or DL-PCBs (PCB126, etc.), chaperones dissociate from the 
cytosolic AhR complex leading to AhR translocating into the nucleus 
and  dimerizing with ARNT (AhR nuclear translocator), resulting in changes 
in gene transcription. AhR activation regulates the transcription of many 
genes, such as the cytochrome P4501A (CYP1A) family. 
CAR is a member of the nuclear receptor superfamily and in human is 
encoded by the NR1I3 gene (11). Along with pregnane X receptor (PXR), it 
functions as a sensor of xenobiotic substances, CAR regulates expression of 
genes associated with all three phases of hepatic metabolism and transport 
including phase I monooxygenation, phase II conjugation, and phase III 
transporters that include multidrug resistance-associated proteins and organic 
anion transporting polypeptides. CAR is expressed primarily in the liver and 
intestinal enterocytes. 
PXR, also known as the steroid and xenobiotic sensing nuclear receptor 




receptor that in humans is encoded by the NR1I2 gene (12, 13). PXR is 
activated by many endogenous and exogenous chemicals including steroids 
(progesterone, 17α-hydroxyprogesterone, 17α-hydroxypregnenolone, etc.), 
antimycotics, bile acids, and many herbal and other compound (e.g., 
meclizine, paclitaxel) (14). PXR can sense the presence of toxic foreign 
substances and upregulate the expression of proteins involved in the 
detoxification and clearance of these substances from the body. Activation of 
PXR induces expression of target genes of the Cyp3a family, including 
Cyp3a11 in mice and Cyp3a4 in human. On the other hand, CAR target 
genes of the Cyp2b10 family, such as Cyp2b10 in mice and Cyp2b6 in 
human, are induced upon activation. 
PCBs have been found in fatty tissues of animals and humans due to their 
hydrophobic nature and resistance towards metabolism. Several PCBs have 
been shown to have toxic effects like those caused by 2, 3, 7, 8-
tetrachlorodibenzo-p-dioxin (TCDD), the most potent congener to activate 
AhR. To estimate the toxicity of PCBs to human, the World Health 
Organization (WHO) has set up toxic equivalency factors (TEFs) for AhR 
ligands (15). TCDD is assigned a TEF of 1 as the prototypical ligand. The 
TEFs of other chemicals are calculated based on relative effect potency 
(REP) values compared to that of TCDD. PCB 126, having highest AhR 
binding affinity of DL-PCBs, has the TEF 0.1 and is the major contributor to 
the total TEQ from PCBs. 




1968) and in Taiwan (Yucheng, 1979) due to rice oil contamination. The 
Yusho study showed that the standardized mortality ratios (SMRs) for all 
types of cancer (SMR = 1.26; 95% CI: 1.03–1.53) and lung cancer 
(SMR = 1.56; 95% CI: 1.03–2.27) were significantly increased among males, 
but not among females. Several follow-up studies of the Yucheng events 
(PCB poisoning) demonstrated increased mortality from chronic liver disease 
and cirrhosis in men (3, 16), increased rates of DM in females (4) and 
neurocognitive deficits in elderly women patients (17).    
In The Anniston Community Health Survey (ACHS) and ACHS-II study 
supported by the Agency for Toxic Substances and Disease Registry 
(ATSDR), the association between PCB exposure and steatohepatitis was 
observed; a high prevalence of diabetes (27%) was also observed, which was 
almost 3-times higher than the US prevalence rate (9.3%), and higher blood 
pressure was observed in high-PCB exposure residents.  Another 
epidemiological study, National Health and Nutrition Examination Survey 
(NHANES) in the US demonstrated that in NHANES 2003-2004 adult 
participants, PCBs were associated with unexplained ALT elevation, a proxy 
marker of NAFLD (18). 
Non-alcoholic fatty liver disease  
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of excessive 
fat in liver cells that is not caused by alcohol.  NAFLD includes a spectrum of 
fatty liver diseases, from hepatic steatosis to hepatic steatohepatitis (NASH), 




than 5% – 10% of the liver’s weight is fat, it is called steatosis, which reflects 
abnormal processes of synthesis and elimination of triglyceride fat. When 
steatosis progresses to become associated with inflammation, it is known as 
steatohepatitis, characterized by liver injury, inflammation, oxidative stress 
and fibrosis, and elevation in appearance of hepatic enzymes in serum (e.g., 
ALT, AST) and is seen clinically. In the spectrum of NAFLD, steatosis and 
steatohepatitis can be reversible, but when it advances to cirrhosis, the 
progress cannot be reversed and is linked to elevated risk of HCC. 
Dramatic modifications in lifestyle in the past century have changed the 
disease profile in most areas of the world, owing to a growing incidence of 
noncommunicable disease especially NAFLD, diabetes, obesity, etc. The 
increased prevalence of NAFLD parallels the worldwide increase of obesity 
and type 2 diabetes and the estimated global prevalence of NAFLD is 
currently 24%(16). Different continents have different levels, and the highest 
rates are from South America (31%) and the Middle East (32%), followed by 
Asia (27%), the USA (24%) and Europe (23%), whereas is lowest in Africa 
(14%) (16). 70%-80% of obese and diabetic populations develop NAFLD, 5-
10 % of individuals with steatosis progress to NASH, and 30 % of NASH 
patients develop cirrhosis. Unfortunately, 1-2 % of patients will progress to 
HCC within 10 years after developing cirrhosis (19). 
NAFLD is also associated with increased morbidity and mortality of 
cardiovascular disease due to abnormal levels of blood lipids. 




with NAFLD. For patients with end stage liver disease, there is no better 
treatment for end stage liver disease like cirrhosis than liver transplantation. 
NAFLD has been a heavy burden on public health worldwide. In the USA, 
estimated annual direct medical costs for NAFLD are about $103 billion (20). 
The predicament clinicians are facing is that there are still no FDA approved 
drugs for NAFLD/NASH treatment, and lifestyle modification through body 
weight loss and physical exercise, is the only way to improve NAFLD/NASH 
(21). 
NAFLD is associated with the dysfunction of glucose and lipid metabolism 
in the liver and the loss of homeostasis of hepatic lipid metabolism plays an 
important role in its pathogenesis. The homeostasis of lipid metabolism 
includes lipid input and output in liver. On the input side, chylomicrons (CM) 
from dietary fat ingestion and free fatty acids derived mainly from lipolysis can 
be taken up by the liver via the blood stream. Lipids can be synthesized (de 
novo) from carbohydrates and other precursors. The key proteins involved in 
the absorption of fatty acid in liver include fatty acid transport proteins 
(FATPs), plasma membrane fatty acid binding protein (FABP) and fatty acid 
translocase (CD36/FAT), which are associated with hepatic steatosis (21-23). 
Three key enzymes (ATP-citrate lyase (Acly), acetyl-CoA carboxylase (ACC) 
and fatty acid synthase (Fasn) ) and some transcription factors like liver X 
receptor (LXR), sterol regulatory element-binding protein-1c (SREBP-1c), and 
carbohydrate response element binding protein (ChREBP) regulate the de 




into triglycerides and are stored in hepatocytes. On the output side, lipids can 
either be transferred into lipoprotein (e.g., very-low-density-lipoprotein 
(VLDL) ) and be secreted into the blood (26), or be utilized in mitochondria by 
β-oxidation to produce ATP (27). When the total lipid influx rate exceeds efflux 
rate, excessive lipid deposition arises, resulting in hepatic steatosis. Any 
factor that affect these steps of lipid metabolism may cause NAFLD. 
There are "two-hit" and“multiple parallel hits”hypotheses used to explain 
the pathogenesis of NAFLD/NASH. One scenario is that fat accumulation, as 
the first hit, increases susceptibility to a subsequent second hit, which is 
responsible for liver injury, inflammation and hepatic steatosis. Exposures to 
occupational and environmental chemicals are the second hit. The toxicant-
associated fatty liver disease (TAFLD) and/or toxicant-associated 
steatohepatitis (TASH) have been used to describe this condition (28). 
Because the similar histopathology exists between NAFLD/NASH and 
TAFLD/TASH, the distinction between these will not be considered here. In 
our previous acute PCB exposure study, different PCBs had different effects 
on liver and pancreas structure and function, which may be attributed to 
activation of different ‘cross-talking’ PCB receptors. PCB 126 phenotypically 
induced fatty liver disease and novel mechanisms for PCBs in fatty liver 
disease were identified, like the PNPLA3 gene: environment interaction in 
fatty liver disease (29). 




Diabetes has been a major and rising health concern in the US population 
and across the world. According to the National Diabetes Statistics Report 
(2020) of the Centers for Disease Control and Prevention (CDC), 34.2 million 
people or 10.5% of the US population have diabetes. In 2017, diabetes was 
the seventh leading cause of death in the United States and the total direct 
and indirect estimated costs of diagnosed diabetes in the United States in 
2017 was $327 billion (30).  
As EDCs/MDCs, PCBs increase susceptibility to diabetes. Multiple 
epidemiological studies and animal experiments have revealed associations 
between PCBs exposure and DM (31). The studies of Yucheng event showed 
higher prevalence rate of DM in high PCB exposed females and ACHS-I & II 
revealed almost 3-times higher morbidity of DM in PCB-exposed residents 
than the average prevalence in the states (4, 6). Our previous acute study 
showed the Aroclor 1260/PCB126 co-exposure caused pancreatic 
histopathology, including acinar cell atrophy, mild steatosis, and fibrosis 
without ductal changes or immune cell infiltration (29). Several novel 
mechanisms for PCBs in diabetes were identified, including hepatokines, 
PCB pancreatopathy and pancreatic islet identity factors in diabetes. 
Hepatokines, including FGF21, IGF1, and betatrophin, have been involved in 
the development of NAFLD, diabetes, and metabolic syndrome. FGF21 plays 
a critical role in regulating obesity, insulin resistance and NAFLD by 




to be both a target and effector organ for PCB-induced endocrine disruption 
(29).  
Proteomics analysis 
As a large-scale study analysis of proteins and proteomes, proteomics is 
able to identify numbers of produced or modified proteins and is widely used 
both in hepatology and environmental research. In proteomics, proteins 
generally are detected by using either antibodies (immunoassays) or mass 
spectrometry. The method of the latter needs to go through detection and 
separation steps using reverse-phase chromatography.  Tandem mass tags 
(TMT) labeling protocol is a cost-effective and robust method for it reduces 
the quantity of required reagent and obtains complete labelling, showing its 
excellent reproducibility. 
Overall goal and specific aims 
Previously, studies on the effects of PCBs have been focused mostly on 
single PCB congeners or NDL-PCBs, and the acute study of different PCB 
exposures (including DL/NDL PCB mixture) effects on liver and pancreas has 
been completed (29). The chronic effects that the mixture of DL/NDL PCBs 
have on liver and/or pancreas require elucidation.  The mechanisms that DL-
PCBs and the mixture of DL/NDL PCBs utilize to induce toxicity remain to be 
elucidated. AhR overactivation was thought to be associated with DL-PCB-
induced hepatotoxicity (32) and activation of AhR could induce hepatic 




was thought to be protective (34), but Ahr-/- mice (1-3 weeks) developed 
spontaneous extensive microvesicular lipidosis (35). Therefore, the complex 
role of the AhR in hepatic lipid metabolism warrants investigation. The overall 
goal of this dissertation is to evaluate the chronic effects of different PCBs 
exposure by phenotypes and untargeted proteomics and examine if AhR 
altered hepatic proteome and lipid metabolism depending on PCB exposure. 
The specific aims of the project are as follows: 
Aim 1: Investigate the chronic exposure effects and potential 
mechanisms of DL-PCBs and NDL-PCBs, or co-exposures to both in a 
diet-induced obesity mouse model. 
In recent years, review of the publications involved in PCB studies mostly 
focus on NDL-PCBs, but in real world, humans are exposed to DL-PCBs and    
NDL-PCBs simultaneously; another issue is whether the combination of DL- 
and NDL-PCB will cause a synergistic effect for different PCBs involves 
different mechanisms of action. The purpose of this chronic exposure study 
was to perform a phenotypic and proteomic analyses to evaluate the 
difference of chronic effects and potential mechanisms of different PCBs 
exposure in HFD obese mice. 
Aim 2: Evaluate the role of AhR plays in the regulating hepatic 
proteome and whether this process is independent of PCB exposure or 




From the results of our acute PCB exposure study, as a potent AhR 
agonist, DL-PCBs (e.g., PCB126) caused hepatic steatosis, while on the flip 
side, AhR activation also is involved in the processes of lipid metabolism and 
there appears to be an over-activation of AhR (33) inducing hepatic steatosis. 
The role that the AhR plays in regulating the hepatic proteome and lipid 
metabolism and whether these processes depend on PCB exposure needs to 
be further elucidated. The present study was performed with PCB126 and 
explored the acute effects in chow diet fed global Ahr-/- mice. Hepatic 
proteomics analysis was performed, and the results from proteomics were 
validated by phenotypic analysis and real-time PCR. Another purpose of the 
study was to explore whether the global AhR ablation will bring about 
beneficiary or deleterious effects on lipid accumulation. 
Aim 3: Investigate the acute exposure effects and potential 
mechanisms of different doses of DL+NDL PCBs on pancreatic 
proteome in a female mouse model. 
In our previous sex difference mice study (36), the co-exposure of 
Aroclor1260/PCB126 decreased INS1 gene expression in female mice, while 
increased pancreas weight/body weight ratio. Some epidemiological studies, 
like ACHS-I and II showed women with high PCB exposure had higher 
prevalence of diabetes than men (6). These results suggested that compared 
with individual PCB congeners, the Aroclor1260/PCB126 mixture were more 




model. In Aim 3, we used two different doses of Aroclor1260/PCB126 


















Figure 1.1. Chemical structure of PCBs.  
PCBs have the basic chemical formula (C12H10-nCln), where n means the 
number of chlorine atoms, and the number means the positions where a 
















Figure 1.2. Relative PCB Composition in human Adipose tissue and 
Aroclor 1260 
Pie charts depicting the relative abundance of PCB congeners in human 
adipose tissue and Aroclor 1260. Figure adapted from Wahlang, et al., Toxicol 













DIOXIN-LIKE AND NON-DIOXIN-LIKE PCBS DIFFERENTIALLY REGULATE 
THE HEPATIC PROTEOME AND MODIFY DIET-INDUCED NONALCOHOLIC 
FATTY LIVER DISEASE SEVERITY 
 
                                                         INTRODUCTION 
The pollutants, polychlorinated biphenyls (PCBs), are metabolism-disrupting 
chemicals associated with nonalcoholic fatty liver disease (NAFLD), obesity, 
dyslipidemia, diabetes, and cardiovascular disease (37-42). PCBs were 
produced during the 1930s–1970s for use in multiple industrial applications (43). 
Although intentional PCB production is banned, their high thermodynamic 
stability imparting resistance to metabolism and degradation make PCBs 
persistent organic pollutants. PCBs bioaccumulate in living organisms and 
exposures increase along trophic levels of the food chain. PCBs have been 
detected in the serum of 100% American adult participants in the National Health 
and Nutrition Examination Survey (NHANES) (38). The 209 possible PCB 
congeners have been generally categorized into two major classes: “coplanar” 
and “noncoplanar”. Coplanar PCBs (no or one chlorine atom in the ortho-position) 
including PCB126 potently activate the aryl hydrocarbon receptor (AhR), thereby 
eliciting a dioxin-like (DL) response similar to TCDD, and are known as “DL” 




the ortho-position, conferring a conformation that precludes AhR binding and 
activation. However, these so-called “non-DL” (NDL) PCBs activate other 
xenobiotic receptors, such as the constitutive androstane receptor (CAR) and 
elicit a phenobarbital-like response (44). Commercially, PCBs were sold as 
mixtures rather than individual congeners. Arclor1260 (60% chlorine by weight) 
was a first-generation PCB mixture manufactured in Anniston Alabama, by 
Monsanto. The Anniston Community Health Survey I reported a high prevalence 
of suspected NAFLD associated with PCB congener exposures in Anniston 
residents (6). The PCB congeners that constitute Aroclor1260 are ones that 
have higher molecular weights and are not easily metabolized; therefore, they 
tend to bioaccumulate in living organisms including humans. In fact, the PCB 
composition in Aroclor1260 more closely resembles human bioaccumulation 
patterns than any other single commercially produced Aroclor mixture (45). 
Because low-dose Aroclor1260 does not activate either the human or murine 
AhR, Aroclor1260 has previously been used to model NDL PCB exposures (2, 
45, 46).  
PCB exposures are associated with NAFLD in human cohort studies and 
either cause or exacerbate diet-induced NAFLD in animal studies (reviewed in 
(45)). NAFLD is a broad spectrum of progressive liver disorders ranging from 
fat accumulation (steatosis) to hepatic inflammation (steatohepatitis), fibrosis, 
cirrhosis, and hepatocellular carcinoma. NAFLD and its more severe form, 
nonalcoholic steatohepatitis (NASH), can be due to various etiological factors, 




chemical exposures. Our group coined the term “toxicant-associated 
steatohepatitis” (TASH) to reflect the steatohepatitis associated with industrial 
chemical exposures (47,48). However, recent studies have implicated known 
PCB receptors such as the AhR, CAR, pregnane-xenobiotic receptor (PXR), 
and epidermal growth factor receptor (EGFR) in PCB-induced TASH (49).  
In the liver, AhR activation by TCDD and PCB126 increased lipid 
accumulation and led to simple steatosis in short-term, rodent studies (50, 51). 
CAR, along with PXR, function as sensors of xenobiotic substances and are 
primarily involved in detoxification and foreign compound metabolism. 
However, previous studies from our group and others have shown that NDL 
PCB-mediated CAR and PXR activation also play a fundamental role in 
regulating hepatic energy metabolism and may contribute to TASH 
development (49). Like phenobarbital, some PCBs appear to indirectly activate 
CAR by diminishing EGFR phosphorylation, leading to reduced hepatic 
phosphoprotein signaling and metabolic disruption in TASH (51-53). 
Nonetheless, these studies only evaluated the effects of either DL or NDL 
PCBs in diet-induced obesity, although both classes of PCBs are concurrently 
present in the human exposome. We recently developed a new PCB exposure 
model, by spiking the potent AhR agonist, PCB126, into Aroclor1260 (51). This 
mixture produced different hepatic effects than either Aroclor1260 or PCB126 
alone in an acute exposure model (51). Therefore, the objective of the current 
study is to evaluate the modulation of diet-induced NAFLD by several different 




exposures include low-dose Aroclor1260 (representative NDL PCB mixture), 
PCB126 (prototypical DL PCB), and Aroclor1260 + PCB126 (NDL + DL PCB 
mixture). Untargeted liver proteomics was performed to elucidate potential 




MATERIALS AND METHODS 
Animal studies 
 The related animal protocol was ratified by the University of Louisville 
Institutional Animal Care and Use Committee. Adult male C57BL/6 mice (8 
weeks old) were purchased from Jackson Laboratory and distributed into four 
equal groups (n = 10). All mice were fed a high-fat diet (HFD, 15.2, 42.7, and 
42.0% of total calories from protein, carbohydrate, and fat, respectively, 
TekLad TD88137) throughout the study period. At 10 weeks of age, ten mice in 
each group were given either corn oil, Aroclor1260 (20 mg/kg), PCB126 (20 μ
g/kg), or a mixture of Aroclor1260 (20 mg/kg) plus 0.1% PCB126 (20 μg/kg) via 
a one-time gavage and followed for 12 weeks (Fig. 2.1). At week 8 post 
gavage, a glucose tolerance test (GTT) was performed as described previously 
(36). Dual energy X-ray absorptiometry (DEXA) scanning (Lunar PIXImus 
densitometer, WI) was performed to measure body fat composition before 
euthanasia. Whole blood for plasma, liver, and fat tissue samples was 
harvested after euthanasia. 
Definition of PCB doses utilized 
The doses of the different PCBs used in the present study were similar to 
those used in the acute study (29) and were designed to mimic doses relevant 
to human exposures. For example, Aroclor1260 at 20 mg/kg was designed to 
reflect serum PCB levels measured in the highest exposed quartile of the 




designed to mimic the percent of serum PCB126 measured in NHANES 2003–
2004, relative to other heavily bioaccumulated PCBs such as PCB153, the 
congener with the highest reported serum levels in NHANES 2003–2004 (54). 
Histological staining 
Liver and pancreas tissues were fixed in 10% neutral buffered formalin for 72 
h and embedded in paraffin for routine histological examination. Hematoxylin–
eosin (H&E) staining was performed to identify histopathological changes. 
Chloroacetate esterase (CAE) activity, macrophage accumulation, and fibrosis 
were evaluated by CAE, immunohistochemical staining, and picro sirius red 
staining, respectively, according to the manufacturer’s protocols. Micrographic 
images were obtained by a high-resolution Olympus digital scanner with an 
Olympus digital camera (BX41). 
Real-time PCR 
Mouse liver and pancreas tissues were homogenized and total RNA was 
extracted using RNA-STAT 60 reagent according to the manufacturer’s 
protocol. The purity and quantity of total RNA were measured with a Nanodrop 
spectrometer (ND-1000, Thermo Fisher Scientific, Wilmington, DE) using ND-
1000 V3.8.1 software and cDNA was reverse transcribed from 1 μg RNA using 
a one-step cDNA synthesis reagent (QScript cDNA Supermix, QuantaBio, 
Beverly, MA). RT-PCR was performed on the CFX384TM Real-Time System 
(Bio-Rad, Hercules, CA) using iTaq Universal Probe Supermix and Taqman 




AhR (Mm00478932_m1); CAR (Mm00731567_m1), and Cyp4a10 
(Mm02601690_gH); peroxisome proliferator-activated receptor alpha (Pparα) 
(Mm00440939_m1); Cd36 (Mm01135198_m1); fatty acid-binding protein 1 
(Fabp1) (Mm00444340_m1); fatty acid synthase (Fasn) (Mm00662319_m1); 
interleukin-6 (Il-6) (Mm00446190_m1); stearoyl coenzyme A desaturase1 
(Scd1) (Mm00772290_m1); Pnpla3 (Mm00504420_m1); Car (Nr1i3) 
(Mm01283978_m1); Pxr (Nr1i2) (Mm01344139_m1); cytochrome P450s, 
including Cyp1a2 (Mm00487224_m1), Cyp2b10 (Mm01972453_s1), Cyp3a11 
(Mm007731567-m1), and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (Mm99999915_g1). All reactions were run in triplicate. The relative 
mRNA expression was calculated using the comparative 2−▵▵Ct method and 
normalized against GAPDH mRNA (55). 
Measurement of hepatic lipids, plasma lipids, and cytokines 
Hepatic lipids were extracted by a mixture of chloroform and methanol (2:1) 
according to a published protocol (56). Triglycerides and free fatty acid 
contents were measured using commercial kits with final values normalized to 
liver wet weight. Plasma alanine transaminase (ALT), aspartate transaminase 
(AST), triglyceride, cholesterol, and lipoproteins were quantified with lipid panel 
plus kits on a Piccolo Xpress Chemistry Analyzer (Abbott Laboratories, IL). 
Plasma cytokine and adipokine levels were acquired using a customized 
Milliplex® MAP mouse adipokine panel on a Luminex® 100 system (Luminex 





Proteins were extracted from liver tissue in RIPA buffer supplemented with 
protease and phosphatase inhibitors using a bead homogenizer and protein 
amounts were quantitated by BCA assay. Protein lysates (200 μg) were 
trypsinized using the modified filter-aided sample preparation method (57) 
and enriched for phosphopeptides by the TiO2–SIMAC–HILIC method (58). 
Briefly, protein samples were reduced with dithiothreitol, denatured with 8M 
urea, and alkylated with iodoacetamide followed by centrifugation through a 
high molecular weight cutoff centrifugal filter (Millipore, 10k MWCO). After 
overnight digestion with sequencing grade trypsin (Promega), the digested 
proteins were collected and cleaned with a C18 Proto™ 300 Å Ultra 
MicroSpin column. Protein digested samples (50µg) were labeled with 
tandem mass tag (TMT) TMT10plex™ Isobaric Label Reagent Set (Thermo 
Fisher, Waltham, MA); samples were then concentrated and desalted with 
Oasis HLB Extraction cartridges (Waters Corporation, Milford, MA) using a 
modified protocol for extraction of the digested peptides (59). Samples were 
then subjected to high pH reversed phase separation with fraction 
concatenation on a Beckman System Gold LC system supplemented with 126 
solvent module and 166 detector in tandem with a Bio-Rad Model 2110 
Fraction Collector (60). Liquid chromatography/mass spectrometry was used 
to measure TMT-labeled peptides. Briefly, every high pH reversed phase 
fraction was dissolved in 50μL solution of the combination of 2% v/v 




EASYnLC 1000 UHPLC system (Thermo Fisher) and an Orbitrap Elite—ETD 
mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Proteome 
Discoverer v2.2.0.388 was used to analyze the raw data collected from the 
mass spectrometer. Hepatic proteins that had significance abundance were 
imported into MetaCore software (Clarivate Analytics, Philadelphia, PA) for 
the following analyses: gene ontology (GO), enrichment by protein function 
(EPF), and interaction by protein function (IPF). 
Statistical analysis and data sharing 
Statistical significance was determined by two-way analysis of variance 
using GraphPad Prism version 7.02 for Windows (GraphPad Software Inc., La 
Jolla, CA, USA). p <0.05 was considered statistically significant. Statistical 
analysis for the proteome data was analyzed using the R package as 
described previously (61, 62). Given the exploratory nature of the study, 
significantly altered proteins were further filtered using an FDR threshold of 
0.2 and proteins exhibiting a fold change of −0.5 <log2FC < 0.5 were rejected 
to rule out false positives. Proteomics data files were deposited in the 
MassIVE (http://massive.ucsd.edu/) data repository, Center for Computational 
Mass Spectrometry at the University of California, San Diego, and shared on 

















Figure 2.1. Experimental design of chronic PCB exposure study.  
Mice were divided into 4 study groups based on the type of exposure. All 
animals were fed a high fat diet and received a one-time gavage of their 
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Effects of PCB exposures on body composition, glucose tolerance, and 
adipokines 
Body weight was measured weekly throughout the 12-week study. There 
was a gradual increase in body weight in all the four groups from week 0 to 
week 12 (Fig. 2.2A). However, there were no significant differences in the 
amount of body weight gain between the groups (Fig. 2.2B). Body fat 
composition was measured using both DEXA scan and by weighing the 
harvested epididymal fat (white adipose tissue) content. Although there was no 
significant difference in overall percent fat composition (Fig. 2.2E), Aroclor1260 
exposure, however, increased white adipose tissue to body weight ratio (Fig. 
2.2C). In addition, neither Aroclor1260 nor PCB126 affected liver weight to 
body weight ratio (Fig. 2.2D) and pancreas weight to body weight ratio in these 
mice (Fig. 2.2F). A GTT was performed to examine PCB effects on glucose 
metabolism; there were no differences between groups for alteration in glucose 
uptake (Fig. 2.2G). PCB effects on plasma lipids and adipocytokines were 
evaluated. The Aroclor1260+PCB126 group significantly decreased plasma 
cholesterol levels via its interacting Aroclor1260 and PCB126 components. 
PCB126 exposure decreased triglycerides levels in the Aroclor1260+ PCB126 
group (Table 1). There was no PCB effect on adipokines including adiponectin, 
leptin, and resistin (Table 1). 
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Figure 2.2. Effects of PCB exposures on body composition and glucose 
metabolism.  
(A) Body weight (BW) was measured weekly throughout the 12-week study 
and (B) % change in body weight relative to the initial body weight taken at 
the beginning of the study was calculated. (E) Percent fat composition was 
measured using a dual energy X-ray absorptiometry (DEXA) scan. White 
adipose tissue (WAT) weight, liver weight (LW) and Pancreas weight (PW) 
were measured and the (C) WAT/BW, (D) LW/BW and (F) PW/BW ratios were 
calculated. (G) A glucose tolerance test was performed and blood glucose 
levels were obtained at baseline and at 15, 30, 60, and 120 minutes.  There 
were no significant differences in (H) AUC (Area under curve) between four 
groups. Values are mean ± SEM; n=10, p <0.05, a = Aroclor1260 effect, b = 







Table 1. Plasma lipids and adipo-cytokines. 
Plasma levels of lipids and adipo-cytokines were measured using either 
Piccolo Chemistry Analyzer or Luminex Milliplex system. Values are mean ± 
SD; n=10, p <0.05, a= Aroclor1260 effect, b=PCB126 effect, c=interaction 
between Aroclor1260 and PCB126. PAI-1: plasminogen activator inhibitor 1. 
Analyte Control Ar1260 PCB126 Ar1260+PCB126 
Triglyceride (mg/dl) 75.2 ± 20.8     78.5 ± 17.2        68.7 ± 14.4     52.1 ± 12b 
Cholesterol (mg/dl) 124.7 ± 26.2     146.2 ± 30        136.5 ± 18.7     118.6 ± 27.4c 
PAI-1 (pg/ml) 873.2 ± 262.6    890.2 ± 354.9      675.2 ± 330.1    577.5 ± 205.6 
Adiponectin (pg/ml)    81982 ± 4811    84484 ± 3753     86390 ± 3874     83272 ± 6660 
Leptin (pg/ml)         6476 ± 2266     8221 ± 1631       6912 ± 3017      8227 ± 4834 











Hepatic steatosis was using H&E staining of liver sections. All HFD-fed mice 
developed variable, centrilobular, macrovesicular steatosis and the different 
PCB exposures did not exacerbate HFD-induced steatosis (Fig. 2.3A). Hepatic 
lipids were measured and PCB exposures had no effect on either hepatic 
triglyceride or cholesterol levels (Fig. 2.3H&I). However, hepatic free fatty acid 
levels were significantly increased by the Aroclor1260 + PCB126 mixture (Fig. 
2.3B). Histological analyses for liver inflammation were assessed using CAE 
and F4/80 staining. CAE staining demonstrated that HFD feeding induced 
neutrophil infiltration in the liver (Fig. 2.3C); however, Aroclor1260 exposure 
exacerbated this effect as shown by the number of inflammatory foci counted 
per field (Fig. 2.3D). Interestingly, the Aroclor1260 + PCB126 group showed a 
lesser number of inflammatory foci counted per field. Likewise, F4/80 staining 
demonstrated that the Aroclor1260 group had increased macrophage 
infiltration compared with any other group (Fig. 2.3E). This observation was 
consistent with hepatic Cd68 gene expression where in Aroclor1260 increased 
Cd68 mRNA levels, indicating a hepatic inflammatory state, while this effect 
was absent with PCB126 exposure (Fig. 2.3F). Commonly used biomarkers of 
liver injury, namely plasma ALT and AST levels, were measured. Elevated 
plasma ALT activity levels were only seen with Aroclor1260 exposure, but not 
with PCB126 (Fig. 2.3G) while PCB126 showed a trend for decreased plasma 
AST activity levels (Fig. 2.3J). In addition, the Aroclor1260 + PCB126 group 
showed attenuation of Aroclor1260-elevated plasma ALT levels, suggesting 




assessed by picro sirius red staining of liver sections to detect collagen 
deposition (Fig. 2.4). While there were no histological differences between 
groups, PCB126 decreased the hepatic gene expression of collagen (Col1a2) 
and actin 2 (Acta2), implicating a suppression of profibrotic gene expression in 
the liver (Fig. 2.4). 
Effects of PCB exposures on the expression of AhR, CAR and their target 
genes 
Known PCB receptor activation such as AhR and CAR activation was 
examined. PCB126 exposure caused upregulation of cytochrome P450 1a2 
(Cyp1a2), an AhR target gene, indicative of AhR activation. In contrast, the 
Aroclor1260 + PCB126 group showed decreased Cyp1a2 mRNA levels (Fig. 
2.5A). With regards to AhR gene expression, PCB126 alone showed a trend 
for decreased AhR mRNA levels (Fig. 2.5B). For CAR activation, the CAR 
target gene, Cyp2b10, was measured. The Aroclor1260 group showed 
upregulated Cyp2b10 mRNA levels, indicative of CAR activation (Fig. 2.5C), 
while CAR expression was increased in the Aroclor1260 + PCB126 groups 
(Fig. 2.5D). 
Effects of PCB exposures on the hepatic proteome 
The various PCB exposures produced distinct hepatic proteomes (Fig. 2.6). A 
total of 8355 unique proteins and their isoforms were detected, corresponding 
to 4609 protein groups. Liver protein content was regulated as follows: 
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Figure 2.3. Effects of PCB exposures on steatosis and inflammation.  
(A) Liver sections were analyzed for steatosis using H&E staining. (B) Hepatic 
free fatty acid levels, (H) triglycerides and (I) cholesterol were measured using 
colorimetric assays. (C) Liver sections were analyzed for neutrophil infiltration 
using CAE staining where red positive cells indicate neutrophil infiltration. (D) 
The number of CAE positive cells per microscopic field were counted. (E) Liver 
sections were analyzed for macrophage infiltration using F4/80 
immunohistochemistry staining and brown positive cells indicate macrophage 
accumulation. (F) Hepatic CD68 mRNA levels were measured using RT-PCR. 
(G) Plasma ALT and (J) plasma AST activity levels were measured using the 
Piccolo Xpress Chemistry Analyzer. Values are mean ± SD, n=10, p <0.05, a - 






Figure 2.4. Effects of PCB exposures on hepatic fibrosis.  
(A) Collagen deposition was analyzed by picro sirius red staining of liver 
sections. There were no differences between groups. Hepatic gene expression 
of fibrotic markers, namely (B) collagen 1a1 (Col1a1), (C) collagen 1a2 
(Col1a2), (D) actin 2 (Acta2), (E) TIMP metallopeptidase inhibitor 1 (Timp1), 
and (F) plasminogen activator inhibitor 1 (PAI-1, Serpine1) were measured 
using RT-PCR. Values are mean ± SD; n=10, p <0.05, b - PCB126 effect. 
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Figure 2.5 Effects of PCB exposures on target gene expression.  
Hepatic mRNA expression for the AhR target gene (A) Cyp1a2 and (B) AhR 
and the CAR target gene target gene Cyp2b10 (C) and (D) CAR (Nr1i3) were 
measured by RT-PCR. Values are mean ± SD; n=10, p <0.05, a - Aroclor1260 










































































































































































238 decreased); and Aroclor1260 + PCB126 (144 increased and 257 decreased) 
(Fig. 2.6 and Supplemental Table 1). The majority of differentially abundant 
proteins for each and Aroclor1260 + PCB126 (144 increased and 257 decreased) 
(Fig. 3.6 and Supplemental Table 1). The majority of differentially abundant 
proteins for each group were unique to that exposure (range 58.7–63.1%). Of 
the 401 proteins associated with Aroclor1260 + PCB126 exposure, only 5.9% 
were also associated with Aroclor1260, while only 33.6% were also associated 
with PCB126. Only three proteins were changed in all three PCB exposure 
groups (BET1-like protein and two isoforms of protein-O-linked-mannose-β-1,4-
N-acetylglucosaminyltransferase 2). Clearly, the proteomic changes associated 
with the Aroclor1260 + PCB126 mixture were not the sum of its parts.  
EPF analysis was performed to determine the protein classes most impacted 
by PCBs (Table 2). Enzymes were the most affected class (Aroclor1260, z-
score= 3.63; PCB126, z-score = 7.11; Aroclor1260 + PCB126, z-score = 4.89). 
Consistent with this observation and the RT-PCR data, the enzyme levels of 
CYP1A1 and CYP1A2 were higher for PCB126 (CYP1A1: 9.09-fold, p = 
7.10E−06 and CYP1A2: 5.85-fold, p = 3.10E−08) and, to a lesser degree, for 
Aroclor1260 + PCB126 (CYP1A2: 2.39-fold, p = 2.39E−08) (Supplemental 
Table 1). While Aroclor1260 increased hepatocyte injury (by histologic and 
plasma ALT enzyme activity biomarkers), plasma AST activity was not 
significantly increased. This could be related to the peculiar proteomic 
observation that hepatic AST enzyme levels were reduced by PCB exposures 




Again, consistent with the liver histology, inflammation-associated enzymes 
and leukocyte markers were increased with Aroclor1260 (e.g., 
macrosialin/CD68, 2.26-fold, p = 1.85E−04) and decreased with either PCB126 
(e.g., myeloperoxidase: 0.51-fold, p = 1.79E−03; α-defensin 20: 0.48-fold, p = 
2.90E−02; and the calprotectin component, protein S100-A8: 0.32-fold, p = 
8.05E−03) or Aroclor1260 + PCB126 (e.g., protein S100-A9: 0.62-fold, p = 
4.35E−02; neutrophil granule protein: 0.58-fold, p = 1.17E−02; protein jagunal 
homolog 1: 0.33-fold, p = 1.20E−02; and neutrophil gelatinase-associated 
lipocalin (0.30-fold, p = 2.41E−02) (Supplemental Table 1). EPF revealed that 
Aroclor1260 altered protein levels of slightly more transcription factors than 
expected (z-score =1.67), while the other exposures changed fewer than 
expected. Several nuclear receptors implicated in steatohepatitis were 
differentially regulated including peroxisome proliferator-activated receptor 
alpha (PPARα, Aroclor1260: 0.7-fold, p = 1.97E−03), liver X receptor alpha 
(PCB126: 1.47-fold, p = 1.81E−02), and V-erbArelated protein 2 (PCB126: 
0.69- fold, p = 1.14E−02 and Aroclor1260 + PCB126: 0.63-fold, p = 2.69E−03). 
Thus, while each PCB exposure was associated with a distinct proteome, EPF 
demonstrated that these proteomes were consistent with the observed 
phenotypes. 
Enrichment by GO processes (Fig. 2.7) revealed that the distinct proteomes 
associated with PCB126 and Aroclor1260 + PCB126 exposures were 
associated with similar top GO processes, although some differences were 




unique to that exposure. These findings are again consistent with the histology 
and phenotyping data. A very limited number of GO processes were enriched 
by Aroclor1260 including “negative regulation of receptor internalization”; 
“negative regulation of catabolic process”; aspartate catabolic metabolism; and 
polyadenylation-dependent RNA catabolic processes (Fig. 2.7). In contrast, 
hundreds of GO processes were significantly enriched by PCB126 and/or 
Aroclor1260 + PCB126 (data not shown). Both exposures enriched: (i) cellular, 
metabolic, and catabolic processes; (ii) protein metabolism processes; (iii) 
cellular localization and organization processes; and (iv) the PCB126 and/or 
Aroclor1260 + PCB126 (data not shown). Both exposures enriched: (i) cellular, 
metabolic, and catabolic processes; (ii) protein metabolism processes; (iii) 
cellular localization and organization processes; and (iv) the “negative 
regulation of neurotransmitter (acetylcholine) secretion”. These processes, 
however, were enriched to a greater degree by Aroclor1260 + PCB126. In 
contrast, while both exposures enriched xenobiotic metabolism processes and 
lipid metabolism processes, these were enriched to a greater degree by 
PCB126. 
GO processes related to cytoskeletal remodeling/fibrosis and metal 
homeostasis were enriched by PCB126 only (Fig. 2.7). The abundance of 
several cytoskeletal-associated proteins were markedly increased by PCB126 
including troponin C (120.33-fold, p = 1.30E−03); actin α, skeletal muscle 
(55.47- fold, p = 7.38E−03); myosin light chain 3 (33.67-fold, p = 1.27E−02); 




However, other cytoskeletal proteins, including type II keratins, were 
differentially regulated by Aroclor1260 (keratin 5: 0.28-fold, p = 2.12E−03) or 
Aroclor1260 + PCB126 (keratin 2: 0.30-fold, p = 3.85E−02; keratin 4: 0.62-fold, 
p = 4.19E−02; and keratin 6a: 1.89-fold, p = 1.34E−02). While the PCB 
exposures were not associated with fibrosis at the histologic level, PCB126 
exposures were associated with reduced expression of several profibrogenic 
genes at the molecular level. Consistent with this observation, PCB126 was 
associated with reduced abundance of several proteins associated with liver 
fibrosis including collagen α-1(IV) chain (0.68-fold, p = 2.26E−02); prolyl 4-
hydroxylase subunit alpha-1 (0.66-fold, p = 1.42E−03); and procollagen-lysine, 
2-oxoglutarate 5-dioxygenase 3 (0.47-fold, p = 2.28E−02). Multiple proteins 
associated with metal homeostasis were likewise reduced only by PCB126 
including ferritin light chain 1 (0.64-fold, p =1.44E−02), light chain 2 (0.63-fold, 
p = 1.24E−02), and heavy chain (0.60-fold, p = 6.11E−03), and zinc transporter 
4 (0.55-fold, p = 3.09E−02). 
Several GO processes related to the epigenetic mechanisms were enriched 
only by Aroclor1260 + PCB126 (Fig. 2.7). These included “regulation of gene 
expression, epigenetic”, “negative regulation of chromatin silencing”, and 
“histone H3-K27 methylation”. Differentially abundant proteins contributing to 
these observations included reduced histone deacetylase 2 (0.68-fold, p = 
1.13E−02); reduced histones H1.2 (0.63-fold, p = 5.98E−04), H1.4 (0.66-fold, p 
= 8.87E−03), H1.5 (0.67-fold, p = 2.45E−02), and H1t (0.67-fold, p = 




fold, p = 7.64E−04); and reduced exportin 5 (0.66-fold, p = 2.07E−02). 
However, several other epigenetics proteins were reduced by PCB126 and 
Aroclor1260 + PCB126, such as RNA binding protein 3 (PCB126: 0.68-fold, p = 
2.64E−03; Aroclor1260 + PCB126: 0.69-fold, p = 2.78E−03); LIM domain-
containing protein 1 (PCB126: 0.66-fold, p = 6.66E−03; Aroclor1260 + 
PCB126: 0.63-fold, p = 2.93E−03); and protein arginine methyltransferase 7 
(PCB126: 0.64-fold, p = 9.69E−04; Aroclor1260 + PCB126: 0.70-fold, p = 
4.74E−03). 
IPF analysis was performed and the top overconnected interactions by z-
score are provided in Fig. 2.8. Seven unique objects, all protein kinases, were 
over-connected with Aroclor1260 exposure. These kinases included the 
mammalian target of rapamycin (mTOR); the adenylate kinase isoenzyme, 
mitochondrial (AK3L1); the alternate mitogen-activated protein kinase, p38γ; 
and protein kinase C α (PKCα). PCB126 and/or Aroclor1260 + PCB126 
exposures were associated with 18 over-connected objects (Fig. 3.8). Eleven 
of these objects were transcription factors and eight of these were common 
between the two groups. Shared transcription factors included protein C-ets-1 
(ETS1), SRY-box transcription factor 17 (SOX17), and GA binding protein 
transcription factor subunit α (GABPα); glucocorticoid receptor; zinc finger 
protein x-linked (ZFX); neuroblastoma MYC oncogene (N-Myc); and acute 
myeloid leukemia 1 (AML1). The z-scores were all higher with the Aroclor1260 
+ PCB126 exposure. Unique transcription factors overconnected by PCB126 




cellular oncogene FOS (c-FOS) was uniquely over-connected by Aroclor1260 + 
PCB126. PCB126 exposure was uniquely over-connected with the bradykinin 
precursor, kininogen 1, and thrombin. Aroclor1260 + PCB126 was uniquely 
overconnected with two enzymes associated with steatohepatitis and liver 
cancer, protein arginine methyltransferase 1 (PRMT1), and hypoxia-associated 
factor (SART1) (63, 64). 
Effects of PCB exposures on hepatic intermediary metabolism and plasma 
profile 
Proteomics analysis revealed that PCBs played a role indictating intermediary 
metabolism such as lipid and protein processes. To further validate these 
findings, hepatic expression of genes involved in a variety of metabolic 
processes, including lipogenesis, lipid transport and mobilization, fatty acid β-
oxidation, and glucose and protein metabolism were measured. The expression 
of genes related to lipogenesis, namely, fatty acid synthase (Fasn), sterol 
regulatory element-binding protein 1 (Srebf1), stearoyl-CoA desaturase-1 
(Scd1), and peroxisome proliferator-activated receptor gamma (Pparg) were 
measured by RT-PCR. PCB exposure did not alter Fasn or Srebf1 mRNA levels 
although the PCB126 group demonstrated a trend for decreased Fasn and 
Srebf1 mRNA levels (Fig. 2.9H&I), consistent with previous findings (65, 66). 
Similarly, Aroclor1260 + PCB126 exposure decreased Scd1 mRNA levels (Fig. 
2.9A), consistent with protein abundance data (0.70-fold, p = 1.35E−02, Table 3) 
and a prior study (51). The same group also showed increased Pparg gene 




of Cd36 and fatty acid binding protein 1 (Fabp1) were determined. Both 
Aroclor1260 and PCB126 contributed to the upregulated Cd36 expression in the 
Aroclor1260 + PCB126 mixture (Fig. 2.9C). There was no significant difference 
for Fabp1 mRNA levels between groups (Fig. 2.9J). In terms of lipid breakdown, 
the mRNA levels of Pparα, a transcription factor that regulates fatty acid β-
oxidation, the Aroclor1260 + PCB126 group decreased Pparα levels (Fig. 2.9D). 
These results differed from the proteomics data that showed decreased protein 
abundance only for Aroclor1260. PCB126 exposure also decreased the 
expression of the lipolytic gene, patatin-like phospholipase domain-containing 
protein 3 (Pnpla3, Fig. 2.9E). In addition, the gene expression of 
phosphoenolpyruvate carboxykinase 1 (Pck1), a gluconeogenic gene, was 
measured and found to be decreased with PCB126 exposure (Fig. 2.9F). 
Proteomics data demonstrated that PCB126 disrupted the coordination of 
glycolysis and gluconeogenesis by simultaneously downregulating abundance 
of hexokinase-3 (0.52-fold, p = 2.53E−03), phosphofructokinase (0.61-fold, p = 
6.53E−03), and glucose-6-phosphatase (0.51-fold, p = 1.33E−02). The gene 
expression of albumin (Alb), a biomarker for protein metabolism, was increased 
in the Aroclor1260 + PCB126 group (Fig. 2.9G). Overall, these results confirm 
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Figure 2.6. Effects of PCB exposures on the hepatic proteome.  
Alterations in hepatic proteins are depicted by volcano plots showing 
significance (y-axis) versus protein fold change (x-axis) for (A) Aroclor1260, (B) 
PCB126 and (C) Aroclor1260+PCB126. Black denotes unaltered proteins, 
green denotes significantly altered proteins, red denotes significantly altered 
protein with (log2FC >1), blue denotes significantly altered protein with (log2FC 
<-1). (D) A multi-dimensional scatter (MDS) plot depicting the pattern for 
protein alterations in the different groups. ExpA - Aroclor1260, ExpB - PCB126, 
ExpC - Aroclor1260+PCB126. (E) The number of proteins and their isoforms 
that were altered for the different exposure groups. (F) Venn diagram showing 
the number of overlapping proteins between the three exposure groups.  
 


















Table 2. Enrichment by protein function analysis 
Enrichment by protein function analysis was performed by MetaCore 
software using the hepatic proteomics data. For a given protein class, a 
positive z-score indicates that more proteins in that class were altered than 
expected. Likewise, a negative z-score means that fewer proteins in the class 




Ar1260 PCB126 Ar1260+PCB 126 
Ligands  -0.687 -1.99 
Phosphatases  1.55 0.892 
Proteases -0.238 0.541 0.117 
Kinases 0.512 0.243 -0.535 
Transcription Factors 1.67 -1.36 -1.97 
Receptors  -0.767 -1.39 -0.940 
Enzymes 3.63 7.11 4.89 















Figure 2.7. Heatmap of PCB effects on gene ontology (GO) processes.  
Heatmap showing different processes that were altered by PCB exposures 
according to the -log(p-value). The processes were obtained by GO analysis 
enrichment of the different proteins altered by PCB exposures using MetaCore. 
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Figure 2.8. Effects of PCB exposures on protein function.  
Heatmap showing different classes of proteins, for the three exposure groups, 
obtained from the Interaction by Protein Function analysis using MetaCore 












































































































































































































































































































                  
Figure 2.9. Effects of PCB exposures on genes involved in hepatic energy 
metabolism.   
Hepatic mRNA levels of genes involved in hepatic energy metabolism 
inlcuding (A) Scd1, (B) Pparg, (C) Cd36, (D) Pparα, (E) Pnpla3, (F) Pck1, (G) 
Alb, (H) Fasn, (I) Srebf1, and (J) Fabp1 were measured by RT-PCR. Values are 
mean ± SD; n=10, p <0.05, a - Aroclor1260 effect, b - PCB126 effect, c - 
interaction between Aroclor1260 and PCB126. 













PCBs, including both DL and NDL congeners, are metabolism-disrupting 
chemicals (37). PCBs exposures are associated with obesity-related diseases 
including diabetes, dyslipidemia, cardiovascular disease, and NAFLD. PCB-
related NAFLD mechanisms was recently reviewed (49). In animal models fed a 
healthy diet, DL, but not NDL PCBs, caused hepatic steatosis and NAFLD. In 
contrast, NDL PCBs exposures compromised the liver, thereby increasing the 
histologic severity of HFD-induced NAFLD. The NDL PCB exposures variably 
increased diet-induced hepatic steatosis, inflammation, and fibrosis while 
interacting with PCB receptors including PXR, CAR, and the EGFR (2, 46, 48, 
51-53, 67). While humans have simultaneous exposures to both PCB classes, 
no previously published studies in the literature have systematically evaluated 
the disease modifying effects of DL PCBs, NDL PCBs, and the more 
environmentally relevant combination of DL + NDL PCBs in a chronic exposure 
model of HFD-induced NAFLD. Few to no published data exist on either DL or 
DL + NDL PCBs in such a model.  
Our recently published acute PCB exposure study demonstrated that 
Aroclor1260, PCB126, and Aroclor1260 + PCB126 exposures differentially 
affected histology and disease mechanisms in liver and related organs in male 
mice fed a healthy diet (29). Based on the direction of these results, 
environmental relevance, and knowledge gaps in the literature, the objective of 
the current study was to elucidate the effects and potential mechanisms of these 




The combination of the phenotyping, histologic, and molecular biomarkers 
demonstrated the following differential PCB effects on metabolic conditions 
related to HFD-induced obesity. Consistent with prior studies (65), Aroclor1260 
increased liver inflammation/ injury and the white adipose tissue to body weight 
ratio. PCB126 decreased liver inflammation and fibrosis at the molecular level. 
PCB126 alone did not increase hepatic free fatty acids and hepatic triglycerides, 
as reported previously (29). These differences are likely related to differences in 
duration of exposure or diet. Aroclor1260 + PCB126 modulated lipid metabolism 
such as hepatic free fatty acids were increased, while the plasma 
cholesterol/triglycerides were decreased, and it decreased liver inflammation. 
The lipid effects were mediated predominantly by the PCB126 component of this 
mixture as previously reported (29). Therefore, PCB126 and co-exposure 
attenuated Aroclor1260-induced hepatic inflammation despite worsening the 
disruption of intermediary and xenobiotic metabolism. None of the exposures 
affected glucose tolerance or adipokines. AhR activation was highest with 
PCB126 alone; increased to a lesser degree with Aroclor1260 + PCB126; and 
absent with Aroclor1260, consistent with Shi et al. (29). The effects on CAR were 
complex. Cyp2b10 gene expression was increased by Ar1260; IPF 
demonstrated enriched CAR interactions with PCB126; and Aroclor1260 + 
PCB126 induced Nr1i3 gene expression. PCBs induced Cyp2b10 gene 
expression to a lower degree in HFD-fed mice compared with mice fed a low fat 
diet (29). 




observed differences in metabolic phenotype and TASH severity, which were 
greatest for Aroclor1260 versus the more similar PCB126 and Aroclor1260 + 
PCB126 exposure groups. The large number of differentially abundant proteins 
between the PCB exposure groups was surprising. For example, 99.58% of 
these proteins were not conserved across all three treatment groups. PCB126 
and Aroclor1260 + PCB126 altered many more proteins than Aroclor1260. 
However, 79.06% of the proteins altered by either of the latter two treatments 
were not common to both groups. Despite these differences, PCB126 and 
Arclor1260 + PCB126 shared many top GO processes consistent with the 
observed similarities in liver histologic phenotype. The observed alterations in 
cholinergic neurotransmission associated with these exposures is novel and 
could be mechanistic. For example, human neonates exposed to PCBs display 
a number of hematologic and immunologic disturbances in neuronal signaling, 
immune regulation via the AhR and other receptors (68, 69). In addition, these 
exposures alter many normal medical biomarkers used in clinical medicine, such 
as cholesterol levels, AST enzyme levels, etc.  
While a number of new putative PCB targets and modes of action in TASH 
were identified, others were reassuringly consistent with known targets. 
Aroclor1260 exposure was associated with the “negative regulation of receptor 
internalization” GO process and overconnected interactions with protein kinases 
including mTOR, AK3L1, p38γ, and PKCα. These findings could be consistent 
with the decreased EGF-stimulated EGFR internalization with consequent 




associated TASH (36, 51-53, 67). These studies reported decreased protein 
kinase B (Akt)/mTOR and extracellular signal-regulated kinases (ERK) signaling. 
AK3L1 is a downstream EGFR target that regulates glycolysis, thereby adding a 
new link between signaling disruption and intermediary metabolism (70). 
Intriguingly, p38γ and PKCα regulate both EGF-dependent ERK signaling (71-
73) and NASH (74, 75). The potential mechanistic roles of these kinases warrant 
future investigation in Aroclor1260-associated TASH. 
The observed alterations in GO processes related to hepatic metal hemostasis 
and cytoskeleton for PCB126 could be mechanistic. PCB126-induced metal 
dysregulation has been described previously (76, 77). However, the specific 
effector proteins identified by the present study (e.g., hepcidin, ferritin, zinc 
transporter 4, etc.) and the hepcidin-regulating transcription factor, ZFPM1(78) , 
warrant future investigation. Several cytoskeleton proteins were the most 
upregulated proteins by PCB126. The other exposures were associated with 
altered abundance of keratins 2, 4, 5, or 6a. Cellular localization analysis of a 
previous hepatic proteomics experiment from our group demonstrated that 
cytoskeletal-associated proteins were the top enriched cellular location for liver 
proteins differentially regulated by Aroclor1260 in mice fed a control diet, but this 
decreased in HFD-fed mice (51). Circulating epithelial cell-derived keratin18 was 
associated with PCB-related TASH in ACHS (6). Ethanol-associated alterations 
of the hepatocyte cytoskeleton may influence the progression of alcohol-related 
steatohepatitis (79). Therefore, the potential mechanistic role of PCB-induced 




reduction in hepatic AST protein abundance is confirmed in humans, the utility 
of circulating AST enzyme activity as a biomarker for PCB-related liver toxicity in 
environmental epidemiology studies would be reduced. Several GO processes 
uniquely enriched with Aroclor1260 + PCB126 co-exposure were discovered, 
including the epigenetic regulation of gene expression and the localization of 
macromolecules including proteins. 
IPF analysis of the PCB126 and Aroclor1260 + PCB126 exposure groups 
revealed overconnected interactions with several transcription factors regulating 
myriad processes involved in the resolution and repair of liver injury including 
inflammation, stellate cell plasticity and fibrosis, stem cells, proliferation, 
differentiation, metabolism, and transformation. These transcription factors are 
new targets for PCB hepatotoxicity in NASH and include ETS1 (80, 81), SOX17 
(82, 83), GABPα (80, 84), c-FOS (85), ZFX (86), N-Myc (87), and AML1 (81). 
While tumors were not observed in the present study, the identification of 
oncogenes is not surprising because PCB126 has previously been associated 
with liver cancer. Although Cyp1a2 message and protein were induced by 
PCB126 and Aroclor1260 + PCB126, MetaCore analyses provided no evidence 
to support the potential AhR-dependence in any of the identified GO processes. 
Moreover, IPF analysis did not identify AhR as an overconnected transcription 
factor. While this could simply be a limitation of the software package, future 
studies are required to determine the AhR-dependence of PCB-related TASH.  
Aroclor1260 and PCB126 did not result in either additive hepatotoxicity or 




model. Hepatic protein abundance is a function of protein synthesis, degradation 
and transport into and out of the liver. Epigenetics-related GO processes were 
enriched in the Aroclor1260 + PCB126 exposure group, and this may have 
influenced the synthesis rates of specific hepatic proteins. The abundance of 
multiple epigenetics-related proteins was reduced including histone deacetylase 
2; histones H1.2, H1.4, H1.5, and H1t; RNA polymerase-associated protein 
CTR9 homolog; RNA binding protein 3; and LIM domain-containing protein 1 and 
protein arginine methyltransferase 7). The proteins are involved in numerous 
epigenetics processes including histone acetylation, methylation, and 
microRNAs. IPF demonstrated overconnected interactions with the 
methyltransferase, PRMT1, and the several transcription factors associated with 
the epigenetic regulation of gene expression such as ETS1 and GABPα (80). 
The abundance of other proteins involved in epigenetics and the regulation of 
gene expression was altered in the other treatment groups (e.g., the 
noncanonical poly(A) RNA polymerase PAPD5, Table 3) in Aroclor1260). Future 
studies are required to establish the mechanistic importance of epigenetic 
mechanisms in the genesis, progression, and potential heritability of PCB-
related liver diseases. 
Although perhaps the most comprehensive analysis of different chronic PCB 
exposures in an animal model of NAFLD, the present study is not without its 
limitations. Most notably, while proteins regulating metal homeostasis and 
epigenetics were implicated, direct measurement of hepatic metals and 




proteomics analyses in the HFD plus Aroclor1260 TASH model (51), the present 
experiment utilized a different, and potentially more sensitive, proteomics 
technique (TMT labeling) as well as different analytic procedures. This may limit 
the comparability of results between studies, and as a result, the MetaCore 
outcomes may vary. Sex differences were previously reported for Aroclor1260-
induced TASH (36), with female mice being more susceptible. Because male 
mice were utilized in the present study, potential sex differences for PCB126 and 
Aroclor1260 + PCB126 exposures in TASH remain unknown. While Aroclor1260 
+ PCB126 exposures were associated with a pancreatic pathology resembling 
diabetic exocrine pancreatopathy in an acute model (51), the present study did 
not evaluate pancreatic endpoints because GTT was unchanged. 
In conclusion, the present study demonstrated the complexity of the hepatic 
effects of PCB mixtures. DL PCBs, NDL PCBs, and a more environmentally 
relevant mixture of both types of PCBs differentially modulated the hepatic 
proteome and the severity of diet-induced NAFLD. Aroclor1260 increased 
hepatic inflammation and phosphoprotein signaling disruption consistent with 
prior research. PCB126 decreased hepatic inflammation and fibrosis at the 
molecular level. Mechanisms including altered cytoskeletal remodeling, metal 
homeostasis, and disruption of intermediary and xenobiotic metabolism were 
implicated in PCB126’s mode of action, and all have been previously reported. 
Neither the histologic nor the proteomic effects of Aroclor1260 and PCB126 were 
additive in the co-exposure model. PCB126 attenuated Aroclor1260-induced 




plasma lipids. The overwhelming majority of differentially regulated hepatic 
proteins associated with Aroclor1260 + PCB126 exposure were not associated 
with either Aroclor1260 or PCB1260 exposure. Likewise, most proteins 
associated with either Aroclor1260 or PCB126 exposures were not associated 
with co-exposure to both. Despite this, many of the top GO processes and 
overconnected interactions by protein function were common to the PCB126 and 
Aroclor1260 + PCB126 exposure groups. These conserved processes were 
broadly related to metabolism and cellular organization and localization. A 
complex web of overconnected transcription factors broadly regulating 
metabolism; liver injury and inflammation; and liver repair was identified. 
Aroclor1260 + PCB126 exposure was strongly associated with multiple 
epigenetic processes, and these could potentially explain the observed 
nonadditive effects of the exposures on the hepatic proteome. When compared 
with our recently published acute study investigating the same PCB exposures, 
the modifying effect on diet (and possibly duration) on PCB-induced 
hepatotoxicity is also demonstrated. More data including translational research 
are required on potential modes of PCB action in NAFLD including 
phosphoprotein signaling disruption; abnormal metal homeostasis; cytoskeletal 
remodeling; and transcriptional reprogramming by epigenetic mechanisms. 
Likewise, potential sex differences and the AhR-dependence of PCB126’s 








AHR PLAYS A PIVOTAL ROLE IN REGULATING HEPATIC PROTEOME 
AND LIPID METABOLISM  
                                                INTRODUCTION 
As a highly stable chemical, polychlorinated biphenyls (PCBs) were used in 
industrial and commercial applications, such as coolant fluids, transformers 
and they were commercially producedBoth contraction of HIK and PE have been 
normalized to length. in the United States from 1929 to 1979.  Although the 
production of PCBs is banned by the US government, 1.3 million tons of PCBs 
were produced, consisting of 130 individual congeners, which has an 
association with a variety of conditions, especially like non-alcoholic fatty liver 
disease (NAFLD), diabetes and hypertension.  According to the National 
Health and Nutrition Examination Survey (NHANES), PCBs can be detected in 
the serum of 100% American adults (38).  
PCBs have been categorized into two major classes: coplanar and 
noncoplanar PCBs. The former have none or only one chlorine atom attached 
to the ortho-position of biphenyl rings, called non-ortho and mono-ortho PCBs, 
respectively. Coplanar PCBs like PCB 126 can activate the aryl hydrocarbon 




response similar to TCDD. Non-coplanar PCB congeners, known as non-
dioxin-like (NDL) PCBs, have two or more chlorine atoms at the ortho-position, 
and do not have dioxin-like properties, which can activate the constitutive 
androstane receptor (CAR) (44).  Aroclor 1260 is a commercial mixture of 
PCBs manufactured by Monsanto, a well-known PCB manufacturer in 
Anniston, Alabama, containing an average chlorine content of 60%. Mostly, it 
contains NDL-PCB, and the PCB profiles in Aroclor 1260 best mimic the PCBs 
present in human adipose tissue (45).  Although Aroclor 1260 contains small 
amounts of DL-PCBs, it cannot activate human or murine AhR (2, 45). 
PCBs are found to be associated with NAFLD either in human studies and in 
animal studies, and NAFLD is a progressive condition with a broad spectrum 
ranging from simple steatosis, non-alcoholic steatohepatitis (NASH), liver 
cirrhosis, hepatocellular carcinoma (HCC) with multiple pathogenic factors 
such as fat accumulation, occupational and environmental chemicals. In 2019, 
we firstly raised the term of the toxicant-associated fatty liver disease (TAFLD) 
and/or toxicant-associated steatohepatitis (TASH) to describe this condition 
(29).  Apart from AhR, our group found PCB receptors involved with CAR, 
pregnane-xenobiotic receptor (PXR), and epidermal growth factor receptor 
(EGFR) in TASH in the last a few years. 
As a ligand-binding activated transcription factor, the AhR regulates a variety 
of physiological and pathological function (88).  The activation of AhR induces 
the transcription of many genes, such as the cytochrome P4501A (CYP1A) 




include 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 1,2-benzo[a]pyrene (BA) 
and DL-PCBs. While, low-affinity binding agonists for AhR are flavonoids and 
indoles, endogenous bilirubin and tryptophan metabolites, and products of the 
microflora (89).  Apart from regulation of immunity, stem cell maintenance and 
cellular differentiation (89), AhR activation also is involved in the processes of 
glucose and lipid metabolism. Over-activation of AhR (33) or constitutively 
activated AhR (90) induces hepatic steatosis via upregulation of fatty acid 
transport genes, such as CD36/FAT. Alteration of hepatic fatty acid 
composition (91) and decreased fatty acid oxidation (92) contribute to AhR 
ligand-induced liver toxicity and steatosis. Some publications showed AhR 
deficiency has a protective effect against high fat diet-induced obesity, and 
mitigates hepatic steatosis (34, 93).  On the other hand, liver-specific AhR 
knockout mice are susceptible to HFD-induced hepatic steatosis, inflammation 
and injury (94), suggesting AhR activation protects against fatty liver disease. 
There is also a report that Ahr-/- mice developed spontaneous microvesicular 
lipidosis (35). The exact role of AhR activation plays in regulating hepatic 









MATERIALS AND METHODS 
Animal studies 
The related animal protocol was approved by the University of Louisville 
Institutional Animal Care and Use Committee. Adult male C57BL/6 mice and  
Ahr-/- mice (8-9 weeks old) were purchased from Taconic Biosciences Laboratory 
and distributed into four equal groups (n=10): WT Vehicle group, WT PCB 126 
group, Ahr-/- Vehicle group and Ahr-/- PCB126 group. All mice were fed a control 
synthetic diet (20.0 %, 69.8 %, and 10.2 % of total calories come from protein, 
carbohydrate, and fat, TekLad TD 06416).  At 10 weeks of age, 10 mice in each 
group were given either corn oil, or PCB126 (20 μg/kg) via a one-time gavage 
and followed for 2 weeks (Fig. 3.1). Dual energy X-ray absorptiometry (DEXA) 
scanning (Lunar PIXImus densitometer, WI) was performed to analyze body fat 
composition before euthanasia. Whole blood for plasma, liver, and fat tissue 
samples were collected after euthanasia.  
Histological staining 
Liver tissues were fixed in 10% Neutral Buffered Formalin for 72 hours and 
embedded in paraffin for routine histological examination. Hematoxylin-eosin 
(H&E) staining was performed to identify histopathological changes. Oil Red O 
stain was used to evaluate lipid accumulation according to the manufacturer's 
protocols. Micrographic images were acquired by a high-resolution Olympus 
digital scanner with an Olympus digital camera (BX41). 
Real-time PCR 




RNA-STAT 60 according to the manufacturer's protocol. The purity and quantity 
of total RNA were assessed with a Nanodrop spectrometer (ND-1000, Thermo 
Fisher Scientific, Wilmington, DE) using ND-1000 V3.8.1 software and cDNA 
was reverse transcribed from 1 ug RNA with a one-step cDNA synthesis reagent 
(QScript cDNA Supermix, QuantaBio, Beverly, MA). Then RT-PCR was 
performed on the CFX384TM Real-Time System (Biorad, Hercules, CA) using 
iTaq Universal probe Supermix and Taqman probes as described previously (36). 
All reactions were run triplicately. The relative mRNA expression was calculated 
using the comparative 2-
△△Ct method and normalized against GAPDH mRNA.   
Measurement of hepatic lipids, plasma lipids and cytokines 
The liver tissues were rinsed in 1× phosphate buffered saline (PBS) and 
homogenized in 50 mM NaCl solution. Hepatic lipids were extracted by a mixed 
solution of chloroform and methanol (2:1) according to a published protocol (56). 
Hepatic triglycerides and free fatty acid contents were assessed using 
commercial kits with final values normalized to liver weight. Plasma alanine 
transaminase (ALT), aspartate transaminase (AST), cholesterol,  triglyceride, 
high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density 
lipoprotein (VLDL), and non-HDL cholesterol (nHDLc) levels were determined 
with lipid panel plus kits on a Piccolo Xpress Chemistry Analyzer (Abbott 
Laboratories, IL).  Plasma cytokine and adipokine levels were evaluated using a 
customized Milliplex® MAP mouse adipokine Panel on a Luminex® 100 system 
(Luminex Corp, Austin, TX). 




Proteins were extracted from liver tissues in RIPA buffer with protease and 
phosphatase inhibitors using a bead homogenizer and protein amounts were 
measured by BCA assay. Protein lysates (200 μg) were trypsinized using the 
modified Filter-Aided Sample Preparation (FASP) method (57) and enriched for 
phosphopeptides by the method of TiO2-SIMAC-HILIC (TiSH) (58). Firstly, 
protein samples were reduced by dithiothreitol, denatured by 8M urea and 
alkylated by iodoacetamide, then they were centrifuged through a high molecular 
weight cutoff centrifugal filter (Millipore, 10k MWCO). Next, after overnight 
digestion with sequencing grade Trypsin (Promega), the digested proteins were 
collected and cleaned with a C18 Proto™ 300 Å Ultra MicroSpin column. 
Digested protein samples (50 μg) were labeled with tandem mass tag (TMT) 
TMT10plex™ Isobaric Label Reagent Set (Thermo Fisher, Waltham, MA), then 
were concentrated and desalted with Oasis HLB Extraction cartridges (Waters 
Corporation, Milford, MA) using a modified protocol for extraction of the digested 
peptides (59). Then samples were separated by high pH reversed phase 
separation with fraction concatenation on a Beckman System Gold LC system 
supplemented with 126 solvent module and 166 detector in tandem with a 
BioRad Model 2110 Fraction Collector (60). Liquid Chromatography/Mass 
Spectrometry (LC/MS) was used to measure TMT-Labeled peptides. Briefly, 
every high pH reversed phase fraction was dissolved in 50 µL solution of the 
combination of 2% v/v acetonitrile/ 0.1% v/v formic acid and 1 µL of each fraction 
was analyzed on EASY-nLC 1000 UHPLC system (Thermo Fisher) and an 




USA). The raw data from the mass spectrometer were analyzed by Proteome 
Discoverer v2.2.0.388. 
Statistical analysis and data sharing  
Statistical evaluation was performed by two-way analysis of variance (ANOVA) 
using GraphPad Prism version 7.02 for Windows (GraphPad Software Inc., La 
Jolla, CA, USA). P <0.05 was considered statistically significant. Statistical 
analysis for the proteome data was carried out using the R package as described 
previously (62).  Significantly altered proteins were further filtered with an FDR 
threshold of 0.2 and proteins exhibiting a fold change of -0.5<log2FC< 0.5 were 
rejected to eliminate false positives. Hepatic proteins that had significance 
abundance were imported into MetaCore software (Clarivate Analytics, 
Philadelphia, PA) for the further analyses: gene ontology (GO process), 
enrichment by protein function (EPF), and interaction by protein function (IPF). 
Proteomics data files were deposited with MassIVE (http://massive.ucsd.edu/) 
data repository, Center for Computational Mass Spectrometry at the University 


















Figure 3.1. Experimental Design of acute AhR knockout study. 
Mice were divided into 4 study groups based on the type of exposure. All 
animals were fed a chow diet and received a one-time gavage of their 
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                                                      RESULTS 
Effects of PCB126 exposure and Ahr-/- on body composition, glucose 
tolerance, plasma lipids 
Body fat composition was measured using Dexascan and white adipocyte 
tissue weight was evaluated by weighing the harvested epididymal fat. Body 
weight was measured weekly throughout the 2-week study. There was a 
gradual increase in body weight in PCB126-free groups from Week 0 to Week 
2, while the weight of PCB 126 exposure mice groups did not change 
significantly, suggesting PCB126 had an effect of decreasing body weight, 
which was showed in percentage change in body weight (Fig. 3.2A, 2B & 2C). 
Compared to wildtype (WT) mice, Ahr-/- mice had lower body weight, lower liver 
weight/body weight ratio, decreased lean body mass percentage and higher 
body fat composition. (Fig. 3. 2C, 2D, 2E & 2F). Additionally, Ahr-/- mice also 
showed higher pancreas weight/body weight ratio (Fig. 3.2G). These results 
showed AhR deprivation caused or deteriorated lipid accumulation. A glucose 
tolerance test was performed to evaluate whether PCB126 or AhR gene 
knockout affects glucose metabolism; GTT curve and AUC graph showed 
PCB126 exposure groups had significant lower AUC, suggesting PCB126 
improves glucose uptake (Fig. 3.2I & 2J).  PCB126 exposure and Ahr-/- effects 
on plasma lipids were also evaluated. Although there was no significant 
differences in plasma LDL-c between groups (Fig. 3.2N), AhR gene deletion 
caused a trend to decrease plasma VLDL (p=0.06) (Fig. 3.2O), meanwhile, 




glucose levels (Fig. 3.2K, L & M).  Apart from these above, AhR gene ablation 
had the effect of lowering the plasma triglyceride in Ahr-/- mice. (Fig. 3.2P).   
Effects of PCB126 exposure and Ahr-/- on hepatic steatosis, associated 
hepatic gene expression, hepatic lipids and liver enzymes 
Hepatic steatosis was evaluated by H&E stain of liver sections. WT PCB126 
group developed small droplet macrovesicular steatosis, while Ahr-/- Vehicle 
and Ahr-/- PCB126 groups both showed severe centrilobular, large droplet 
macrovesicular steatosis. No significant difference was found between these 
two groups in the severity of steatosis by H&E stain (Fig. 3.3A). To confirm the 
results further from H&E stain, Oil Red O stain was performed. WT PCB126 
group developed a few lipid droplets (Red spots), while Ahr-/- Vehicle and Ahr-/- 
PCB126-exposed groups demonstrated much more larger lipid droplets (Fig. 
3.3B). The expression of hepatic genes related to lipid metabolism like Cd36, 
Pnpla3 and Perilipin-2 were evaluated by RT-PCR. Both PCB126 exposure 
and Ahr-/- increased the expression levels of Cd36, promoting hepatic lipid 
uptake (Fig. 4.3E), while global AhR deletion decreased the expression of 
Pnpla3, essential for lipid hydrolysis (Fig. 3.3F). Apart from these genes above, 
the mRNA expression levels of Perilipin-2, which relates to the formation of 
lipid droplets, was upregulated by Ahr-/- (Fig. 3.3G). Additionally, the mRNA 
expression level of tyrosine aminotransferase (Tat) gene, a target gene of 
Glucocorticoid receptor (GCR) was evaluated by RT-PCR. Ahr-/- also increased 
the expression of Tat gene, meanwhile, there was a trend that PCB126 also 




measured biochemically to further evaluate hepatic steatosis. Both Ahr-/- and 
PCB126 increased the hepatic triglyceride (Fig. 3.3J). Meanwhile whole AhR 
ablation increased hepatic free fatty acids. (Fig. 3.3K). There was a trend for 
PCB126 to increase hepatic cholesterol level (p=0.05) (Fig. 3.3I). As for liver 
enzymes, Ahr-/- significantly increased plasma ALT and AST levels, showing 
whole AhR gene deletion caused hepatic injury (Fig. 3.3C & D). 
Effects of PCB exposure and Ahr-/- on hepatic expression of AhR, Pxr, Car 
and their target genes 
The activation of AhR, Pxr, Car and their target genes was assessed by RT-
PCR. As expected, compared to WT Vehicle group, Ahr-/- groups showed totally 
inhibited AhR mRNA expression (2 –ΔΔCt value from 1.02 in WT Vehicle group to 
0 in Ahr-/- Vehicle and Ahr-/- PCB126 group, both p<0.01), suggesting the AhR 
knockout was achieved (Fig. 3.4A).  As for the target genes of AhR: Cyp1a1 and 
Cyp1a2, AhR ablation had the effect on downregulating the mRNA expression 
of both genes (both p<0.01). (Fig. 4.4B & C).  Although AhR mRNA level was not 
significantly increased, Cyp1a1 and Cyp1a2 were upregulated significantly by 
PCB126 (2615.6-fold & 10.6-fold), indicative of AhR activation (Fig. 3.4B & C). 
With regards to Pxr gene and its target gene (Cyp3a11) expression, AhR gene 
depletion showed the effect of upregulating Pxr and Cyp3a11 mRNA expression 
(p=0.01 and p<0.01) (Fig. 3.4D &E); compared to WT Vehicle, the expression of 
Pxr in Ahr-/- Vehicle and Ahr-/- PCB126 group increased by 1.39 (p=0.07) and 1.51 
fold (p=0.01), while the expression of Cyp3a11 in Ahr-/- Vehicle and Ahr-/- PCB126 




activation. Meanwhile PCB126 also showed a trend to increase Pxr gene 
expression (p=0.05) (Fig. 3.4F & G). Both Ahr-/- Vehicle and Ahr-/- PCB126-
exposed groups had increased Cyp2b10 (the target gene of Car) mRNA levels 
(35.29-fold, p=0.00 and 44.44-fold, p=0.01 respectively vs WT Vehicle), 
consistent with Car activation, despite the decreased level of Car mRNA 
expression (Fig. 3.4F & G). 
Effects of PCB126 exposure and Ahr-/- on plasma adipo-cytokines 
       Plasma adipo-cytokine levels were determined using a customized Milliplex® 
MAP mouse adipokine Panel on a Luminex® 100 system (Luminex Corp, Austin, 
TX). AhR ablation had effect of decreasing the level of IL-6 (Fig. 3.5A), Ahr-/- 
Vehicle showed a lower IL-6 level than WT Vehicle, while there was no 
significant difference of PAI-1 and MCP-1 levels between the groups (Fig. 3.5C 
& F). Meanwhile, AhR knockout decreased the levels of plasma insulin and 
resistin (Fig. 3.5B & E), but increased the level of leptin (Fig. 3.5D), suggesting 
the improvement of insulin resistance.  
Effects of PCB126 exposure and Ahr-/- on hepatokine expression 
Protective hepatokines (e.g. Fgf21, Igf1, and betatrophin) were measured by 
RT PCR. AhR gene deletion resulted in increasing Fgf21 expression, while both 
Ahr-/- and PCB126 exposure decreased the expression of betatrophin.  With 
respect to Igf1, PCB126 slightly increased the expression, but there was a trend 
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% Change in 
BW 
0.26 0.01 0.13 0.75 0.01 0.99 0.25 
Body weight  <0.01 0.81 0.41 0.87 0.97 0.00 <0.01 
Fat 
Composition 
<0.01 0.73 0.68 >0.99 0.95 0.00 0.01 
LW/BW <0.01 0.66 0.67 >0.99 0.92 <0.01 <0.01 
% Lean Body 
Mass 
<0.01 0.78 0.64 0.95 1.00 0.00 0.01 
PW/BW <0.01 0.24 0.77 0.71 0.92 <0.01 <0.01 
WATW/BW 0.02 0.48 0.54 >0.99 0.80 0.56 0.15 
AUC 0.16 0.00 0.45 0.23 >0.99 <0.01 <0.01 
Plasma 
Cholesterol 
<0.01 0.66 0.31 0.73 0.98 <0.01 <0.01 
Plasma HDL-c <0.01 0.60 0.20 0.55 0.95 <0.01 <0.01 
Plasma TG 0.01 0.65 0.96 0.99 0.98 0.16 0.20 
LDL-c 0.21 0.19 0.28 0.23 1.00 1.00 0.39 
VLDL 0.06 0.63 0.70 1.00 0.93 0.68 0.39 
Plasma 
Glucose 





Figure 3.2. Effects of PCB126 exposure and Ahr-/- on body composition, 
glucose tolerance, plasma lipids.   
(A, C) Body weight was measured weekly throughout the 2-week study. AhR-/- 
mice had a significant lower body weight than WT mice. (B) % change in body 
weight relative to the initial body weight taken at the beginning of the study was 
calculated. (D) the body fat composition was measured by calculating the white 
adipose tissue weight to body weight ratio. Liver weight (LW) and White adipose 
tissue (WAT) weight were measured, and WATW/BW was calculated by the 
epididymal fat weight divide body weight. (E & G) The liver and pancreas were 
weighed and their respective weights relative to body weight were calculated. 
(F) % lean body mass was calculated by lean body mass divide body fat weight.  
Lean body mass= Body weight – body weight * % body fat percentage. A glucose 
tolerance test was performed after the second PCB gavage and blood glucose 
levels were measured; (I) GTT curve was made and (J) AUC (Area Under the 
Curve) of four groups was calculated.（K）Plasma cholesterol, (L) Plasma HDL- 
c, (M) Plasma triglyceride, (N) Plasma LDL-c, (O) Plasma VLDL, and (P) Plasma 
glucose were measured by Piccolo Xpress chemical analyzer. Values are mean 
± SD. Values for p < 0.05 are in bold, a – Ahr-/- effect, b – PCB126 effect, c – 











































































































































































































0.00 0.66 0.96 0.99 0.98 0.03 0.02 
Plasma 
AST 
<0.01 0.63 0.84 1.00 0.96 <0.01 <0.01 
Cd36 <0.01 0.03 0.53 0.24 0.63 <0.01 <0.01 
Pnpla3 0.03 0.26 0.29 0.43 >0.99 0.10 0.83 
Perilipin-2 <0.01 0.63 0.34 0.99 0.72 0.08 0.00 




0.35 0.05 0.64 0.71 0.30 0.99 0.75 
Liver TG <0.01 0.04 0.09 1.00 0.04 <0.01 <0.01 
Liver FFA 0.00 0.23 0.70 0.64 0.94 0.05 0.22 
 
Figure 3.3. Effects of PCB126 exposure and Ahr-/- on hepatic steatosis, 
expression of genes related to lipid metabolism, hepatic lipids and liver 
enzymes.   
Hepatic steatosis was evaluated using (A) hematoxylin-eosin (H&E) staining 
of liver sections and hepatic lipids (G-H).  (B) Oil Red O stain was performed to 
confirm the existence of neutral triglyceride and lipids on frozen sections.  (C) 
Plasma ALT and (D) Plasma AST were measured to indicate hepatic injury using 
Piccolo Xpress chemical analyzer.  (E) Cd36, (F) Pnpla3, (G) Perilipin-2, and (H) 
Tat mRNA expression levels were evaluated by RT-PCR. (I) Hepatic cholesterol, 
(J) Hepatic triglyceride, (K) Hepatic free fatty acid and were analyzed. Values 
are mean ± SD. Values for p < 0.05 are in bold, a - Ahr-/- effect, b – PCB126 
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Outco
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AhR  <0.01 0.17 0.17 0.23 >0.99 <0.01 <0.01 
Cyp1
a1 
<0.01 <0.01 <0.01 <0.01 >0.99 >0.99 <0.01 
Cyp1
a2 
<0.01 <0.01 <0.01 <0.01 >0.99 0.82 <0.01 
Pxr 0.01 0.05 0.36 0.19 0.86 0.07 0.62 
Cyp3
a11 
<0.01 0.30 0.77 0.95 0.77 <0.01 <0.01 
Car <0.01 0.01 0.02 0.00 0.98 0.00 <0.01 
Cyp2
b10 






Figure 3.4. Effects of PCB126 exposure and Ahr-/- on hepatic expression of 
AhR, Pxr, Car and their target genes.   
The expression of AhR, Pxr, Car and their target genes were assessed by RT-
PCR.  (A) Hepatic AhR mRNA expression & the expression of its target genes: 
(B) Cyp1a1, (C) Cyp1a2.  (D) Hepatic Pxr mRNA expression and the expression 
of its target gene: (E) Cyp3a11. (F) Car mRNA expression and the expression of 
its target gene: (G) Cyp2b10. Values are mean ± SD.  Values for p < 0.05 are in 





































IL-6 0.04 0.14 0.03 0.06 0.95 0.02 1.00 
Insulin 0.01 0.64 0.41 1.00 0.79 0.56 0.08 
PAI-1 0.27 0.34 0.67 0.98 0.74 0.70 0.96 
Leptin <0.01 0.89 0.97 1.00 1.00 0.00 0.00 
Resistin 0.01 0.22 0.53 0.56 0.97 0.10 0.50 
MCP-1 0.34 0.08 0.06 0.06 1.00 0.17 0.90 
 
Figure 3.5. Effects of PCB126 exposure and Ahr-/- on plasma adipo-
cytokines.   
Plasma adipo-cytokine levels were measured using a customized Milliplex® 
MAP mouse adipokine Panel on a Luminex® 100 system (Luminex Corp, 
Austin, TX), including IL-6 (A), Insulin (B), PAI-1 (C), Leptin (D), Resistin (E), 
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Fgf21  <0.01 0.19 0.14 1.00 0.19 0.01 <0.01 
Igf1 0.07 0.01 0.57 0.09 0.32 0.77 0.34 
Betatrop
hin 







Figure 3.6. Effects of PCB126 exposure and Ahr-/- on hepatokines 
expression.   
Hepatic mRNA levels of Fgf21 (A), Igf1 (B), and betatrophin (C) were evaluated 
by RT-PCR. Values are mean ± SD.  Values for p < 0.05 are in bold, a - Ahr-/- 

















Effects of PCB126 exposure and Ahr-/- on the hepatic proteome 
PCB126 exposure and AhR gene knockout produced distinct hepatic 
proteomes. 5,075 unique proteins and their isoforms were detected, and 
alterations in hepatic proteins were demonstrated by Volcano plots showing 
significance (y-axis) versus protein fold change (x-axis) for comparisons 
between these four groups. The graphs were denoted as follows: (A) B vs A: 
WT PCB126 group vs WT Vehicle group, (B) C vs A: Ahr-/- Vehicle group vs 
WT Vehicle group, (C) D vs A: Ahr-/- PCB126 group vs WT Vehicle group, (D) 
D vs B: Ahr-/- PCB126 group vs WT PCB126 group & (E) D vs C: Ahr-/- PCB126 
group vs Ahr-/- Vehicle group. Black denotes unaltered proteins, green denotes 
significantly altered proteins, red denotes significantly upregulated protein with 
(log2FC≥1), blue denotes significantly downregulated protein with (log2FC-1). 
(F) A multi-dimensional scatter (MDS) plot depicting the pattern for protein 
alterations in the different groups (Fig. 3.7A-F). The differentially abundant 
hepatic proteins were listed at Table 4. The comparisons of hepatic abundance 
proteins content between groups were regulated as follows: WT PCB126 group 
vs WT Vehicle group (5 increased and 3 decreased), Ahr-/- Vehicle group vs 
WT Vehicle group (279 increased and 61 decreased), Ahr-/- PCB126 group vs 
WT Vehicle group (209 increased and 92 decreased), Ahr-/- PCB126 group vs 
WT PCB126 group (185 increased and 77 decreased) and Ahr-/- PCB126 
group vs Ahr-/- Vehicle group (0 increased and 0 decreased) (Fig. 3.7G). A 
Venn diagram showed the number of overlapping proteins in different groups 




PCB126 caused much less proteomic changes which are shown in Graph A 
(8 proteins) and Graph E (0 protein) than AhR deprivation in Graph B (301 
proteins) and Graph C (262 proteins) (Fig. 3.7G). Notably, there were no 
alterations of proteins in Ahr-/- PCB126 group vs Ahr-/- Vehicle group, 
suggesting that without AhR gene involvement, PCB126 did not cause 
significant differentially abundance hepatic protein changes. 3 proteins were 
altered in all comparisons of groups except Ahr-/- PCB126 vs Ahr-/- Vehicle 
group , namely, cytochrome P450 1A2, Isoform 2 of cytochrome P450 2C50, 
and Fatty acid-binding protein 5, showing these proteins were affected by both 
AhR ablation and PCB126 exposure (Supplemental Table 2). Of the 340 
abundant proteins in mice not exposed to PCB126 (Ahr-/- Vehicle vs WT 
Vehicle) regulated by AhR gene deletion, 91 proteins were unique (26.8%); of 
the 262 altered proteins in PCB126-exposed mice (Ahr-/- PCB126 vs WT 
PCB126) related to AhR deprivation, only 46 proteins were exclusive (17.6%). 
EPF analysis was performed to evaluate the protein classes most impacted 
by PCB126 exposure or AhR gene deletion (Table 4). Enzymes were the most 
affected class (WT PCB126 vs WT Vehicle: z-score=6.423; Ahr-/- Vehicle vs 
WT Vehicle : z-score=17.84; Ahr-/- PCB126B vs WT PCB126: z-score=15.52). 
This ending was consistent with the results of abundance proteins which 
showed 6/8 proteins in WT PCB126 vs WT Vehicle regulated by PCB126 were 
enzymes and most of the proteins in other comparisons altered by AhR gene 
knockout also belong to enzymes (Supplemental Table 2).  AhR knockout 




enzyme activity biomarkers). The abundance proteins in the comparisons of  
Ahr-/- Vehicle vs WT Vehicle  and Ahr-/- PCB126 vs WT PCB126 related to AhR 
ablation, indicating hepatic steatosis, hepatic injury and inflammation, were 
upregulated. These proteins included Glutathione S-transferase A1 (Ahr-/- 
Vehicle vs WT Vehicle: Log2FC=4.97, p=9.68E-09; Ahr-/- PCB126 vs WT 
PCB126: Log2FC=5.13, p=8.00E-08), Glutathione S-transferase Mu3 (Ahr-/- 
Vehicle vs WT Vehicle: Log2FC=3.76, p=7.63E-09; Ahr-/- PCB126 vs WT 
PCB126: Log2FC=3.21, p=8.00E-08), Glutathione S-transferase A4 (Ahr-/- 
Vehicle vs WT Vehicle: Log2FC=3.06, p=1.03E-08; Ahr-/- PCB126 vs WT 
PCB126: Log2FC=2.17, p=1.34E-06), Annexin A5 (Ahr-/- Vehicle vs WT 
Vehicle: Log2FC=2.35, p=9.70E-09; Ahr-/- PCB126 vs WT PCB126: 
Log2FC=2.10, p=5.83E-08), Protein S100-A11 (Ahr-/- Vehicle vs WT Vehicle: 
Log2FC=2.29, p=3.13E-07; Ahr-/- PCB126 vs WT PCB126: Log2FC=2.45, 
p=1.70E-07), Perilipin-2 (Ahr-/- Vehicle vs WT Vehicle: Log2FC=2.24, p=1.18E-
03; Ahr-/- PCB126 vs WT PCB126: Log2FC=1.97, p=3.88E-03), Glutathione S-
transferase Mu 1 (Ahr-/- Vehicle vs WT Vehicle: Log2FC=2.23, p=5.45E-08; Ahr-
/- PCB126 vs WT PCB126: Log2FC=1.66, p=3.09E- 06), Long-chain-fatty-acid-
CoA ligase 4 (Ahr-/- Vehicle vs WT Vehicle: Log2FC=1.87, p=3.20E-05; Ahr-/- 
PCB126 vs WT PCB126: Log2FC=2.12, p=9.24E-06), Isoform Short of Long-
chain-fatty-acid-CoA ligase 4 (Ahr-/- Vehicle vs WT Vehicle: Log2FC=1.87, 
p=3.20E-05; Ahr-/- PCB126 vs WT PCB126: Log2FC=2.12, p=9.24E-06), 
Apolipoprotein A-IV (Ahr-/- Vehicle vs WT Vehicle: Log2FC=1.51, p=3.65E-06; 




(Ahr-/- Vehicle vs WT Vehicle: Log2FC=1.11, p=9.66E-04; Ahr-/- PCB126 vs WT 
PCB126: Log2FC=1.32, p=2.17E-04). Consistent with the results that AhR null 
mice displayed decreased plasma glucose levels and plasma insulin levels. 
The effect of AhR ablation in Ahr-/- Vehicle vs WT Vehicle and Ahr-/- PCB126 vs 
WT PCB126, was to decrease the levels of proteins promoting insulin 
resistance and glycogenolysis like glycogen phosphorylase, brain form (Ahr-/- 
Vehicle vs WT Vehicle: Log2FC=3.00, p=1.21E-08, Ahr-/- PCB126 vs WT 
PCB126: Log2FC=2.43, p=3.01E-07), and glycogen phosphorylase, liver form 
(Ahr-/- Vehicle vs WT Vehicle: Log2 FC= -1.09, p=7.20E-04, Ahr-/- PCB126 vs 
WT PCB126: Log2FC=-1.51, p=3.11E-05). The liver form of glycogen 
phosphorylase serves the glycemic demands of the body in general, while the 
brain form of glycogen phosphorylase supplies just the brain, AhR gene 
ablation caused an increase in glucose supply for brain, while decreased 
glucose supply level for the body, in general. 
Enrichment by GO processes (Fig. 3.8) revealed that the proteomes 
associated with AhR gene deletion shared similar top GO processes with those 
related to PCB126 exposure, although Ahr-/- caused a much higher degree of 
enrichment. These top GO processes mostly involved in two classes of 
processes: Lipid processes and Xenobiotic metabolism processes.  Lipid 
processes, included “Fatty acid metabolic process”, “Long-chain fatty acid 
metabolic process”, “Cellular lipid metabolic process”, “Monocarboxylic acid 
metabolic process”, “Lipid metabolic process”, “Carboxylic acid metabolic 




metabolism processes incorporated “epoxygenase P450 pathway”, “small 
molecule metabolic process”, “arachidonic acid metabolic process”, “oxidation-
reduction process”, “omega-hydroxylase P450 pathway“, “oxidation-reduction 
process”, “oxoacid metabolic process”, “organic acid metabolic process”, “drug 
metabolic process”, “organic acid biosynthetic process” and “generation of 
precursor metabolites and energy”.  Compared to PCB126 effect in the 
comparison of WT PCB126 vs WT Vehicle, the effect of ablated AhR in Ahr-/- 
Vehicle vs WT Vehicle and Ahr-/- PCB126 vs WT PCB126, enriched lipid 
processes to a much greater extent mostly (-Log10 (p-value): 6.510-45.110), 
consistent with the histology and phenotyping data. The abundance of 8 
proteins was altered in WT PCB126 vs WT Vehicle; 3 of which belonged to 
P450 enzymes were increased, and 1 protein (Acyl-coenzyme A thioesterase 
1) related to lipid metabolism was upregulated to promote free fatty acid 
production (Log2FC=2.05, p=1.79E-02) (Supplemental Table 2), while Ahr-/- 
resulted in severe large droplet macrovesicular steatosis. The abundance of 
lipid processes-associated proteins were increased significantly by AhR 
ablation in Ahr-/- Vehicle vs WT Vehicle and/or Ahr-/- PCB126 vs WT PCB126,  
including:  Acyl-coenzyme A thioesterase 1 (Ahr-/- Vehicle vs WT Vehicle: 
Log2FC=2.97, p=2.57E-06), Acyl-coenzyme A thioesterase 2, mitochondrial 
(Ahr-/- Vehicle vs WT Vehicle: Log2FC=2.90, p=7.77E-12, Ahr-/- PCB126 vs WT 
PCB126: Log2FC=1.99, p=2.74E-09), Perilipin-2 (Ahr-/- Vehicle vs WT Vehicle: 
Log2FC=2.24, p=1.18E-03, Ahr-/- PCB126 vs WT PCB126: Log2FC=1.97, 




Log2FC=2.24, p=1.18E-03, Ahr-/- PCB126 vs WT PCB126: Log2FC=1.97, 
p=3.88E-03), Acyl-CoA desaturase 2 (Ahr-/- Vehicle vs WT Vehicle: 
Log2FC=1.87, p=3.41E-02), Acyl-CoA desaturase 3 (Ahr-/- Vehicle vs WT 
Vehicle: Log2FC=1.87, p=3.41E-02), Long-chain-fatty-acid--CoA ligase 4 (Ahr-/- 
Vehicle vs WT Vehicle: Log2FC=1.87, p=3.20E-03, Ahr-/- PCB126 vs WT 
PCB126: Log2FC=2.12, p=9.24E-06), Isoform Short of Long-chain-fatty-acid--
CoA ligase 4 (Ahr-/- Vehicle vs WT Vehicle: Log2FC=1.87, p=3.20E-03, Ahr-/- 
PCB126 vs WT PCB126: Log2FC=2.12, p=9.24E-06), Acyl-coenzyme A 
thioesterase 10, mitochondrial (Ahr-/- Vehicle vs WT Vehicle: Log2FC=1.71, 
p=3.67E-07, Ahr-/- PCB126 vs WT PCB126: Log2FC=1.56, p=1.59E-06), Acyl-
coenzyme A thioesterase 9, mitochondrial (Ahr-/- Vehicle vs WT Vehicle: 
Log2FC=1.71, p=3.67E-07, Ahr-/- PCB126 vs WT PCB126: Log2FC=1.56, 
p=1.59E-06), Acyl-CoA desaturase 1 (Ahr-/- Vehicle vs WT Vehicle: 
Log2FC=1.62, p=2.87E-02), and Elongation of very long chain fatty acids 
protein 2 (Ahr-/- Vehicle vs WT Vehicle: Log2FC=1.57, p=8.38E-04, Ahr-/- 
PCB126 vs WT PCB126: Log2FC=1.34, p=3.58E-03).  Apart from lipid 
processes, PCB126 exposure enriched xenobiotic metabolism processes, 
especially “epoxygenase P450 pathway” and “omega-hydroxylase P450 
pathway”, showing that the P450 pathway played a vital role in the effect of 
PCB126 as expected.  Unlike PCB126 exposure, AhR ablation in Ahr-/- Vehicle 
vs WT Vehicle and Ahr-/- PCB126 vs WT PCB126 enriched other xenobiotic 
processes greatly except the two processes above, like “oxidation-reduction 




vs WT PCB126: -Log10 (p-value)= 26.75), “oxoacid metabolic process” (Ahr-/- 
Vehicle vs WT Vehicle: -Log10 (p-value)= 42.94, Ahr-/- PCB126 vs WT PCB126: 
-Log10 (p-value)= 44.58), “organic acid metabolic process” (Ahr-/- Vehicle vs WT 
Vehicle: -Log10 (p-value)= 42.94, B vs D: -Log10 (p-value)= 44.58), “drug 
metabolic process” (Ahr-/- Vehicle vs WT Vehicle: -Log10 (p-value)= 42.94, Ahr-/- 
PCB126 vs WT PCB126: -Log10 (p-value)= 44.58), etc. (Fig. 4.8) Consistently, 
differentially abundant proteins contributing to these processes included 
upregulated objects: Glutathione S-transferase A1 (Ahr-/- Vehicle vs WT 
Vehicle: Log2FC=4.97, p=9.68E-08, Ahr-/- PCB126 vs WT PCB126: 
Log2FC=5.13, p=8.00E-08), Glutathione S-transferase Mu 3 (Ahr-/- Vehicle vs 
WT Vehicle: Log2FC=3.76, p=7.63E-09, Ahr-/- PCB126 vs WT PCB126: 
Log2FC=3.21, p=8.00E-08), Aldehyde dehydrogenase family 1 member A3 
(Ahr-/- Vehicle vs WT Vehicle: Log2FC=3.56, p=4.50E-09, Ahr-/- PCB126 vs WT 
PCB126: Log2FC=3.50, p=8.05E-09), Aldehyde dehydrogenase X, 
mitochondrial (Ahr-/- Vehicle vs WT Vehicle: Log2FC=3.06, p=1.03E-08, Ahr-/- 
PCB126 vs WT PCB126: Log2FC=2.17, p=1.34E-06), Glutathione S-
transferase A4 (Ahr-/- Vehicle vs WT Vehicle: Log2FC=3.06, p=1.03E-08, Ahr-/- 
PCB126 vs WT PCB126: Log2FC=2.17, p=1.34E-06), transferase Mu1 (Ahr-/- 
Vehicle vs WT Vehicle: Log2FC=2.23, p=5.45E-08, Ahr-/- PCB126 vs WT 
PCB126: Log2FC=1.66, p=3.09E-06), NADH dehydrogenase [ubiquinone] 1 
beta subcomplex subunit 9 (Ahr-/- Vehicle vs WT Vehicle: Log2FC=1.38, 
p=1.88E-02), NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 




Aldehyde dehydrogenase, and cytosolic 1 (Ahr-/- Vehicle vs WT Vehicle: 
Log2FC=1.26, p=2.77E-06).  Notably, the process “Steroid metabolic process” 
was greatly enriched by AhR KO in Ahr-/- Vehicle vs WT Vehicle and B vs D 
(Ahr-/- Vehicle vs WT Vehicle: -Log10 (p-value)= 12.34, Ahr-/- PCB126 vs WT 
PCB126: -Log10 (p-value)= 26.75), the abundance of proteins associated with 
steroid metabolism included upregulated: 17-beta-hydroxysteroid 
dehydrogenase type 6 (Ahr-/- Vehicle vs WT Vehicle: Log2FC=3.02, p=3.51E-
08, Ahr-/- PCB126 vs WT PCB126: Log2FC=2.24, p=2.18E-06), 17-beta-
hydroxysteroid dehydrogenase 13 (Ahr-/- Vehicle vs WT Vehicle: Log2FC=3.02, 
p=2.68E-09, Ahr-/- PCB126 vs WT PCB126: Log2FC=2.29, p=1.71E-07), and 
Isoform 2 of 17-beta-hydroxysteroid dehydrogenase 13 (Ahr-/- Vehicle vs WT 
Vehicle: Log2FC=2.94, p=1.86E-09, Ahr-/- PCB126 vs WT PCB126: 
Log2FC=2.35, p=5.83E-08), downregulated: 3 beta-hydroxysteroid 
dehydrogenase type 5 (Ahr-/- Vehicle vs WT Vehicle: Log2FC=-4.28, p=9.00E-
12, Ahr-/- PCB126 vs WT PCB126: Log2FC=-4.59, p=3.47E-12). All of these 
enzymes were essential in the synthesis of glucocorticoid and other steroid 
hormones (Supplemental Table 2). In particular, there was no significant 
alteration of protein abundance in Ahr-/- PCB126 vs Ahr-/- Vehicle representing 
the effect of PCB126 in AhR null mice, resulting in no processes being 
enriched in Ahr-/- PCB126 vs Ahr-/- Vehicle.   
IPF analysis was performed and the top over-connected interactions by z-
score, are provided in Fig. 4.9. Eight unique objects, 5 enzymes and 3 other 




included: Acyl-CoA desaturase 3 (SCD3), NADH-cytochrome b5 reductase 3 
(CYB5R3), NAD(P)H steroid dehydrogenase-like (NSDHL), UDP-
glucuronosyltransferase 1-4 (UGT1A4) and DEU-B, the other 3 proteins were 
visinin-like protein 3 (VILIP3).  Ahr-/- Vehicle vs WT Vehicle for AhR knockout 
effect in PCB126-free mice and Ahr-/- PCB126 vs WTPCB126 for AhR ablation 
effect in PCB126 exposed mice shared 23 over-connected objects, their only 
difference was that NADH- dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 11, mitochondrial (NDUFB11) was not overconnected in Ahr-/- PCB126 
vs WT PCB126 (Fig. 4.9). 23 objects included 10 transcription factors, 1 
receptor, two proteases, two enzymes, seven other objects. Shared 
transcription factors included: Zinc finger protein 125 (Zfp125), Liver X 
receptor-alpha (LXR-alpha), Glucocorticoid receptor (GCR), Sterol regulatory 
element-binding protein 1 (nuclear) (SREBP1 (nuclear)), Peroxisome 
proliferator-activated receptor-alpha (PPAR-alpha), Thyroid hormone receptor 
beta (TR-beta), cellular oncogene FOS (c-FOS), cAMP‑responsive element‑
binding protein H (CREB-H), Specificity protein 1 (SP1), and LIM domain only 
protein 7 (LMO7);  the receptor was Insulin receptor, and two proteases were 
Coagulation factor XIII A, and Matrix metalloproteinase-2 (MMP-2); two 
common enzymes were DEAD-box helicase 19B (DDX19B) and 
Transglutaminase 2 (TGM2); seven other objects were microRNA-132-5p 
(miR-132-5p), Complement receptor 1 (Cr1), Alpha-synuclein, Diaphanous-
related formin-1 (DIA1), Glucose transporter 4 (GLUT4), Transient receptor 




Enamelin.  No significant alterations of abundance proteins were found in Ahr-/- 
PCB126 group vs Ahr-/- Vehicle group, accordingly, there was no 
overconnected objects in this comparison in IPF analysis. The common top 
overconnected objects shared by all three comparisons were Zinc finger 
protein 125 (Zfp125), Liver X receptor-alpha (LXR-alpha), Peroxisome 
proliferator-activated receptor-alpha (PPAR-alpha), Insulin receptor and miR-
132-5p; the former 3 transcription factors were associated with lipid 
metabolism, showing both PCB 126 and AhR deletion had effect on lipid 
metabolism.   
Effects of PCB126 exposure and Ahr-/- on the microRNAs (miRNAs) in the 
IPF analysis 
In the IPF analysis from proteomic data, totally 9 miRNAs were 
overconnected by PCB126 exposure and Ahr-/-, listed at Table 4. Of these 9 
miRNAs, 7 miRNAs were over-connected with PCB126 exposure, which were 
miR-122-5p, miR-132-5p, miR-142-5p, miR-150- 5p, miR- 221-3p, miR-222-3p 
and miR-223-3p; meanwhile, 4 miRNAs overconnected with Ahr-/- were miR-
122-5p, miR-132-5p, miR-192-3p and miR-544-3p. With respect to the over-
connection with the combination of PCB126 exposure and Ahr-/-, only 3 
miRNAs were included, namely, miR-122-5p, miR-132-5p and miR-544-3p. 
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Figure 3.7. Effects of PCB126 exposure and Ahr-/- on the hepatic 
proteome.   
Alterations in hepatic proteins were demonstrated by volcano plots showing 
significance (y-axis) versus protein fold change (x-axis) for comparisons 
between these four groups, which are (A) WT PCB126 vs WT Vehicle , (B) Ahr-
/- Vehicle vs WT Vehicle, (C) Ahr-/- PCB126 vs WT Vehicle, (D) Ahr-/- PCB126 
vs WT PCB126 & (E) Ahr-/- PCB126 vs Ahr-/- Vehicle.  Black denotes unaltered 
proteins, green denotes significantly altered proteins, red denotes significantly 
altered protein with (log2FC≥0.5), blue denotes significantly altered protein with 
(log2FC-0.5).  (F) A multi-dimensional scatter (MDS) plot depicting the pattern 
for protein alterations in the different groups. A – WT Vehicle, B – WT PCB126, 
C – Ahr-/- Vehicle, D – Ahr-/- PCB126. (G) The number of proteins and their 
isoforms that were altered for the four comparisons between different groups 
(The data was adjusted by FDR=0.2). (H) Venn diagram showing the number 
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Figure 3.8. Effects of PCB126 exposure and Ahr-/- on gene ontology (GO) 
processes.   
Heatmap showing different processes that were altered by PCB exposures and 
Ahr-/- according to the -log(p-value). The processes were obtained by GO 
analysis enrichment of the different proteins altered by PCB exposures and/or 
AhR knockout using MetaCore.  No processes were obtained from the 
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   Fig. 3.9. Effects of PCB exposures and Ahr-/- on protein function.  
Heatmap showing different classes of proteins, for the different groups, 
obtained from the Interaction by Protein Function analysis using MetaCore and 
their corresponding z scores. No overconnected proteins were found in Ahr-/- 










Table 3. Enrichment by protein function analysis 
Enrichment by protein function analysis was performed by MetaCore 
software using the hepatic proteomics data. For a given protein class, a positive 
z-score indicates that more proteins in that class were altered than expected. 
Likewise, a negative z-score means that fewer proteins in the class were altered 
than expected. 
      
Protein Class 
WT PCB126 vs       Ahr-/- Vehicle vs        Ahr-/- PCB126 vs   
WT Vehicle               WT Vehicle               WT PCB126 
Ligands                      1.87 2.60 
Phosphatases                     0.90 -0.05 
Proteases                   -0.67 -1.05 
Kinases                   -0.90    -0.40 
Transcription 
Factors 
      
Receptors                    -2.91 -2.57 
Enzymes 6.42          17.84 15.52 












    Table 4. Over-connected miRNAs and their z-scores in IPF analysis 
      Seven miRNAs were over-connected with PCB126 exposure in IPF analysis, 
including miR-122-5p, miR-132-5p, miR-142-5p, miR-150-5p, miR-221-3p, 
miR-222-3p and miR-223-3p; while only 4 miRNAs were over-connected with 
Ahr-/-, namely, miR-122-5p, miR-132-5p, miR-192-3p and miR-544-3p; and 
three miRNAs, such as miR-122-5p, miR-132-5p and miR-544-3p were over-
connected with the combination of PCB126 exposure and AhR gene ablation. 
     
Overconnected 
miRs                    
z-score 
WT PCB126 Vs      Ahr-/- Vehicle vs        Ahr-/- PCB126 vs 
WT Vehicle              WT Vehicle                WT PCB126 
miR-122-5p 3.62                      4.45                             5.30 






miR-192-3p                                  9.16 









                                                 DISCUSSION 
   Polychlorinated biphenyls, as endocrine, metabolism and signaling disrupting 
chemicals, are associated with nonalcoholic steatohepatitis and diabetes (37). 
PCB-induced NAFLD mechanisms were not fully elucidated, but there have 
been some findings found, such as a “two-hit” hypothesis was proposed that 
NAFLD pathogenesis consists of two “hits”. The first “hit” causes lipid 
accumulation in the hepatocytes, while the second “hit” including high fat diet, 
insulin resistance (IR), proinflammatory cytokines, organelle dysfunction, 
oxidative stress, altered organokines like fibroblast growth factor 21 (FGF-21), 
leptin, adiponectin, and alteration in gut microbiome, deteriorate hepatic injury. 
The PCB126 dose used in this present study was 20µg/kg, the same as our 
previous acute study and this dose was enough for the activation of AhR target 
genes, like Cyp1a1 and Cyp1a2.   
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcriptional 
factor that regulates a variety of physiological and pathological function (88). 
The high-affinity ligands for AhR include 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD), and DL PCBs (e.g. PCB126). Many studies have demonstrated that 
AhR plays a critical role in regulation of metabolic disease, including fatty liver 
disease. Excessive activation of AhR or activation of AhR induced hepatic 
steatosis characterized by the accumulation of triglycerides (33), and the effect 
of AhR is likely through the combined upregulation of CD36 and fatty acid 
transport proteins (FATPs), resulting in suppression of fatty acid oxidation, 




mobilization, and increased hepatic oxidative stress (90). In a 12-week study, 
Banrida Wahlang et al. found that PCB126 (4.9 mg/kg) induced hepatic 
steatosis in control diet-fed mice (66). Yulang Chi et. al administered PCB126 
by continuous 6- week gavage (total dose of 300µg/kg) in adult female mice, 
not only causing hepatic steatosis histologically, but increasing the mRNA 
expression of lipogenetic genes including Srebf1, Fasn, Scd1, Cd36, PPARg at 
the genetic level (95). A 2-week study showed the gavage of PCB126 
(1.5mg/kg) resulted in a significant lipid accumulation and increased the 
hepatic triglyceride (TG) level (96). In the 12-day and 28-day studies performed 
by Gopi S. Gadupudi et al., PCB126 (1.63 mg/kg) induced hepatic steatosis by 
intraperitoneal injection (IP) in rats fed a defined AIN-93 diet (92, 97). In our 
previous acute PCB exposure study, two weeks of exposure to PCB126 
(20µg/kg) induced mild hepatic steatosis due to increased hepatic lipid import 
and associated hypolipidemia (29). The publications above showed that 
PCB126 did cause hepatic steatosis, while in the present study did not show 
PCB126 had significant hepatic lipotoxicity in wild type mice. The inconsistency 
may be due to these reasons below: (1) the difference in exposure time of 
PCB126: the time length of most studies above were more than 4 weeks, while 
the present study only lasted 2 weeks; (2) different doses of PCB126: most 
studies administer the doses of PCB126 ranging from 50µg/kg to 4.9mg/kg, far 
more higher the one of my study. (3) different administration routes of PCB126: 
some studies administered PCB126 by intraperitoneal injection (ip), having 




different species: some studies used male Sprague Dawley rats as models, 
compared to C57BL/6 mice, having a higher body mass. Whether the effects of 
DL-PCBs are AhR dependent or not and what exact role AhR plays in the 
regulation of hepatic proteome and lipid metabolism needs to be elucidated. 
AhR deficiency enhances insulin sensitivity and reduces PPARα pathway 
activity (93), as well as protects against high fat diet (HFD)-induced obesity, 
hepatic steatosis, insulin resistance and inflammation (34). However, liver-
specific AhR knockout mice are susceptible to HFD-induced hepatic steatosis, 
inflammation and injury (94), suggesting AhR activation protects against fatty 
liver disease. Whole Ahr-/- mice showed early growth defects, hepatic defects, 
reduced liver weight, spontaneous microvesicular fatty accumulation and 
fibrosis, also suggesting the role of AhR in protecting against hepatic lipidosis 
(35). 
The combination of the phenotype, histology and molecular biomarkers 
showed a variety of PCB126 effects on metabolism. Similar to our previous 
study (29), PCB126 activated AhR target genes, namely, Cyp1a1 and Cyp1a2. 
It also activated Car mRNA expression; PCB126 decreased percent change in 
body weight (showing the wasting syndrome), and caused mild lipidosis in H&E 
stain and Oil red O stain, although neither hepatic TG nor FFA were increased 
on biochemical measurement. Meanwhile, PCB126 increased liver triglyceride, 
and demonstrated a trend to upregulate the liver cholesterol (p=0.05), 
suggesting lipid accumulation in liver. Proteomics was performed to explore 




groups. WT PCB126 vs WT Vehicle reflecting the PCB126 effect in WT mice 
had 8 altered abundance proteins, mostly belonging to enzymes, consistent 
with the results of EPF. Two enzymes, namely, Cyp1A1 and Cyp1A2, were 
increased as expected; another upregulated enzyme: Acyl-coenzyme A 
thioesterase 1 facilitated fatty acid production. Consistent with the results from 
abundance protein analysis, IPF in WT PCB126 vs WT Vehicle revealed over-
connected interactions with 3 transcription factors, namely, Zfp125, LXR-alpha, 
PPAR-alpha, regulating lipid metabolism. GO processes analysis 
demonstrated top processes enriched by PCB126 in WT PCB126 vs WT 
Vehicle were associated with lipid metabolism and xenobiotic metabolism. The 
results from hepatic proteome in WT PCB126 vs WT Vehicle were consistent 
with the phenotype and other biomarkers. An important finding was the fact of 
alterations of hepatic differentially abundant proteins in Ahr-/- PCB126 vs Ahr-/- 
Vehicle group, meaning in Ahr-/- mice, PCB126 did not cause significant protein 
changes. This demonstrated that the effects of PCB126 on protein abundance 
were AhR dependent.  
In the present study, the differentially abundant proteins analysis showed 
Cyp1A1 was downregulated by AhR ablation in PCB126 exposed mice 
(Log2FC=-4.90, p=4.66E-06), while Cyp1A2 decreased in Ahr-/- Vehicle vs WT 
Vehicle (Log2FC=-1.91, p=4.33E-04) and Ahr-/- PCB126 vs Ahr-/- Vehicle 
(Log2FC=-6.43, p=1.58E-10) (Supplemental Table 2). The RT-PCR showed not 
only AhR mRNA expression was totally inhibited by AhR ablation (2 –ΔΔCt value 




significantly downregulated by AhR gene deletion (both p<0.01). Meanwhile, in 
the table of abundant proteins, Cyp3a11 was upregulated by AhR deletion in 
Ahr-/- Vehicle vs WT Vehicle (Log2FC=3.61, p=2.33E-07) and Ahr-/- PCB126 vs 
Ahr-/- Vehicle (Log2FC=2.38, p=4.83E-05).  With regard to RT-PCR, Cyp3a11, 
the target gene of Pxr, was increased by global AhR knockout (Ahr-/- Vehicle: 
4.33-fold, Ahr-/- PCB126: 4.74-fold relative to WT Vehicle, both p<0.01).     
PCB126 did not cause NAFLD in the present study due to no increased hepatic 
lipids by biochemical analysis. In hepatic differentially abundant proteins 
analysis in hepatic proteome, AhR knockout altered much more proteins than 
PCB126 exposure (Ahr-/- Vehicle vs WT Vehicle: 340 proteins, Ahr-/- PCB126 vs 
Ahr-/- Vehicle: 262 proteins). In hepatic differentially abundant proteins table 
(Supplemental Table 2), AhR deletion upregulated at least 12 proteins involved 
in lipid accumulation, including Acyl-coenzyme A thioesterase 1, Acyl-
coenzyme A thioesterase 2, mitochondrial, Perilipin-2, Acyl-coenzyme A 
thioesterase 4, Acyl-CoA desaturase 2, Acyl-CoA desaturase 3, Long-chain-
fatty-acid--CoA ligase 4, Isoform Short of Long-chain-fatty-acid--CoA ligase 4, 
Acyl-coenzyme A thioesterase 10, mitochondrial, Acyl-coenzyme A 
thioesterase 9, mitochondrial, Acyl-CoA desaturase 1, and Elongation of very 
long chain fatty acids protein 2 (Supplemental table 2). Hepatic lipid 
accumulation originates from an imbalance between lipid acquisition and lipid 
disposal, which is determined by four major pathways: hepatic lipid uptake, de 
novo lipogenesis (DNL), oxidation of fatty acids (FAO), and lipid export in 




of free fatty acids; upregulated Acyl-CoA desaturases, Elongation of very long 
fatty acids protein 2, Long-chain-fatty-acid--CoA ligase 4, and its isoform 
induce synthesis of triglycerides; these regulation above lead to promoted 
hepatic lipid uptake and DNL, resulting in liver fat accumulation. Consistently, 
enriched top processes related to lipid metabolism in GO process analysis in 
Ahr-/- Vehicle vs WT Vehicle and Ahr-/- PCB126 vs WT PCB126, were listed as 
follows: “Fatty acid metabolic process”, “Long-chain fatty acid metabolic 
process”, “Cellular lipid metabolic process”, “Monocarboxylic acid metabolic 
process”, “Lipid metabolic process”, “Carboxylic acid metabolic process” and 
“Monocarboxylic acid biosynthetic process”, most of them were associated with 
synthesis and processing of fatty acids (Fig. 4.8). IPF analysis of Ahr-/- effect in 
Ahr-/- Vehicle vs WT Vehicle and Ahr-/- PCB126 vs WT PCB126 revealed 
several overconnected transcription factors involved in lipid steatosis, like 
Zfp125 (causes lipidosis by reducing liver secretion of triglycerides), LXR-
alpha, SREBP1 (nuclear), PPAR-alpha, c-Fos; notably, LXRα activates the 
transcription factor SREBP-1c, resulting in lipogenesis and c-Fos, as a new 
target of NASH, induces hepatic PPARγ signaling and lipid accumulation (Fig. 
4.9). RT-PCR results further validated the results of phenotype s and hepatic 
proteomes, which showed Ahr-/- increased Cd36 expression, facilitating the 
fatty acid transport, and upregulated perilipin-2 gene expression, promoting 
lipid droplets formation, meanwhile, Ahr-/- decreased Pnpla3 gene expression, 
downregulating lipolysis. All these alterations in gene expression caused the 




biomarker and RT-PCR, were consistent with the results from hepatic 
proteome. AhR ablation increased liver triglyceride, liver FFA, while decreased 
liver weight/body weight ratio, plasma triglyceride, plasma cholesterol, plasma 
HDL-c, and plasma VLDL in a trend (p=0.06). Meanwhile, in H&E stain and Oil 
Red O stain, AhR null mice showed conspicuous lipid steatosis. RT-PCR for 
genes involved in lipid metabolism demonstrated that AhR knockout increased 
Cd36 gene expression, related to lipid uptake, and decreased Pnpla3 
expression (associated with lipolysis).  Combined with all the results, AhR gene 
deletion did not bring about the beneficiary effect on lipid metabolism, on the 
contrary, caused significant lipidosis, the mechanism of global AhR knockout-
induced NAFLD is that AhR deletion promoted the production of fatty acid, 
increasing hepatic lipid uptake, promoting formation of lipid droplets and 
downregulated lipolysis. This also suggested a potential role of AhR in the 
negative regulation of the expression of these genes involved in hepatic 
steatosis. In the present study, the effects of PCB126 were not all AhR-
dependent. However, its effects on the hepatic proteome were AhR dependent.  
In IPF analysis, notably, GCR was over-connected with Ahr-/- (Ahr-/- Vehicle 
vs WT Vehicle: z-score=12.43, Ahr-/- PCB126 vs WT PCB126: z-score=10.80); 
whether GCR expression was upregulated or downregulated needs to be 
elucidated, then the expression level of Tat gene, the target gene of GCR was 
measured, and it showed Tat gene expression was increased by Ahr-/- 
indicating Tat gene and GCR activation. As cytoplasmic protein complexes, GR 




potentially complex receptor cross-talk, showing AhR-mediated responses 
include effects on GR expression, and vice versa (98), although their exact 
interaction pattern needs to be elucidated. Moreover, global AhR knockout 
affected the steroid hormone which was shown in the GO process analysis in 
Ahr-/- Vehicle vs WT Vehicle and Ahr-/- PCB126 vs WT PCB126; check through 
the hepatic differentially abundance proteins, 3 important enzymes regulating 
the steroid hormone synthesis were altered, including 17-beta-hydroxysteroid 
dehydrogenase type 6, 17-beta-hydroxysteroid dehydrogenase 13, Isoform 2 of 
17-beta-hydroxysteroid dehydrogenase 13, 3 beta-hydroxysteroid 
dehydrogenase type 5 (Supplemental table 2). Upregulated 17-beta-
hydroxysteroid dehydrogenases (17β-HSD) and its isoform and decreased 3 
beta-hydroxysteroid dehydrogenase (3β-HSD) promoted the production of sex 
hormone and decreased the production of glucocorticoid; IPF analysis in Ahr-/- 
Vehicle vs WT Vehicle and Ahr-/- PCB126 vs WT PCB126, showed 
overconnected transcription factor: GCR (glucocorticoid receptor). These 
results suggest AhR-/- affected the enzymes in the steroidogenesis and showed 
actual impacting of GCR. Another possible mechanism for overconnected GCR 
is that GCR was affected by the existence of hepatic lipidosis which may be 
accompanied by inflammation, and GCR regulated annexins to reduce 
inflammation (99).   
With respect to glucose metabolism, AhR ablation lowered plasma glucose, 
plasma insulin and resistin level, increased plasma leptin concentration, 




hepatic differentially abundant proteins analysis, several altered proteins 
regulating glucose homeostasis by AhR deletion in Ahr-/- Vehicle vs WT 
Vehicle and  Ahr-/- PCB126 vs WT PCB126, were found as follows: like 
Glycogen phosphorylase, brain form, and Glycogen phosphorylase, liver form; 
the liver form of glycogen phosphorylase serves the glycemic demands of the 
body in general while the brain form of glycogen phosphorylase supply just 
brain, so here, AhR KO caused the increase of glucose supply for brain, but 
decreased the blood glucose level for the body.  Additionally, IPF analysis 
showed two over-connected proteins associated with glucose homeostasis, 
which are insulin receptor (Ahr-/- Vehicle vs WT Vehicle: z-score=9.049, Ahr-/- 
PCB126 vs WT PCB126: z-score=7.595), and glucose transporter 4 (GLUT4) 
(Ahr-/- Vehicle vs WT Vehicle: z-score=8.153, Ahr-/- PCB126 vs WT PCB126: z-
score=9.295); insulin receptor stimulates glycogen synthesis and promotes the 
degradation of insulin; unlike GLUT2 mostly expresses in liver to uptake 
glucose for glycolysis and glycogenesis, GLUT4 mostly expresses in adipose 
tissues and striated muscle to uptake glucose to promote fat accumulation and 
muscle contraction. Overconnected insulin receptor and GLUT4 facilitated the 
transport and utilization of glucose and conversion of glucose into fat and 
decreased the glucose level. Combined with the results from phenotype, 
plasma glucose level, plasma insulin and resistin level, hepatic proteome etc., 
AhR gene ablation had a potential beneficiary effect on glucose metabolism, 





MicroRNAs (miRNAs) are small non-coding RNAs that maintain cellular 
homeostasis and potentially modulate responses to environmental exposures. 
In the present animal study, totally seven over-connected miRNAs were shown 
with PCB126 exposure in IPF analysis, including   miR-122-5p, miR-132-5p, 
miR-142-5p, miR-150-5p, miR-221-3p, miR-222-3p and miR-223-3p; while only 
4 miRNAs were over-connected with Ahr-/-, namely, miR-122-5p, miR-132-5p, 
miR-192-3p and miR-544-3p; and three miRNAs, such as miR-122-5p, miR-
132-5p and miR-544-3p were over-connected with the combination of PCB126 
exposure and AhR gene ablation. This suggested different treatments may 
have their different targets of alteration in miRNAs, like Ahr-/- over-connected 
only four miRNAs. In our previous human epidemiological study (ACHS), PCB-
associated liver necrosis was associated with circulating miRNAs. It showed 
the necrotic liver disease category (n=359) was associated with four up-
regulated miRNAs (miR-99a-5p, miR-122-5p, miR-192-5p, and miR-320a) and 
five down-regulated miRNAs (let-7d-5p, miR-17-5p, miR-24-3p, miR197-3p, 
and miR-221-3p). Compared our animal data with human data, they shared 3 
common miRNAs, which were miR-122-5p, miR-221-3p, and miR-192-3p, 
although having different PCB exposures and different species. These primary 
results provided some insights into the potential mode of action of PCBs, 
although the exact mechanism of miRNA-induced toxicity needs further study. 
There are some limitations for the present study.  AhR null mice had severe 
lipidosis in histology, significantly higher ALT and AST in biomarkers, increased 




Growth arrest-specific protein 2 (Supplemental table 2), all of which suggested 
the existence of inflammation or apoptosis. On the flip side, inflammation-
associated factors including plasma IL-6 and PAI-1 determination were not 
elevated in AhR null mice. Inflammation and cell death mechanisms can be 
more rigorously evaluated in the future. In conclusion, the present study 
showed global AhR gene deletion caused significantly lipid accumulation; AhR 
activation plays a pivotal role in lipid metabolism; the mechanism of AhR 
knockout-induced lipidosis was probably through the enhancement of 
production of fatty acid and decrease of lipid breakdown. At the same time, 
AhR ablation affected the steroid hormone metabolism, influenced the 
enzymes in the steroidogenesis and downregulated the synthesis of 
glucocorticoid leading to the activation of GCR. Besides, AhR ablation 
demonstrated a beneficiary effect on glucose metabolism, generally lowering 
the glucose level through increased transport, utilization of glucose in 
peripheral tissue and promoted conversion of glucose into fat.  Lastly, PCB126 
did not have significant effect in AhR null mice, suggesting AhR regulates the 
hepatic proteome and lipid metabolism independent of PCB exposure. 






THE ACUTE EXPOSURE EFFECTS AND POTENTIAL MECHANISMS OF 
DIFFERENT DOSES OF DL+NDL PCBS ON  
THE PANCREATIC PROTEOME  
                                              
INTRODUCTION 
Diabetes has been a major health concern in the US population and across 
the world. According to the data from Disease Control and Prevention (CDC), 
10.5% of the US population has diabetes (30). Diabetes patients aged 50 years 
or older die 4.6 years earlier, develop disability 6 to 7 years earlier, and spend 
about 1 to 2 more years in a disabled state than adults without diabetes (100). 
From 2012 until 2017, excess medical costs per person associated with 
diabetes increased from $8,417 to $9,601 (30). 
Diabetes is characterized by elevated blood sugar levels due to either the 
result of inadequate amounts of insulin production, inadequate utilization of 
insulin or a combination of both. Diabetes is categorized as type 1, type 2, 
gestational diabetes mellitus (GDM), specific types of diabetes due to other 
causes, e.g., monogenic diabetes syndromes (such as maturity-onset diabetes 
of the young [MODY]), diseases of the exocrine pancreas (such as cystic 




Multiple epidemiological studies and animal experiments have revealed 
associations between PCB exposure and DM (101, 102). In a 24-year follow-up 
study of the Yucheng cohort (PCB poisoning), increased rates of DM in 
females were observed (4). In 736 PCB-exposed human subjects in the 
Anniston Community Health Survey (ACHS), a high prevalence of diabetes 
(27%) was observed, which was almost 3-times higher than the US prevalence 
rate (6).  Also, some papers in animal models reported the correlation between 
PCBs exposure and DM. Zhang S et.al reported that the treatment with Aroclor 
1254 (5, 50, and 500 µg/kg) resulted in a significant increase in blood glucose 
concentrations in male mice (103).  Aroclor1254 is high in both DL PCB 
(PCB105, PCB118, and PCB156) and non-dioxin-like PCB (PCB 99, PCB 138, 
and PCB153).  PCB77 and PCB126 were found to increase the blood glucose 
in male C57BL/6 mice (104).  The mechanisms by which PCBs cause DM are 
still controversial with some literature reporting decreased insulin production 
and others reporting increased IR (105, 106). ACHS-II study showed with the 
increase of PCBs concentration, the level of insulin decreased (6). In our acute 
PCB exposure study, the Aroclor1260/PCB126 mixture caused histological 
changes in pancreas and Ins1 gene expression was decreased, hinting at the 
effect of PCB mixture on pancreas (29). Banrida Wahlang’s sex difference 
acute PCB exposure study showed Aroclor1260/PCB126 mixture decreased 
Ins1 gene expression, while increased pancreas weight/body weight ratio, 
suggesting PCB mixture potentially had affected the pancreas function (36).  




mixture on pancreas, untargeted proteomics was performed in a female mouse 
model.   




















MATERIALS AND METHODS 
Animal studies 
The related animal protocol was ratified by the University of Louisville Institutional 
Animal Care and Use Committee. Adult female C57BL/6 mice (8 weeks old) were 
purchased from Jackson Laboratory and distributed into three equal groups (n = 
10). All mice were fed a control synthetic diet (20.0 %, 69.8 %, and 10.2 % of 
total calories come from protein, carbohydrate, and fat, TekLad TD 06416) 
throughout the study period. At 10 weeks of age, ten mice in each group were 
given either corn oil, low dose of Aroclor1260/PCB126 mixture (20 mg/kg/20 
µg/kg) (LD), or high dose of Aroclor1260/PCB126 mixture (100 mg/kg/100 µg/kg) 
(HD) via a one-time gavage and followed for 2 weeks (Fig. 4.1). At week 2 post 
gavage, a glucose tolerance test (GTT) was performed as described previously 
(36). Whole blood for plasma, and pancreas tissue samples were harvested after 
euthanasia. 
Proteomics analysis 
Proteins were extracted from liver tissue in RIPA buffer supplemented with 
protease and phosphatase inhibitors using a bead homogenizer and protein 
amounts were quantitated by BCA assay. Protein lysates (200 μg) were 
trypsinized using the modified filter-aided sample preparation method (57) and 
enriched for phosphopeptides by the TiO2–SIMAC–HILIC method (58). Briefly, 
protein samples were reduced with dithiothreitol, denatured with 8M urea, and 




weight cutoff centrifugal filter (Millipore, 10k MWCO). After overnight digestion 
with sequencing grade trypsin (Promega), the digested proteins were collected 
and cleaned with a C18 Proto™ 300 Å Ultra MicroSpin column. Protein digested 
samples (50 μg) were labeled with tandem mass tag (TMT) TMT10plex™ 
Isobaric Label Reagent Set (Thermo Fisher, Waltham, MA); samples were then 
concentrated and desalted with Oasis HLB Extraction cartridges (Waters 
Corporation, Milford, MA) using a modified protocol for extraction of the digested 
peptides (59). Samples were then subjected to high pH reversed phase 
separation with fraction concatenation on a Beckman System Gold LC system 
supplemented with 126 solvent module and 166 detector in tandem with a Bio-
Rad Model 2110 Fraction Collector (60). Liquid chromatography/mass 
spectrometry was used to measure TMT-labeled peptides. Briefly, every high pH 
reversed phase fraction was dissolved in 50μL solution of the combination of 2% 
v/v acetonitrile/0.1% v/v formic acid and 1 μL of each fraction was analyzed on 
EASYnLC 1000 UHPLC system (Thermo Fisher) and an Orbitrap Elite—ETD 
mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Proteome 
Discoverer v2.2.0.388 was used to analyze the raw data collected from the mass 
spectrometer. Hepatic proteins that had significance abundance were imported 
into MetaCore software (Clarivate Analytics, Philadelphia, PA) for the following 
analyses: gene ontology (GO) processes analysis and transcription factor 
analysis (TFA). 




Statistical significance was determined by two-way analysis of variance using 
GraphPad Prism version 7.02 for Windows (GraphPad Software Inc., La Jolla, 
CA, USA). p <0.05 was considered statistically significant. Statistical analysis for 
the proteome data was analyzed using the R package as described previously 
(61, 62). Given the exploratory nature of the study, significantly altered proteins 


























Figure 4.1. Experiment Design of female mice acute PCB mixture study. 
Mice were divided into 3 study groups based on the type of exposure. All 
animals were fed a chow diet and received a one-time gavage of their 
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                                                 RESULTS 
Effects of different doses of PCB mixture exposures on body composition 
and glucose tolerance. 
Body weight was measured weekly throughout the 2-week study. There was 
a gradual increase in body weight in all three groups from week 0 to week 2 (Fig. 
4.2A). However, there were no significant differences in body weight and percent  
change in body weight between these three groups (Fig. 4.2B, 2D). As for the 
pancreas weight to body weight ratio, no significant differences were found 
between the groups (Fig. 4.2C). A GTT was performed to examine the effects of 
different doses of PCB mixture on glucose tolerance (Fig. 4.2E); there were no 
differences between groups for alteration in glucose uptake (Fig. 4.2F).  
Effects of different doses of PCB mixture exposures on the pancreatic 
proteome 
A total of 7671 unique proteins and their isoforms were detected. The 
alterations of pancreatic abundance proteins content were regulated as follows: 
Low Dose Aroclor1260/PCB126 group (LD) vs Control (38 increased and 82 
decreased) and High Dose Aroclor1260/PCB126 group (HD) vs Control group  
(256 increased and 288 decreased) (Table 5).  
Enrichment by GO processes (Fig. 4.3) showed that both doses of PCB 
mixture enriched the process of “peptide biosynthetic process”. With regard to 
processes related to inflammation and immunity, low dose Aroclor1260/PCB126 
enriched the processed such as “antigen processing and presentation of 
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Figure 4.2 Effects of different doses of PCB mixture exposures on body 
composition and glucose tolerance. 
(A, B) Body weight was measured weekly throughout the 2-week study. No 
signifcant differences were found between the three groups. (D) % change in 




was calculated. Three groups had no significant differences in % change in BW. 
(C) The pancreas was weighed and their respective weights relative to body 
weight were calculated. Three groups had no differences in PW/BW. A glucose 
tolerance test was performed after the second PCB gavage and blood glucose 
levels were measured; (E) GTT curve was made and (F) AUC (Area Under the 
Curve) of three groups was calculated. Values are mean ± SD. n=10, Values for 




















“antigen processing and presentation of peptide antigen”, while the other dose 
enriched four processes, including “ Inflammation_IL-6 signaling”, “Immune 
response_Antigen presentation”, “Apoptosis_Apoptotic nucleus” and 
“Inflammation_NK cell cytotoxicity”.  In addition, processes associated with 
insulin signal pathway were enriched by low dose or high dose Aroclor 
1260/PCB126 exposure. These processes were “insulin-like growth factor 
receptor signaling pathway”, “receptor tyrosine kinase signaling pathway”, 
“Signal transduction_Insulin signaling” and “Signal transduction_WNT signaling”. 
Enrichment by transcription factor analysis (TFA) (Fig. 4.4A) showed that low 
dose and high dose group shared similar overconnected transcription factors. 
Transcription factors associated with inflammation were overconnected by both 
doses of Aroclor1260/PCB126, including  NF-kB1 (p105), NF-kB2 (p52), and NF-
kB1 (p50). Notably, 5 transcription factors related to pancreas function and 
glucose metabolism by over-connected with low dose or high dose PCB mixture. 












Table 5. Alterations of diffentially abundant pancreatic proteins 
The number of proteins and their isoforms that were altered for the two 
comparisons between different groups (The data were adjusted by FDR=0.2). 
Differentially abundant 
pancreatic proteins 
LD vs Control HD vs Control 
Altered 120 544 
Increased 38 256 
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insulin-like growth factor receptor signaling pathway









Figure 4.3 Effects of different doses of Aroclor1260/PCB126 exposure on 
gene ontology (GO) processes. 
Heatmap showing different processes that were altered by different doses of 
Aroclor1260/PCB126 exposure according to the -log(p-value). The processes 





































































Figure 4.4 Effects of different doses of Aroclor1260/PCB126 exposure on 
Enrichment by transcription factor analysis (TFA)  
Heatmap showing different transcription factors, for the different groups, 
obtained from the Enrichment by transcription factor analysis (TFA) using 









                                                   DISCUSSION 
 Considered as a group of multifactorial disease, diabetes is caused by some 
combination of genetic and environmental factors including environmental 
pollutants. In recent years, the association between PCB and diabetes has 
gained concern.  
Multiple epidemiological studies and animal studies demonstrated the 
association of PCB and diabetes. In the follow-up study of Yucheng cohort, 
females with high PCB exposure had higher prevalence of diabetes (4). In  the 
ACHS study, insulin level was associated with increased PCB concentration. 
The mechanisms of PCB-induced diabetes remain unclear. Our previous acute 
PCB exposure study (29) showed Aroclor1260/PCB126 mixture exposure 
caused “PCB pancreatopathy”, presenting with acinar cell atrophy, mild 
steatosis, and fibrosis absent of ductal changes or immune cell infiltration. PCB 
mixture decreased Ins1 gene expression, downregulated the expression of 
Nkx6-1, NR4a1, NR4a3 gene, associated with beta-cell islet identity, 
suggesting DL/NDL PCB mixture had more effects on pancreas than PCB 
congeners. Consistent with previous study (107), the potential mechanism of 
PCB-induced diabetes was associated with impaired islet identity. Our previous 
sex difference study also showed Aroclor1260/PCB126 mixture decreased Ins1 
gene expression in female mice, while increased the pancreas weight to body 
weight ratio (36).  
In the present study, TFA showed that 5 transcription factors associated with 




low dose Aroclor1260/PCB126 or high dose Aroclor1260/PCB126, including 
NEUROD5, HNF1-beta, HNF4-alpha, E2F1, FOXP3, and HNF1-alpha. All 
these factors were involved in pancreas development, and three of them, 
namely, HNF1-beta, HNF4-alpha, and HNF1-alpha, were associated with 
MODY in human. 
 Maturity onset diabetes of the young (MODY) is referred to as monogenic 
diabetes, caused by mutations in an autosomal dominant gene disrupting 
insulin production. There have been 11 different types of MODY caused by 
changes in eleven different genes. MODY 1 is caused due to a loss-of-function 
mutation in the HNF4α gene; MODY 3 is due to mutations of the HNF1α gene 
(a homeobox gene); MODY 5 is a less common forms of MODY due to defect 
in HNF-1 beta gene, has some distinctive clinical features, such as atrophy of 
the pancreas and renal disease.  
Here, over-connected HNF1-beta were associated with MODY 5, HNF4-
alpha with MODY 1 and HNF1-alpha with MODY 3. This finding from 
proteomics may provide us new insight towards the pathogenesis of PCB-
induced diabetes. Will this potential mechanism of PCB-induced diabetes have 
some similarity with MODY? In PCB-induced diabetes, some patients have 
insulin resistance while others present as pancreatic failure, like type 1 
diabetes. And different MODY have diverse presentations, some present 
similar to type 1 diabetes, and some just like type 2 diabetes. And the 
mechanisms of MODYs are not fully clear. What caused the mutations of 




GO processes analysis showed either low dose or high dose 
Aroclor1260/PCB126 exposure enriched the processes related to insulin signal 
pathway, including “insulin-like growth factor receptor signaling pathway”, 
“receptor tyrosine kinase signaling pathway”, “Signal transduction_Insulin 
signaling” and “Signal transduction_WNT signaling”. The results were 
consistent with the results from TFA. 
Although AUC did not show differences between groups, we got some 
meaningful data from proteomics. There are a couple of reasons for this 
inconsistency, first, although GTT is relatively easy to perform and minimally 
invasive, the interpretation of these tests can be strongly influenced by variable 
experimental conditions (like the accurate time point of measurement, the 
emotion changes of mice, and the accuracy of glucometer) and data analysis. 
Second, the results from GTT may not be able to reflect the early changes in 
pancreatic function. 
In ongoing research, the results from proteomics will be validated by other 
methods, like Western blots, phenotype, plasma insulin, adipokines, HOMA-IR, 
HOMA-B, etc.   
In conclusion, transcription factor analysis showed transcription factors 
related to pancreas function were over-connected with low dose and high dose 
Aroclor 1260/PCB 126, like HNF1-alpha, HNF1-beta and HNF4-alpha, which 
were associated with MODY 3, MODY 5 and MODY 1 in human. Processes 
associated with insulin signal pathway were enriched by either low dose or high 




signaling pathway”, “receptor tyrosine kinase signaling pathway”, “Signal 
transduction_Insulin signaling”. The study is an ongoing research, and more 





















OVERALL SUMMARY  
Overall goal and specific aims  
As persistent organic pollutants PCBs are associated with non-alcoholic fatty 
liver disease (NAFLD) and metabolic disruption. Previous studies focus mostly 
on the effect of NDL PCBs and single PCB congeners. But in real life, people 
are exposed to DL-PCB and NDL-PCB mixtures.  We have built a relevant 
model, Aroclor1260/PCB126, which increases the amount of DL-PCB 
(PCB126) (20µg /kg) to activate the AhR. The chronic effects of DL/NDL- PCB 
mixture need to be investigated. The mechanism of PCB-induced NAFLD still 
remains unclear.  PCBs are predicted to interact with many receptors 
previously implicated in xenobiotic/energy metabolism and NAFLD, including 
AhR, Pxr, Car etc. And DL- PCBs are potent AhR ligand, and cause steatosis. 
The overactivation of AhR can be found in NAFLD. The exact role of AhR in 
hepatic proteome and lipid metabolism needs to be elucidated. The overall 
goal of this dissertation was to evaluate the chronic effects of different PCBs 
exposure by phenotype and untargeted proteomics. To fulfill the goal, we 




Aim 1: Investigate the chronic exposure effects and potential 
mechanisms of DL-PCBs and NDL-PCBs, or co-exposures to both in a 
diet-induced obesity mouse model. 
Aim 2: Evaluate the role of AhR plays in the regulating hepatic 
proteome and whether this process is independent of PCB exposure or 
not in an AhR knockout mouse model. 
Aim 3: Investigate the acute exposure effects and potential 
mechanisms of different doses of DL+NDL PCBs on pancreatic proteome 
in a female mouse model. 
Major findings of this dissertation 
Chronic PCB exposure study adopted proteomics to observe the effects of 
different PCB exposures in protein production differences, which provided us 
new insights towards the mechanism of PCB toxicity.  In this study, we found 
PCB126 rather than Aroclor 1260 decreased hepatic inflammation and fibrosis 
at the molecular level, while it altered cytoskeletal remodeling, metal 
homeostasis, and damaged intermediary and xenobiotic metabolism. 
In acute AhR knockout study, we used global AhR null mice to observe 
without AhR, how PCB126 altered hepatic proteome and lipid metabolism 
whether the process was AhR independent or not. Global AhR gene deletion 
caused significant lipid accumulation. The effects of PCB126 were not all AhR-




finding is the first research to confirm the role AhR plays in the regulation of 
hepatic proteome and lipid metabolism. 
In female mice acute PCB mixture exposure study, we found  transcription 
factors (such as HNF1-alpha, HNF1-beta and HNF4-alpha) related to pancreas 
function were over-connected with both doses of Aroclor 1260/PCB 126 
exposure, and observed  that processes associated with insulin signal pathway 
were enriched by low dose or high dose Aroclor 1260/PCB126, including 
“insulin-like growth factor receptor signaling pathway”, “receptor tyrosine kinase 
signaling pathway”, “Signal transduction_Insulin signaling” and “Signal 
transduction_WNT signaling”.  
Strengths of this dissertation  
There is much strength in this dissertation. First and foremost, for the first 
time, we discovered the role of AhR in regulating the hepatic proteome and 
lipid metabolism which was independent of PCB exposure. And we confirmed 
AhR plays a pivotal physiological role in maintaining lipid homeostasis and 
hormone production. And we clarify the misunderstanding towards AhR, which 
is deletion of AhR may bring about a protective effect against lipidosis, on the 
contrary, whole deletion of AhR gene will cause severe NAFLD.  
Secondly, we used hepatic proteomics to explore the underlying 
mechanisms of PCB exposure effect, which provided us new insights toward 
their action modes, like PCB126 altered cytoskeletal remodeling and metal 




Another finding is that in acute AhR knockout study, several miRNAs were 
found to be associated with PCB126 and AhR ablation in mouse model; 
several miRNAs can also be observed in human samples; some of the miRNAs 
have strong association with some NASH biomarkers. All these will provide us 
new direction to our future research.  
Lastly, in female mice acute PCB mixture study, for the first time, we 
observed the association between PCB exposure and some responsible genes 
involved in MODY in humans, it provides us new insights to explore the 
association between MODY and PCB exposure, the potential mechanisms of 
both. 
Limitations of this dissertation  
There are several weaknesses of this dissertation. Although we described 
the phenotypic effects of different types of PCB exposure on liver and 
pancreatic disease, the precise molecular mechanisms, underpinning these 
observations were not determined. They need further investigation in the 
future. Potential species differences due to differential AhR ligand binding 
affinity were not examined. Moreover, potential sex differences need to be 
pointed out for in PCB exposed populations, men tend to have a slightly higher 
prevalence of liver disease, while women tended to have a higher prevalence 
of type 2 diabetes. While proteins regulating metal homeostasis and 
epigenetics were implicated, direct measurement of hepatic metals and 




acute PCB mixture study, although we got some valuable data from 
proteomics, all of these remain to be validated by other methods. 
Future directions 
1. Evaluate the potential effects of species and sex differences on the 
endocrine disruption and TASH induced by PCB exposures.  
2. Use proteomics technique and TMT labelling to analyze different chronic 
PCB-exposed pancreas samples, to explore the potential mechanism of PCB-
induced diabetes. 
3. Since PCB-exposure mostly is a chronic process, studies with a longer 
period may be needed (e.g., 6 months). 
Conclusion 
Taken together, this dissertation evaluated the acute and chronic effects of 
PCB exposure on liver and pancreas, also explored the role of AhR in 
regulating hepatic proteome and lipid metabolism. The chronic exposure study 
demonstrated PCBs, NDL PCBs, and a more environmentally relevant mixture 
of both types of PCBs differentially modulated the hepatic proteome and the 
severity of diet- induced NAFLD. PCB 126 decreased hepatic inflammation at 
the molecular level, while Aroclor1260 increased hepatic inflammation and 
promote phosphoprotein signaling disruption consistent with prior research. 
PCB126 altered cytoskeletal remodeling, and disrupted metal homeostasis, 
and the intermediary and xenobiotic metabolism; all of them implicated in 




epigenetic processes, and these could potentially explain the observed 
nonadditive effects of the exposures on the hepatic proteome. Acute AhR 
knockout study showed 12 differentially abundant hepatic proteins related to 
lipid metabolism were altered by AhR deletion; Gene ontology analysis showed 
metabolic processes including ‘oxidation-reduction process’ and ‘lipid metabolic 
process’ were enriched in Ahr-/- mice; transcription factors involved in lipid 
metabolism including Zfp125, LXRα, SREBP1 (nuclear), c-Fos were over-
connected with Ahr-/- . Global AhR gene deletion caused significantly lipid 
accumulation rather than had protective effect against NAFLD. The mechanism 
of AhR knockout-induced lipidosis was probably through the upregulation of 
lipogenic genes (CD36, Perilipin-2) and downregulation of lipolytic gene 
(Pnpla3). Most importantly, the study discovered how Ahr regulated hepatic 
proteome and lipid metabolism independent of PCB exposure. In the female 
mice acute PCB mixture study, pancreatic proteomics showed transcription 
factors related to pancreas function were over-connected with low dose and 
high dose Aroclor 1260/PCB 126, like HNF1-alpha, HNF1-beta and HNF4-
alpha, responsible genes of MODY in human; processes related to insulin 
signal pathway were enriched by low dose or high dose Aroclor 1260/PCB126, 
including ‘insulin-like growth factor receptor signaling pathway’, ‘receptor 
tyrosine kinase signaling pathway’, ‘Signal transduction_Insulin signaling” and 
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Supplemental Table 1: Differentially Hepatic Abundant Proteins  
Altered by  Different PCBs in Chronic Study 
List of hepatic proteins (fold change, p-value) altered by PCB exposure.  
Fold change >1 , protein upregulation; fold change <1, protein downregulation. 
 
Accession Number (Protein Name) PCB Exposure 
 Ar1260 PCB126 Ar1260+PCB126 
Q62293 (T-cell-specific guanine 
nucleotide triphosphate-binding protein 
1) 
2.57, 1.62E-04   
P31996-2 (Isoform Short of Macrosialin) 2.26, 1.83E-04   
P31996 (Macrosialin) 2.26, 1.85E-04   
O08800 (Serpin B8) 2.18, 6.19E-04 1.81, 5.72E-03  
Q922Z0 (D-aspartate oxidase) 2.17, 2.31E-04  1.63, 9.89E-03 
Q9D1X0 (Nucleolar protein 3) 1.91, 2.19E-03 1.56, 2.58E-02  
Q9D0M0 (Exosome complex 
exonuclease RRP42) 
1.87, 3.30E-03   
Q8R4U6 (DNA topoisomerase I) 1.76, 2.30E-03  1.56, 1.31E-02 
Q9EPA7 (Nicotinamide/nicotinic acid 
mononucleotide adenylyltransferase 1) 
1.76, 1.61E-03   
Q8BW41 (Protein O-linked-mannose 
beta-1,4-N-acetylglucosaminyltransferase 
2) 
1.67, 1.09E-03 1.55, 3.83E-03 2.21, 1.14E-05 
Q8BW41-2 (Isoform 2 of Protein O-
linked-mannose beta-1,4-N-
acetylglucosaminyltransferase 2) 
1.67, 1.09E-03 1.55, 3.83E-03 2.21, 1.14E-05 
Q8BX09 (Retinoblastoma-binding 
protein 5) 
1.66, 2.67E-03   
Q68ED3 (Non-canonical poly(A) RNA 
polymerase PAPD5) 
1.65, 4.27E-04   
P56400 (Platelet glycoprotein Ib beta 
chain) 
1.65, 9.86E-04   
O35730-2 (Isoform 2 of E3 ubiquitin-
protein ligase RING1) 
1.57, 5.01E-05  1.51, 1.27E-04 
O35730 (E3 ubiquitin-protein ligase 
RING1) 
1.57, 5.04E-05  1.51, 1.27E-04 
Q8C8R3-3 (Isoform 3 of Ankyrin-2) 1.55, 8.77E-04  1.61, 4.43E-04 
Q8C8R3 (Ankyrin-2) 1.55, 8.89E-04  1.61, 4.49E-04 
Q8C8R3-5 (Isoform 5 of Ankyrin-2) 1.55, 9.31E-04  1.60, 4.68E-04 
Q8C8R3-4 (Isoform 4 of Ankyrin-2) 1.54, 9.51E-04  1.60, 4.77E-04 
Q8C8R3-2 (Isoform 2 of Ankyrin-2) 1.54, 9.55E-04  1.60, 4.79E-04 
P13808 (Anion exchange protein 2) 1.54, 1.99E-03  1.44, 6.67E-03 
Q60932 (Voltage-dependent anion-
selective channel protein 1) 




Q60932-2 (Isoform Mt-VDAC1 of 
Voltage-dependent anion-selective 
channel protein 1) 
1.54, 1.42E-03  1.68, 2.60E-04 
P13808-3 (Isoform B2 of Anion 
exchange protein 2) 
1.53, 2.06E-03  1.44, 6.92E-03 
P13808-2 (Isoform B1 of Anion 
exchange protein 2) 
1.53, 2.19E-03  1.43, 7.31E-03 
O08992 (Syntenin-1) 1.53, 2.04E-04   
Q60931 (Voltage-dependent anion-
selective channel protein 3) 
1.51, 2.67E-03   
Q99PM3 (Transcription initiation factor 
IIA subunit 1) 
1.48, 5.09E-06   
Q61179 (Interferon regulatory factor 9) 1.48, 2.45E-04   
Q8R2W9 (Pantothenate kinase 3) 1.45, 1.36E-04   
P0DJF2 (Protein PET117 homolog) 1.44, 8.30E-07  1.44, 9.30E-07 
Q8BYK4 (Retinol dehydrogenase 12) 1.44, 4.30E-05   
O35153 (BET1-like protein) 1.42, 5.15E-05 1.57, 2.52E-06 1.56, 3.25E-06 
Q8VDP2 (UPF0428 protein CXorf56 
homolog) 
1.42, 4.19E-05   
Q8VBX6-4 (Isoform 4 of Multiple PDZ 
domain protein) 
0.71, 2.09E-04   
Q99N57-2 (Isoform 2 of RAF proto-
oncogene serine/threonine-protein kinase) 
0.71, 5.52E-04   
Q9D0I8 (mRNA turnover protein 4 
homolog) 
0.71, 9.17E-06   
Q9D0B5 (Thiosulfate 
sulfurtransferase/rhodanese-like domain-
containing protein 3) 
0.71, 1.54E-04   
Q91WP0 (Mannan-binding lectin serine 
protease 2) 
0.70, 1.10E-03   
Q99N57 (RAF proto-oncogene 
serine/threonine-protein kinase) 
0.70, 5.47E-04   
P23204 (Peroxisome proliferator-
activated receptor alpha) 
0.70, 1.97E-03   
Q9DAG5 (Protein STPG4) 0.70, 1.94E-03   
Q69ZZ9 (Uncharacterized protein 
KIAA0754) 
0.70, 9.30E-04   
Q9DCV3 (Diacylglycerol O-
acyltransferase 2) 
0.70, 1.14E-04   
Q6QI06-2 (Isoform 2 of Rapamycin-
insensitive companion of mTOR) 
0.70, 1.09E-04   
O70458-2 (Isoform 2 of Oncostatin-M-
specific receptor subunit beta) 
0.70, 7.66E-04 0.68, 4.96E-04  
B1AY10 (Transcriptional repressor NF-
X1) 
0.70, 1.12E-05   
O70458 (Oncostatin-M-specific receptor 
subunit beta) 
0.70, 7.58E-04 0.68, 4.96E-04  
Q6QI06 (Rapamycin-insensitive 
companion of mTOR) 
0.69, 1.01E-04   
B1AY10-2 (Isoform 2 of Transcriptional 
repressor NF-X1) 
0.69, 1.11E-05   
B1AY10-3 (Isoform 3 of Transcriptional 
repressor NF-X1) 
0.69, 1.12E-05   
Q9CR02-2 (Isoform 2 of Translation 
machinery-associated protein 16) 




Q3UCQ1 (Forkhead box protein K2) 0.69, 2.35E-03   
Q9CR02 (Translation machinery-
associated protein 16) 
0.69, 2.91E-04   
Q8CCB4 (Vacuolar protein sorting-
associated protein 53 homolog) 
0.69, 3.62E-03  0.67, 2.11E-03 
Q3UCQ1-2 (Isoform 2 of Forkhead box 
protein K2) 
0.69, 2.35E-03   
Q8R2R1 (Protein O-mannosyl-
transferase 1) 
0.69, 9.98E-04   
A2AQ25-2 (Isoform 2 of Sickle tail 
protein) 
0.69, 2.04E-03   
A2AQ25 (Sickle tail protein) 0.68, 1.93E-03   
Q8QZZ8 (Ras-related protein Rab-38) 0.68, 1.47E-03   
Q9CQ02 (COMM domain-containing 
protein 4) 
0.68, 3.69E-04   
Q8BGS1-3 (Isoform 3 of Band 4.1-like 
protein 5) 
0.68, 2.25E-03   
Q8BGS1 (Band 4.1-like protein 5) 0.67, 2.08E-03   
P35922-5 (Isoform 5 of Synaptic 
functional regulator FMR1) 
0.67, 1.07E-03  0.66, 8.56E-04 
Q6P9R4-2 (Isoform 2 of Rho guanine 
nucleotide exchange factor 18) 
0.67, 2.85E-03  0.62, 6.89E-04 
Q6P9R4 (Rho guanine nucleotide 
exchange factor 18) 
0.67, 2.85E-03  0.62, 6.90E-04 
P35922-4 (Isoform 4 of Synaptic 
functional regulator FMR1) 
0.67, 1.07E-03  0.66, 8.68E-04 
P35922-11 (Isoform 11 of Synaptic 
functional regulator FMR1) 
0.67, 1.06E-03  0.66, 8.92E-04 
P35922-10 (Isoform 10 of Synaptic 
functional regulator FMR1) 
0.67, 1.06E-03  0.66, 9.10E-04 
P35922-6 (Isoform 6 of Synaptic 
functional regulator FMR1) 
0.67, 1.05E-03  0.66, 9.36E-04 
P35922-12 (Isoform 12 of Synaptic 
functional regulator FMR1) 
0.67, 1.05E-03  0.66, 9.38E-04 
Q8VDH1-2 (Isoform 2 of F-box only 
protein 21) 
0.66, 1.97E-03   
P01592 (Immunoglobulin J chain) 0.66, 1.17E-03   
Q8VDH1 (F-box only protein 21) 0.66, 1.78E-03   
P05201 (Aspartate aminotransferase) 0.64, 2.18E-03 0.68, 5.82E-03  
Q69ZR9 (Protein TASOR) 0.64, 3.76E-07   
Q69ZR9-2 (Isoform 2 of Protein 
TASOR) 
0.64, 3.86E-07   
Q8BH97 (Reticulocalbin-3)  0.61, 1.95E-03   
P01659 (Ig kappa chain V-III region 
TEPC 124) 
0.49, 1.39E-03 0.50, 1.81E-03  
P01660 (Ig kappa chain V-III region PC 
3741/TEPC 111) 
0.49, 1.39E-03 0.50, 1.81E-03  
P01658 (Ig kappa chain V-III region 
MOPC 321) 
0.49, 1.40E-03 0.49, 1.39E-03  
Q922U2 (Keratin) 0.28, 2.12E-03   
P20801 (Troponin C)  120.33, 1.30E-03  
P68134 (Actin)  55.47, 7.38E-03  




Q9JKS4-3 (Isoform 3 of LIM domain-
binding protein 3) 
 15.36, 7.74E-03  
Q9JKS4-4 (Isoform 4 of LIM domain-
binding protein 3) 
 15.34, 7.76E-03  
Q9JKS4-5 (Isoform 5 of LIM domain-
binding protein 3) 
 15.28, 7.82E-03  
Q9JKS4-6 (Isoform 6 of LIM domain-
binding protein 3) 
 15.28, 7.83E-03  
Q9JKS4-2 (Isoform 2 of LIM domain-
binding protein 3) 
 15.27, 7.85E-03  
Q9JKS4 (LIM domain-binding protein 3)  15.24, 7.88E-03  
P00184 (Cytochrome P450 1A1)  9.09, 7.10E-06  
Q9QZ47-10 (Isoform B3e17 of Troponin 
T) 
 8.60, 3.35E-02  
Q9QZ47-3 (Isoform A3e17 of Troponin 
T) 
 8.59, 3.37E-02  
Q9QZ47-12 (Isoform B4e17 of Troponin 
T) 
 8.59, 3.37E-02  
Q9QZ47-5 (Isoform A5e17 of Troponin 
T) 
 8.57, 3.38E-02  
Q9QZ47-2 (Isoform A2e17 of Troponin 
T) 
 8.57, 3.39E-02  
Q9QZ47-4 (Isoform A4e17 of Troponin 
T) 
 8.56, 3.40E-02  
Q9QZ47-6 (Isoform A6e17 of Troponin 
T) 
 8.55, 3.39E-02  
Q9QZ47-8 (Isoform B2e17 of Troponin 
T) 
 8.55, 3.40E-02  
Q9QZ47 (Troponin T)  8.54, 3.40E-02   
P00186 (Cytochrome P450 1A2)  5.85, 3.10E-08 2.39, 2.68E-04 
Q8CHY6 (Transcriptional repressor p66 
alpha 
 3.95, 4.49E-04  
Q9JIY8 (Probable N-acetyltransferase 
CML3) 
 3.37, 1.39E-02  
O35127 (Protein C10)  3.21, 1.45E-05 2.59, 1.43E-04 
Q8JZU0 (Nucleoside diphosphate-linked 
moiety X motif 13) 
 2.89, 9.89E-05 3.44, 1.70E-05 
Q9D6N5 (Dr1-associated corepressor)  2.79, 4.53E-04 2.41, 1.77E-03 
Q8C7V3 (U3 small nucleolar RNA-
associated protein 15 homolog) 
 2.78, 3.37E-02  
Q9D0B1 (Zinc finger protein 524)  2.30, 2.47E-03  
B5X0G2 (Major urinary protein 17)  2.30, 3.35E-02  
Q9D816 (Cytochrome P450 2C55)  2.28, 1.01E-03 1.66, 2.66E-02 
Q8CGR7 (Uridine phosphorylase 2)  2.27, 2.65E-04 2.99, 9.95E-06 
P86049 (Probable RNA-binding protein 
46) 
 2.21, 1.59E-02  
P11589 (Major urinary protein 2)  2.16, 2.38E-02 2.34, 1.37E-02 
O88573 (AF4/FMR2 family member 1)  2.16, 5.14E-05  
Q6ZWQ0 (Nesprin-2)  2.15, 1.21E-03 2.24, 7.56E-04 
Q8VC19 (5-aminolevulinate synthase)  2.13, 4.05E-03 2.49, 8.81E-04 
Q62452 (UDP-glucuronosyltransferase 1-
9) 




Q9CY34 (NEDD8-conjugating enzyme 
UBE2F) 
 2.11, 9.57E-03  
Q91XQ0 (Dynein heavy chain 8)  2.06, 8.14E-03  
Q91XQ0-2 (Isoform 2 of Dynein heavy 
chain 8) 
 2.05, 8.19E-03  
Q8K0V2 (DCN1-like protein 3)  2.03, 2.32E-04 1.55, 1.10E-02 
Q3TZ89 (Protein transport protein 
Sec31B) 
 2.02, 6.51E-03 1.72, 2.89E-02 
Q3TZ89-2 (Isoform 2 of Protein transport 
protein Sec31B) 
 2.02, 6.51E-03 1.72, 2.89E-02 
Q9D3A8 (Carboxyl-terminal PDZ ligand 
of neuronal nitric oxide synthase protein) 
 1.99, 1.08E-03 1.90, 1.93E-03 
Q9D3A8-2 (Isoform 2 of Carboxyl-
terminal PDZ ligand of neuronal nitric 
oxide synthase protein) 
 1.98, 1.11E-03 1.89, 1.98E-03 
Q8BKI2-2 (Isoform 2 of Trinucleotide 
repeat-containing gene 6B protein) 
 1.96, 3.61E-05  
Q80V94 (AP-4 complex subunit epsilon-
1) 
 1.87, 3.98E-02  
Q8VHP7 (Leukocyte elastase inhibitor B)  1.86, 7.05E-05  
Q5SV42 (Leukocyte elastase inhibitor C)  1.85, 8.47E-05  
Q68FL4-2 (Isoform 2 of Putative 
adenosylhomocysteinase 3) 
 1.85, 1.71E-05 1.52, 9.17E-04 
Q8VHI3 (GDP-fucose protein O-
fucosyltransferase 2) 
 1.84, 1.02E-02  
Q91WG0 (Acylcarnitine hydrolase)  1.84, 6.97E-04 1.46, 2.17E-02 
P56654 (Cytochrome P450 2C37)  1.84, 2.11E-03  
P20852 (Cytochrome P450 2A5)  1.83, 3.91E-04  
Q8VBV3 (Exosome complex component 
RRP4) 
 1.83,1.51E-03 1.78, 2.13E-03 
Q8VCE1 (DnaJ homolog subfamily C 
member 28) 
 1.83,1.51E-03 2.54, 3.71E-06 
Q9D0R4 (Probable ATP-dependent RNA 
helicase DDX56) 
 1.78,1.32E-02   2.39, 5.91E-04 
Q8CHT6 (Protein FAM169B)  1.77,5.57E-06 1.53, 1.52E-04 
B2RSH2 (Guanine nucleotide-binding 
protein G(i) subunit alpha-1) 
 1.77,3.02E-03  
Q8K0C9 (GDP-mannose 4,6 
dehydratase) 
 1.76,3.71E-03  
P46425 (Glutathione S-transferase P 2)  1.76,1.76E-02  
Q91ZJ9-2 (Isoform 2 of Hyaluronidase-1) 
 1.75,2.91E-08 1.71, 5.24E-08 
Q8C0L9-2 (Isoform 2 of 
Glycerophosphocholine 
phosphodiesterase GPCPD1) 
 1.75,2.67E-04 1.83, 1.25E-04 
Q91ZJ9 (Hyaluronidase-1)  1.74, 3.25E-08 1.70, 5.88E-08 
Q9CQB7 (LYR motif-containing protein 
1) 
 1.70, 3.20E-04  
P10628 (Homeobox protein Hox-D4)  1.66, 6.61E-05 1.54, 3.50E-04 
Q8C0L9 (Glycerophosphocholine 
phosphodiesterase GPCPD1) 
 1.66, 7.71E-04 1.76, 2.76E-04 
P21570 (Angiogenin)  1.66, 2.03E-03  
Q9D7B1 (tRNA-dihydrouridine(20) 
synthase [NAD(P)+]-like) 




O88502 (High affinity cAMP-specific 
and IBMX-insensitive 3',5'-cyclic 
phosphodiesterase 8A) 
 1.65, 1.55E-02  
Q9Z0H8 (CAP-Gly domain-containing 
linker protein 2) 
 1.65, 1.55E-02  
Q9Z0H8-2 (Isoform 2 of CAP-Gly 
domain-containing linker protein 2) 
 1.65, 1.55E-02  
Q8K012 (Formin-binding protein 1-like)  1.63, 1.19E-02  
Q8K012-2 (Isoform 2 of Formin-binding 
protein 1-like) 
 1.63, 1.19E-02  
P09926 (Surfeit locus protein 2)  1.62, 1.73E-02  
Q8K419 (Galectin-4)  1.62, 3.40E-03 1.72, 1.28E-03 
Q8BG60-2 (Isoform 2 of Thioredoxin-
interacting protein) 
 1.62, 2.51E-08 1.80, 1.14E-09 
Q8BR90 (UPF0600 protein C5orf51 
homolog) 
 1.62, 1.49E-03 1.51, 5.06E-03 
Q8BR90-2 (Isoform 2 of UPF0600 
protein C5orf51 homolog) 
 1.62, 1.49E-03  
P11590 (Major urinary protein 4)  1.61, 4.01E-02 1.66, 3.13E-02 
O54891 (Galectin-6)  1.61, 3.48E-03  
Q641P0-2 (Isoform 2 of Actin-related 
protein 3B) 
 1.61, 4.00E-02  
Q8BG60 (Thioredoxin-interacting 
protein) 
 1.61, 2.43E-08 1.78, 1.06E-09 
Q3U6N9-3 (Isoform 3 of UPF0488 
protein C8orf33 homolog) 
 1.59, 2.87E-03  
Q8QZZ7 (EKC/KEOPS complex subunit 
Tprkb) 
 1.58, 1.17E-06 1.68, 1.91E-07 
Q9D845 (Testis-expressed protein 9)  1.58, 6.66E-05 1.70, 1.11E-05 
Q3U6N9 (UPF0488 protein C8orf33 
homolog) 
 1.57, 3.28E-03  
Q9DBN9 (Probable ATP-dependent 
RNA helicase DDX59) 
 1.57, 6.93E-05 1.69, 1.14E-05 
Q3U6N9-2 (Isoform 2 of UPF0488 
protein C8orf33 homolog) 
 1.57, 3.47E-03  
D3Z423 (RING finger protein 212B)  1.57, 6.94E-05  
Q8C4Y3 (Negative elongation factor B)  1.56, 6.97E-06  
Q9WTK7-2 (Isoform 2 of 
Serine/threonine-protein kinase STK11) 
 1.56, 4.30E-05  
Q8K0R6 (Glycolipid transfer protein 
domain-containing protein 2) 
 1.56, 1.35E-04 1.58, 1.00E-04 
Q9WTK7 (Serine/threonine-protein 
kinase STK11) 
 1.56, 4.54E-05  
Q9CYI4 (Putative RNA-binding protein 
Luc7-like 1) 
 1.56, 2.83E-02  
Q3TKT4 (Transcription activator BRG1)  1.55, 6.91E-06 1.52, 1.20E-05 
Q3TKT4-2 (Isoform 2 of Transcription 
activator BRG1) 
 1.54, 7.41E-06 1.51, 1.29E-05 
B1AVY7 (Kinesin-like protein KIF16B)  1.54, 2.61E-04 1.67, 4.03E-05 
Q80TF6 (StAR-related lipid transfer 
protein 9) 
 1.54, 2.61E-04 1.67, 4.03E-05 
Q80TJ1-4 (Isoform 4 of Calcium-
dependent secretion activator 1) 




Q80TJ1-2 (Isoform 2 of Calcium-
dependent secretion activator 1) 
 1.54, 5.83E-03  
Q8BXL7 (ADP-ribosylation factor-
related protein 1) 
 1.54, 6.64E-04 1.47, 1.68E-03 
Q80TJ1 (Calcium-dependent secretion 
activator 1) 
 1.53, 5.94E-03  
Q9CZP0 (Ufm1-specific protease 1)  1.53, 5.42E-04  
Q8C0L9-3 (Isoform 3 of 
Glycerophosphocholine 
phosphodiesterase GPCPD1) 
 1.52, 2.05E-03 1.63, 5.70E-04 
Q641P0 (Actin-related protein 3B)  1.52, 4.02E-02  
Q80XC2 (tRNA (adenine(58)-N(1))-
methyltransferase catalytic subunit 
TRMT61A) 
 1.52, 6.09E-03  
P56656 (Cytochrome P450 2C39)  1.52, 2.96E-02  
Q99388 (Component of Sp100-rs)  1.51, 3.73E-04 1.43, 1.40E-03 
Q99L43 (Phosphatidate 
cytidylyltransferase 2) 
 1.51, 6.36E-05 2.10, 2.47E-08 
Q9Z0E8 (Solute carrier family 22 
member 5) 
 1.50, 1.23E-05 1.48, 1.85E-05 
Q80V62 (Fanconi anemia group D2 
protein homolog) 
 1.50, 8.40E-04 1.94, 4.09E-06 
P49813 (Tropomodulin-1)  1.49, 1.62E-04  
Q9JKK7 (Tropomodulin-2)  1.49, 1.62E-04  
Q9JKK7-3 (Isoform 3 of Tropomodulin-
2) 
 1.49, 1.62E-04  
Q9D902 (General transcription factor IIE 
subunit 2) 
 1.49, 3.23E-04  
Q8C1A9-3 (Isoform 3 of Protein 
ABHD18) 
 1.48, 8.72E-05  
Q8C1A9-2 (Isoform 2 of Protein 
ABHD18) 
 1.48, 7.64E-05  
Q6PDD0 (UDP-glucuronosyltransferase 
2A2) 
 1.47, 4.69E-04 1.55, 1.32E-04 
Q80X89 (UDP-glucuronosyltransferase 
2A1) 
 1.47, 4.69E-04 1.55, 1.32E-04 
Q9JJ59 (ATP-binding cassette sub-family 
B member 9) 
 1.47, 1.64E-03 1.73, 4.60E-05 
Q9JJ59-2 (Isoform 2 of ATP-binding 
cassette sub-family B member 9) 
 1.47, 1.64E-03 1.73, 4.60E-05 
Q9Z0Y9 (Oxysterols receptor LXR-
alpha) 
 1.47, 1.81E-02  
Q91X77-2 (Isoform 2 of Cytochrome 
P450 2C50) 
 1.47, 1.98E-02  
Q91X77 (Cytochrome P450 2C50)  1.46, 1.92E-02  
Q64458 (Cytochrome P450 2C29)  1.46, 2.30E-02  
Q61056 (Short transient receptor 
potential channel 1) 
 1.46, 1.35E-03  
Q61056-2 (Isoform Beta of Short 
transient receptor potential channel 1) 
 1.46, 1.35E-03  
Q8BGT6-2 (Isoform 2 of MICAL-like 
protein 1) 
 1.46, 7.28E-05  






 1.46, 2.38E-03  
Q8BGT6 (MICAL-like protein 1)  1.45, 6.17E-05  
Q5U4E2 (Replication initiator 1)  1.45, 6.08E-03  
Q8CEC0 (Nuclear pore complex protein 
Nup88) 
 1.45, 8.97E-06  
Q8CEC0-2 (Isoform 2 of Nuclear pore 
complex protein Nup88) 
 1.45, 9.64E-06  
Q8CEC0-3 (Isoform 3 of Nuclear pore 
complex protein Nup88) 
 1.44, 9.73E-06  
Q9DBB5 (Eukaryotic translation 
initiation factor 4E type 3) 
 1.44, 2.62E-04  
Q9R1C8 (5-hydroxytryptamine receptor 
6) 
 1.44, 5.39E-04 1.61, 3.30E-05 
Q9CPQ8 (ATP synthase subunit g, 
mitochondrial) 
 1.43, 4.41E-03  
Q3UYK3 (TBC1 domain family member 
9) 
 1.43, 9.52E-05 1.45, 7.03E-05 
Q3UYK3-2 (Isoform 2 of TBC1 domain 
family member 9) 
 1.43, 9.52E-05 1.45, 7.03E-05 
Q8BZR9 (Nuclear cap-binding protein 
subunit 3) 
 1.43, 7.61E-04 1.84, 1.78E-06 
Q5ND34-3 (Isoform 3 of WD repeat-
containing protein 81) 
 1.43, 5.05E-04  
Q9JHI2 (tRNA-specific adenosine 
deaminase 1) 
 1.42, 1.72E-02  
Q9JHI2-2 (Isoform 2 of tRNA-specific 
adenosine deaminase 1) 
 1.42, 1.72E-02  
Q9JHI2-3 (Isoform 3 of tRNA-specific 
adenosine deaminase 1) 
 1.42, 1.72E-02  
Q8R0T6 (Adhesion G protein-coupled 
receptor G3) 
 1.42, 2.14E-02  
Q5ND34-2 (Isoform 2 of WD repeat-
containing protein 81) 
 1.42, 5.29E-04  
Q5ND34 (WD repeat-containing protein 
81) 
 1.42, 5.34E-04  
Q9JHW9 (Aldehyde dehydrogenase 
family 1 member A3) 
 1.42, 2.91E-02 1.43, 2.67E-02 
Q3V0M2 (Leucine-rich repeat-containing 
protein 36) 
 1.42, 1.93E-02  
Q9DA03 (Complex III assembly factor 
LYRM7) 
 1.42, 2.03E-05  
Q91Z69 (SLIT-ROBO Rho GTPase-
activating protein 1) 
 1.42, 3.41E-03  
Q9JLJ5 (Elongation of very long chain 
fatty acids protein 1) 
 1.41, 4.03E-02  
Q80W54 (CAAX prenyl protease 1 
homolog) 
 0.71, 2.75E-03  
Q9QYF1 (Retinol dehydrogenase 11)  0.71, 1.51E-02  
P61226 (Ras-related protein Rap-2b)  0.71, 1.39E-02  
D3Z5L6 (MFS-type transporter 
SLC18B1) 
 0.71, 1.12E-02  
Q8BXB6 (Solute carrier organic anion 
transporter family member 2B1) 
 0.70, 2.02E-03  




P62254 (Ubiquitin-conjugating enzyme 
E2 G1) 
 0.70, 1.66E-02 0.59, 9.59E-04 
Q91V01 (Lysophospholipid 
acyltransferase 5) 
 0.70, 2.92E-04  
P01631 (Ig kappa chain V-II region 26-
10) 
 0.70, 3.30E-02  
Q91VA3 (Calpain-8)  0.70, 4.01E-03  
Q99MX0 (Transketolase-like protein 1)  0.70, 5.96E-03  
Q9D735 (Telomerase RNA component 
interacting RNase) 
 0.70, 1.46E-03  
Q5M8N4 (Epimerase family protein 
SDR39U) 
 0.70, 4.19E-04  
Q5M8N4-2 (Isoform 2 of Epimerase 
family protein SDR39U1) 
 0.70, 4.19E-04  
O70456 (14-3-3 protein sigma)  0.70, 2.75E-02 0.57, 1.26E-03 
Q69ZP3 (Probable hydrolase PNKD)  0.70, 4.50E-03 0.69, 3.97E-03 
Q69ZP3-3 (Isoform 3 of Probable 
hydrolase PNKD) 
 0.70, 4.50E-03 0.69, 3.97E-03 
Q69ZP3-4 (Isoform 4 of Probable 
hydrolase PNKD) 
 0.70, 4.50E-03 0.69, 3.97E-03 
Q6P6M5-2 (Isoform 2 of Peroxisomal 
membrane protein 11C) 
 0.70, 9.89E-05  
Q8C0E2-2 (Isoform 2 of Vacuolar 
protein sorting-associated protein 26B) 
 0.70, 1.78E-03  
P55772 (Ectonucleoside triphosphate 
diphosphohydrolase 1) 
 0.70, 2.88E-02 0.70, 2.86E-02 
P48453 (Serine/threonine-protein 
phosphatase 2B catalytic subunit beta 
isoform) 
 0.70, 8.27E-03  
P48453-2 (Isoform 1 of Serine/threonine-
protein phosphatase 2B catalytic subunit 
beta isoform) 
 0.70, 8.27E-03  
Q3UDW8 (Heparan-alpha-glucosaminide 
N-acetyltransferase) 
 0.69, 7.67E-07  
Q3UDW8-2 (Isoform 2 of Heparan-
alpha-glucosaminide N-acetyltransferase) 
 0.69, 7.67E-07  
Q8BG18 (N-terminal EF-hand calcium-
binding protein 1) 
 0.69, 1.46E-02  
Q62167 (ATP-dependent RNA helicase 
DDX3X) 
 0.69, 7.83E-03 0.64, 1.89E-03 
P21300 (Aldose reductase-related protein 
1) 
 0.69, 3.84E-02  
P54227 (Stathmin)  0.69, 1.79E-02  
Q5PR73 (GTP-binding protein Di-Ras2)  0.69, 3.33E-03 0.57, 6.52E-05 
Q91Z61 (GTP-binding protein Di-Ras1)  0.69, 3.33E-03 0.57, 6.52E-05 
Q91Y47 (Coagulation factor XI)  0.69, 2.40E-03  
P43136 (Nuclear receptor subfamily 2 
group F member 6) 
 0.69, 1.14E-02 0.63, 2.69E-03 
P55821 (Stathmin-2)  0.69, 1.88E-02  
O70311 (Glycylpeptide N-
tetradecanoyltransferase 2) 
 0.69, 4.75E-04  
P97287 (Induced myeloid leukemia cell 
differentiation protein Mcl-1 homolog) 
 0.69, 1.49E-02  




P36916-2 (Isoform 2 of Guanine 
nucleotide-binding protein-like 1) 
 0.69, 3.04E-02  
P35922-3 (Isoform 3 of Synaptic 
functional regulator FMR1) 
 0.69, 3.42E-03 0.66, 1.81E-03 
P35922-9 (Isoform 9 of Synaptic 
functional regulator FMR1) 
 0.69, 3.42E-03 0.66, 1.81E-03 
Q920L1 (Fatty acid desaturase 1)  0.68, 9.32E-03 0.70, 1.35E-02 
O89086 (RNA-binding protein 3)  0.68, 2.64E-03 0.69, 2.78E-03 
Q99MR1 (GRB10-interacting GYF 
protein 1) 
 0.68, 3.67E-02  
Q61464 (Zinc finger protein 638)  0.68, 4.06E-04  
Q61464-2 (Isoform 2 of Zinc finger 
protein 638) 
 0.68, 4.06E-04  
Q61464-3 (Isoform 3 of Zinc finger 
protein 638) 
 0.68, 4.06E-04  
Q61464-4 (Isoform 4 of Zinc finger 
protein 638) 
 0.68, 4.06E-04  
Q61464-5 (Isoform 5 of Zinc finger 
protein 638) 
 0.68, 4.06E-04  
Q61464-7 (Isoform 7 of Zinc finger 
protein 638) 
 0.68, 4.06E-04  
Q99J83 (Autophagy protein 5)  0.68, 1.90E-03  
Q9WV91 (Prostaglandin F2 receptor 
negative regulator) 
 0.68, 2.93E-03  
Q61474 (RNA-binding protein Musashi 
homolog 1) 
 0.68, 1.72E-05  
Q61474-2 (Isoform 2 of RNA-binding 
protein Musashi homolog 1) 
 0.68, 1.72E-05  
P12399 (Protein CTLA-2-alpha)  0.68, 3.84E-03  
Q9CYL5 (Golgi-associated plant 
pathogenesis-related protein 1) 
 0.68, 4.36E-03  
Q91WG2-2 (Isoform 3 of Rab GTPase-
binding effector protein 2) 
 0.68, 3.40E-03  
Q8K4G1 (Latent-transforming growth 
factor beta-binding protein 4) 
 0.68, 4.03E-02  
Q8K4G1-2 (Isoform 2 of Latent-
transforming growth factor beta-binding 
protein 4) 
 0.68, 4.03E-02  
Q8K4G1-3 (Isoform 3 of Latent-
transforming growth factor beta-binding 
protein 4) 
 0.68, 4.03E-02  
P02463 (Collagen alpha-1(IV) chain)  0.68, 2.26E-02  
Q8C052 (Microtubule-associated protein 
1S) 
 0.68, 5.94E-04  
Q3SXB8 (Collectin-11)  0.68, 3.63E-03  
Q3SXB8-2 (Isoform 2 of Collectin-11)  0.68, 3.63E-03  
O35988 (Syndecan-4)  0.68, 1.08E-03 0.63, 1.97E-04 
Q9CQB5 (CDGSH iron-sulfur domain-
containing protein 2) 
 0.68, 1.56E-03  
Q8BZN6-4 (Isoform 4 of Dedicator of 
cytokinesis protein 10) 
 0.68, 2.76E-02  
Q99J47 (Dehydrogenase/reductase SDR 
family member 7B) 




Q99J47-2 (Isoform 2 of 
Dehydrogenase/reductase SDR family 
member 7B) 
 0.67, 1.38E-02  
Q9CWU6 (Ubiquinol-cytochrome-c 
reductase complex assembly factor 1) 
 0.67, 9.88E-04  
Q9JHH6 (Carboxypeptidase B2)  0.67, 9.18E-03 0.65, 5.26E-03 
Q9CZR2 (N-acetylated-alpha-linked 
acidic dipeptidase 2) 
 0.67, 2.28E-04  
Q810U5-2 (Isoform 2 of Coiled-coil 
domain-containing protein 50) 
 0.67, 4.20E-02  
Q64337 (Sequestosome-1)  0.67, 1.55E-03 0.67, 1.78E-03 
Q6ZWY8 (Thymosin beta-10)  0.67, 1.11E-02  
P28666 (Murinoglobulin-2)  0.67, 3.30E-02  
Q64337-2 (Isoform 2 of Sequestosome-1)  0.66, 4.60E-04 0.70, 1.43E-03 
Q571B6 (WASP homolog-associated 
protein with actin) 
 0.66, 1.83E-03 0.59, 1.74E-04 
P28740-2 (Isoform 2 of Kinesin-like 
protein KIF2A) 
 0.66, 5.69E-03 0.69, 1.22E-02 
P56542 (Deoxyribonuclease-2-alpha)  0.66, 7.41E-03  
Q6ZPR6 (Inhibitor of Bruton tyrosine 
kinase) 
 0.66, 6.62E-05  
Q6ZPR6-2 (Isoform 2 of Inhibitor of 
Bruton tyrosine kinase) 
 0.66, 6.62E-05  
Q8R121 (Protein Z-dependent protease 
inhibitor) 
 0.66, 5.20E-03  
Q8R121-2 (Isoform 2 of Protein Z-
dependent protease inhibitor) 
 0.66, 5.20E-03  
Q9QXD8 (LIM domain-containing 
protein 1) 
 0.66, 6.66E-03 0.63, 2.93E-03 
Q91YT2 (E3 ubiquitin-protein ligase 
RNF185) 
 0.66, 2.66E-02 0.56, 3.62E-03 
Q91YT2-2 (Isoform 2 of E3 ubiquitin-
protein ligase RNF185) 
 0.66, 2.66E-02 0.56, 3.62E-03 
Q9DBQ7-2 (Isoform 2 of Protein-
associating with the carboxyl-terminal 
domain of ezrin) 
 0.66, 2.04E-02  
Q8BIL5 (Protein Hook homolog 1)  0.66, 1.27E-02 0.62, 5.51E-03 
Q8BIL5-2 (Isoform 2 of Protein Hook 
homolog 1) 
 0.66, 1.27E-02 0.62, 5.51E-03 
P11835 (Integrin beta-2)  0.66, 3.07E-02 0.62, 1.39E-02 
Q8CGA4 (Maturin)  0.66, 1.91E-02  
Q501J2 (Protein FAM173A)  0.66, 5.97E-03  
Q8JZV9 (3-hydroxybutyrate 
dehydrogenase type 2) 
 0.66, 7.11E-04  
Q6P6M5 (Peroxisomal membrane protein 
11C) 
 0.66, 1.22E-04 0.69, 4.16E-04 
Q61029 (Lamina-associated polypeptide 
2, isoforms beta/delta/epsilon/gamma) 
 0.66, 1.68E-03 0.61, 3.77E-04 
Q3TJ91 (Lethal(2) giant larvae protein 
homolog 2) 
 0.66, 2.61E-04  
Q60715 (Prolyl 4-hydroxylase subunit 
alpha-1) 
 0.66, 1.42E-03  
Q60715-2 (Isoform 2 of Prolyl 4-
hydroxylase subunit alpha-1) 




Q9DBQ7-3 (Isoform 3 of Protein-
associating with the carboxyl-terminal 
domain of ezrin) 
 0.66, 1.89E-02  
Q9DBQ7 (Protein-associating with the 
carboxyl-terminal domain of ezrin) 
 0.65, 1.90E-02  
P18654 (Ribosomal protein S6 kinase 
alpha-3) 
 0.65, 1.28E-04  
Q61029-3 (Isoform Epsilon of Lamina-
associated polypeptide 2) 
 0.65, 1.54E-03  
O88822 (Lathosterol oxidase)  0.65, 8.23E-03 0.71, 2.59E-02 
P35922 (Synaptic functional regulator 
FMR1) 
 0.65, 4.71E-03 0.63, 2.31E-03 
P35922-2 (Isoform 2 of Synaptic 
functional regulator FMR1) 
 0.65, 4.71E-03 0.63, 2.31E-03 
P35922-7 (Isoform 7 of Synaptic 
functional regulator FMR1) 
 0.65, 4.71E-03 0.63, 2.31E-03 
P35922-8 (Isoform 8 of Synaptic 
functional regulator FMR1) 
 0.65, 4.71E-03 0.63, 2.31E-03 
Q99J45 (Nuclear receptor-binding 
protein) 
 0.65, 2.17E-02  
Q9Z247 (Peptidyl-prolyl cis-trans 
isomerase FKBP9) 
 0.65, 4.60E-04  
Q9DBE0 (Cysteine sulfinic acid 
decarboxylase) 
 0.65, 2.54E-02  
Q91UZ5 (Inositol monophosphatase 2)  0.65, 1.26E-02  
Q640M1 (U3 small nucleolar RNA-
associated protein 14 homolog A) 
 0.65, 7.63E-03 0.62, 4.48E-03 
P59222 (Scavenger receptor class F 
member 2) 
 0.65, 6.67E-03  
Q0VFX2 (Cilia- and flagella-associated 
protein 157) 
 0.65, 3.03E-02 0.53, 3.35E-03 
O89001 (Carboxypeptidase D)  0.64, 4.00E-03  
Q922X9 (Protein arginine N-
methyltransferase 7) 
 0.64, 9.69E-04 0.70, 4.74E-03 
Q61205 (Platelet-activating factor 
acetylhydrolase IB subunit gamma) 
 0.64, 6.05E-04  
P01837 (Ig kappa chain C region)  0.64, 3.42E-02  
Q9Z2Z9 (Glutamine--fructose-6-
phosphate aminotransferase [isomerizing] 
2) 
 0.64, 1.50E-03  
P49945 (Ferritin light chain 2)  0.64, 1.44E-02  
Q8K2F8 (Protein LSM14 homolog A)  0.64, 3.54E-04 0.56, 2.90E-05 
Q9D1G2-3 (Isoform 3 of 
Phosphomevalonate kinase) 
 0.63, 4.19E-04 0.69, 2.85E-03 
P29391 (Ferritin light chain 1)  0.63, 1.24E-02  
Q91X84 (CREB-regulated transcription 
coactivator 3) 
 0.63, 1.40E-02  
P70236 (Dual specificity mitogen-
activated protein kinase  6) 
 0.63, 8.90E-03 0.59, 3.58E-03 
Q8VDM6-3 (Isoform 3 of Heterogeneous 
nuclear ribonucleoprotein U-like protein 
1) 
 0.63, 6.43E-03 0.52, 4.44E-04 
Q8K4I3 (Rho guanine nucleotide 
exchange factor 6) 




O54998 (Peptidyl-prolyl cis-trans 
isomerase FKBP7) 
 0.62, 1.51E-03 0.66, 4.27E-03 
Q9CZS1 (Aldehyde dehydrogenase X)  0.62, 7.33E-03  
Q8CF02 (Protein FAM25C)  0.62, 3.19E-03 0.56, 6.17E-04 
Q9WUA3 (ATP-dependent 6-
phosphofructokinase, platelet type) 
 0.61, 6.53E-03  
Q9WUA3-2 (Isoform 2 of ATP-
dependent 6-phosphofructokinase, 
platelet type) 
 0.61, 6.53E-03  
Q3TFQ1 (SPRY domain-containing 
protein 7) 
 0.61, 5.54E-03 0.53, 6.46E-04 
Q6ZWR4-2 (Isoform 2 of 
Serine/threonine-protein phosphatase 2A 
55 kDa regulatory subunit B beta 
isoform) 
 0.61, 2.75E-03 0.65, 7.78E-03 
Q6ZWR4-3 (Isoform 3 of 
Serine/threonine-protein phosphatase 2A 
55 kDa regulatory subunit B beta 
isoform) 
 0.61, 2.75E-03 0.65, 7.76E-03 
Q6ZWR4 (Serine/threonine-protein 
phosphatase 2A 55 kDa regulatory 
subunit B beta isoform) 
 0.61, 2.78E-03 0.65, 7.83E-03 
P48455 (Serine/threonine-protein 
phosphatase 2B catalytic subunit gamma 
isoform) 
 0.61, 5.93E-03  
Q8K4Q8 (Collectin-12)  0.60, 2.16E-02 0.65, 4.20E-02 
Q6P9J9 (Anoctamin-6)  0.60, 2.62E-03  
Q6P9J9-2 (Isoform 2 of Anoctamin-6)  0.60, 2.62E-03  
Q08481 (Platelet endothelial cell 
adhesion molecule) 
 0.60, 3.16E-02 0.55, 1.38E-02 
Q08481-2 (Isoform 2 of Platelet 
endothelial cell adhesion molecule) 
 0.60, 3.16E-02 0.55, 1.38E-02 
Q08481-3 (Isoform 3 of Platelet 
endothelial cell adhesion molecule) 
 0.60, 3.16E-02 0.55, 1.38E-02 
Q08481-4 (Isoform 4 of Platelet 
endothelial cell adhesion molecule) 
 0.60, 3.16E-02 0.55, 1.38E-02 
Q62507 (Cochlin)  0.60, 2.11E-02  
Q80YR6 (DNA endonuclease RBBP8)  0.60, 3.49E-02  
P09528 (Ferritin heavy chain)  0.60, 6.11E-03  
O35930 (Platelet glycoprotein Ib alpha 
chain) 
 0.60, 3.13E-03  
P27545 (Ceramide synthase 1)  0.59, 2.07E-02  
Q62036 (Centrosomal protein of 131 
kDa) 
 0.59, 2.07E-02  
Q9D454 (Uncharacterized protein 
CXorf49 homolog) 
 0.59, 2.07E-02  
Q8R5L3-2 (Isoform 2 of Vam6/Vps39-
like protein) 
 0.59, 1.79E-04  
Q8R5L3 (Vam6/Vps39-like protein)  0.59, 1.73E-04  
Q60738 (Zinc transporter 1)  0.59, 3.16E-03 0.54, 1.11E-03 
Q3U269 (Thiosulfate 
sulfurtransferase/rhodanese-like domain-
containing protein 2) 
 0.58, 2.27E-04  
Q9Z0G0 (PDZ domain-containing 
protein GIPC1) 




Q08761 (Vitamin K-dependent protein S)  0.58, 6.12E-03  
Q7TSE6 (Serine/threonine-protein kinase 
38-like) 
 0.57, 4.26E-02 0.44, 5.16E-03 
Q7TSE6-2 (Isoform 2 of 
Serine/threonine-protein kinase 38-like) 
 0.57, 4.26E-02 0.44, 5.16E-03 
Q8BPB5 (EGF-containing fibulin-like 
extracellular matrix protein 1) 
 0.57, 9.35E-04  
Q8CAQ8-3 (Isoform 3 of MICOS 
complex subunit Mic60) 
 0.56, 1.15E-02  
Q9JJI6 (GPI ethanolamine phosphate 
transferase 3) 
 0.55, 6.05E-03  
Q9CQ45 (Neudesin)  0.55, 3.46E-03  
Q78IQ7 (Zinc transporter ZIP4)  0.55, 3.09E-02  
Q78IQ7-2 (Isoform 2 of Zinc transporter 
ZIP4) 
 0.55, 3.09E-02  
Q9CQ19 (Myosin regulatory light 
polypeptide 9) 
 0.55, 2.93E-02  
A2ARA8 (Integrin alpha-8)  0.55, 8.86E-03  
Q8BP99 (UPF0500 protein C1orf216 
homolog) 
 0.55, 7.38E-03 0.55, 8.11E-03 
P01633 (Ig kappa chain V19-17)  0.54, 3.57E-02  
Q61285 (ATP-binding cassette sub-
family D member 2) 
 0.54, 2.45E-02  
Q80UG1 (Fatty acid desaturase 6)  0.53, 2.82E-02 0.46, 8.86E-03 
Q80UG1-2 (Isoform 2 of Fatty acid 
desaturase 6) 
 0.53, 2.82E-02 0.46, 8.86E-03 
Q80YV4 (Pantothenate kinase 4)  0.53, 3.59E-03  
Q80YV4-2 (Isoform 2 of Pantothenate 
kinase 4) 
 0.53, 3.59E-03  
Q9CR41-2 (Isoform 2 of Huntingtin-
interacting protein K) 
 0.53, 3.17E-04  
P08905 (Lysozyme C-2)  0.53, 5.81E-04  
P17897 (Lysozyme C-1)  0.53, 5.81E-04  
Q9WVH9 (Fibulin-5)  0.53, 2.82E-02 0.55, 3.81E-02 
Q3TRM8 (Hexokinase-3)  0.52, 2.53E-03  
P04942 (Ig kappa chain V-VI region 
NQ5-61.1.2) 
 0.52, 1.30E-02  
P84750 (Ig kappa chain V region Mem5 
(Fragment)) 
 0.52, 1.68E-02  
P35576 (Glucose-6-phosphatase)  0.51, 1.33E-02  
P04940 (Ig kappa chain V-VI region 
NQ2-17.4.1) 
 0.51, 8.52E-03  
P04941 (Ig kappa chain V-VI region 
NQ2-48.2.2) 
 0.51, 8.52E-03  
P04943 (Ig kappa chain V-VI region 
NQ6-8.3.1) 
 0.51, 8.52E-03  
P04944 (Ig kappa chain V-VI region 
NQ5-78.2.6) 
 0.51, 8.52E-03  
P11247 (Myeloperoxidase)  0.51, 1.79E-03  
Q62393 (Tumor protein D52)  0.51, 1.58E-02  
Q62393-2 (Isoform 2 of Tumor protein 
D52) 
 0.51, 1.58E-02  
Q62393-3 (Isoform 3 of Tumor protein 
D52) 




Q68FF7 (SLAIN motif-containing 
protein 1) 
 0.51, 1.92E-02  
Q68FF7-2 (Isoform 2 of SLAIN motif-
containing protein 1) 
 0.51, 1.92E-02  
Q6DID3 (Protein SCAF8)  0.50, 2.22E-02  
P03987 (Ig gamma-3 chain C region)  0.50, 1.52E-03  
P03987-2 (Isoform 2 of Ig gamma-3 
chain C region) 
 0.50, 1.52E-03  
Q9CQA1 (Trafficking protein particle 
complex subunit 5) 
 0.50, 4.16E-02  
P01872 (Ig mu chain C region)  0.49, 8.90E-03  
P01872-2 (Isoform 2 of Ig mu chain C 
region) 
 0.49, 8.90E-03  
Q3U0J8 (TBC1 domain family member 
2B) 
 0.49, 6.57E-04  
Q80T19 (Hepcidin-2)  0.49, 3.71E-05  
Q9EQ21 (Hepcidin)  0.49, 3.71E-05  
P08071 (Lactotransferrin)  0.48, 1.42E-03  
Q45VN2 (Alpha-defensin 20)  0.48, 2.90E-02 0.40, 7.95E-03 
P01680 (Ig kappa chain V-IV region 
S107B) 
 0.48, 5.70E-03  
Q9R0E1 (Procollagen-lysine,2-
oxoglutarate 5-dioxygenase 3) 
 0.47, 2.28E-02  
O70333 (Cysteine-rich PDZ-binding 
protein) 
 0.47, 1.67E-04  
Q3U487-2 (Isoform 2 of E3 ubiquitin-
protein ligase HECTD3) 
 0.47, 1.18E-03  
Q9CZW4 (Long-chain-fatty-acid--CoA 
ligase 3) 
 0.47, 2.13E-04 0.44, 9.27E-05 
P01635 (Ig kappa chain V-V region K2 
(Fragment)) 
 0.46, 6.36E-03 0.47, 7.31E-03 
Q8CI12 (Smoothelin-like protein 2)  0.44, 2.78E-03  
Q9R0I7 (YLP motif-containing protein 1)  0.44, 3.05E-02 0.43, 2.44E-02 
A2BE28 (Ribosomal biogenesis protein 
LAS1L) 
 0.44, 5.76E-03 0.44, 5.85E-03 
A2BE28-2 (Isoform 2 of Ribosomal 
biogenesis protein LAS1L) 
 0.44, 5.76E-03 0.44, 5.85E-03 
P00688 (Pancreatic alpha-amylase)  0.44, 2.96E-02  
Q64362 (AKT-interacting protein)  0.44, 2.05E-03  
P10648 (Glutathione S-transferase A2)  0.43, 2.69E-03 0.52, 1.55E-02 
Q9WU56 (tRNA pseudouridine synthase 
A) 
 0.42, 8.39E-03  
Q9WU56-2 (Isoform 2 of tRNA 
pseudouridine synthase A) 
 0.42, 8.39E-03  
Q9WU56-3 (Isoform 3 of tRNA 
pseudouridine synthase A) 
 0.42, 8.39E-03  
Q9WU56-4 (Isoform 4 of tRNA 
pseudouridine synthase A) 
 0.42, 8.39E-03  
Q61093 (Cytochrome b-245 heavy chain)  0.42, 3.96E-02  
G5E8P0 (Gamma-tubulin complex 
component 6) 
 0.41, 2.30E-02  
P01634 (Ig kappa chain V-V region 
MOPC 21) 
 0.41, 1.03E-02  




Q5NBX1 (Protein cordon-bleu)  0.38, 4.57E-03  
Q5NBX1-2 (Isoform 2 of Protein cordon-
bleu) 
 0.38, 4.57E-03  
Q5NBX1-3 (Isoform 3 of Protein cordon-
bleu) 
 0.38, 4.56E-03  
P11404 (Fatty acid-binding protein, 
heart) 
 0.36, 2.85E-02  
Q6ZPS6 (Ankyrin repeat and IBR 
domain-containing protein 1) 
 0.36, 1.73E-04  
Q6P8U6(Pancreatic triacylglycerol 
lipase) 
 0.32, 1.15E-02  
P27005 (Protein S100-A8)  0.32, 8.05E-03  
P17892 (Pancreatic lipase-related protein 
2) 
 0.23, 2.54E-03  
P11588 (Major urinary protein 1)   3.54, 1.58E-02 
O88843 (Death domain-containing 
protein CRADD) 
  3.54,1.58E-02    
Q9CRA5-2 (Isoform 2 of Golgi 
phosphoprotein 3) 
  2.33, 2.08E-04 
Q8R088-3 (Isoform 3 of Golgi 
phosphoprotein 3-like) 
  2.33, 2.14E-04 
Q8R088 (Golgi phosphoprotein 3-like)   2.32, 2.26E-04 
Q3TZM9 (GDP-Man:Man(3)GlcNAc(2)-
PP-Dol alpha-1,2-mannosyltransferase 
  2.17, 9.12E-03 
Q3TZM9-2 (Isoform 2 of GDP-
Man:Man(3)GlcNAc(2)-PP-Dol alpha-
1,2-mannosyltransferase) 
  2.17, 9.12E-03 
Q3TZM9-3 (Isoform 3 of GDP-
Man:Man(3)GlcNAc(2)-PP-Dol alpha-
1,2-mannosyltransferase) 
  2.17, 9.12E-03 
Q3U2I3-2 (Isoform 2 of FTS and Hook-
interacting protein) 
  2.09, 3.75E-02 
Q3U2I3-3 (Isoform 3 of FTS and Hook-
interacting protein) 
  2.09, 3.75E-02 
Q3U2I3 (FTS and Hook-interacting 
protein) 
  2.08, 3.77E-02 
Q99MZ3-5 (Isoform 5 of Carbohydrate-
responsive element-binding protein) 
  2.05, 3.82E-03 
Q8BZF8 (Phosphoglucomutase-like 
protein 5) 
  2.02, 3.57E-02 
O09043 (Napsin-A)    1.90, 1.55E-04 
P50446 (Keratin, type II cytoskeletal 6A)   1.89, 1.34E-02 
Q9Z331 (Keratin, type II cytoskeletal 6B)   1.89, 1.34E-02 
Q1HKZ5 (Mitogen-activated protein 
kinase 13) 
  1.88, 3.13E-04 
O08532 (Voltage-dependent calcium 
channel subunit alpha-2/delta-1) 
  1.81, 6.26E-03 
O08532-2 (Isoform 2B of Voltage-
dependent calcium channel subunit alpha-
2/delta-1) 
  1.81, 6.26E-03 
O08532-3 (Isoform 2C of Voltage-
dependent calcium channel subunit alpha-
2/delta-1) 




O08532-4 (Isoform 2D of Voltage-
dependent calcium channel subunit alpha-
2/delta-1) 
   1.81, 6.26E-03 
O08532-5 (Isoform 2E of Voltage-
dependent calcium channel subunit alpha-
2/delta-1) 
   1.81, 6.26E-03 
Q8BZM1 (Glomulin)    1.79, 2.31E-02 
A2AFR3 (FERM and PDZ domain-
containing protein 4) 
   1.78, 4.11E-02 
Q9JMD1 (Scm-like with four MBT 
domains protein 1) 
  1.78, 8.40E-04 
Q02013 (Aquaporin-1)   1.76, 2.68E-03 
P26011 (Integrin beta-7)   1.75, 4.37E-03 
Q6P5G6 (UBX domain-containing 
protein 7) 
  1.72, 2.18E-04 
Q9R0H0-2 (Isoform 2 of Peroxisomal 
acyl-coenzyme A oxidase 1) 
  1.70, 4.60E-03 
Q8QZZ7 (EKC/KEOPS complex subunit 
Tprkb) 
  1.68, 1.91E-07 
Q9QUM0 (Integrin alpha-IIb)   1.67, 1.97E-02 
P12787 (Cytochrome c oxidase subunit 
5A, mitochondrial) 
  1.67, 1.14E-03 
P02798 (Metallothionein-2)   1.66, 3.79E-02 
Q61982 (Neurogenic locus notch 
homolog protein 3) 
  1.65, 1.11E-03 
Q8C1D8 (Protein IWS1 homolog)   1.64, 8.84E-04 
Q8C1D8-2 (Isoform 2 of Protein IWS1 
homolog) 
  1.64, 8.84E-04 
Q61206 (Platelet-activating factor 
acetylhydrolase IB subunit beta) 
  1.58, 9.17E-06 
Q791V5(Mitochondrial carrier homolog 
2) 
  1.57, 6.46E-04 
Q8CI61 (BAG family molecular 
chaperone regulator 4) 
  1.57, 1.70E-02 
Q8BRH0 (Transmembrane and TPR 
repeat-containing protein 3) 
  1.56, 6.50E-03 
P19783 (Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial) 
  1.54, 1.75E-03 
Q99JY8 (Phospholipid phosphatase 3)   1.54, 1.12E-02 
Q78XF5 (Oligosaccharyltransferase 
complex subunit OSTC) 
  1.53, 1.67E-05 
P58466 (Carboxy-terminal domain RNA 
polymerase II polypeptide A small 
phosphatase 1) 
  1.52, 9.20E-04 
Q3TBW2 (39S ribosomal protein L10, 
mitochondrial) 
  1.52, 6.86E-04 
P62305 (Small nuclear ribonucleoprotein 
E) 
  1.52, 2.26E-05 
P34928 (Apolipoprotein C-I)   1.50, 2.01E-04 
Q80VR3 (Sulfotransferase 1C1)   1.49, 3.55E-02 
Q09M05 (Cytosolic carboxypeptidase 4)   1.49, 2.24E-02 
Q09M05-2 (Isoform 2 of Cytosolic 
carboxypeptidase 4) 




Q09M05-3 (Isoform 3 of Cytosolic 
carboxypeptidase 4) 
  1.49, 2.24E-02 
Q09M05-4 (Isoform 4 of Cytosolic 
carboxypeptidase 4) 
  1.49, 2.24E-02 
Q8K561 (Otoancorin)   1.49, 2.24E-02 
Q9CQ58 (Prolactin-8A9)   1.49, 2.24E-02 
G5E870 (E3 ubiquitin-protein ligase 
TRIP12) 
  1.48, 2.85E-03 
Q9D0J4 (ADP-ribosylation factor-like 
protein 2) 
  1.47, 2.18E-02 
Q00560 (Interleukin-6 receptor subunit 
beta) 
  1.47, 1.63E-04 
Q9CQ37 (Ubiquitin-conjugating enzyme 
E2 T) 
  1.46, 3.13E-04 
Q9D074-4 (Isoform 4 of E3 ubiquitin-
protein ligase MGRN1) 
  1.46, 1.69E-05 
Q9JI13 (Something about silencing 
protein 10) 
  1.46, 1.11E-02 
Q9JI13-2 (Isoform 2 of Something about 
silencing protein 10) 
  1.45, 1.12E-02 
Q9D074-2 (Isoform 2 of E3 ubiquitin-
protein ligase MGRN1) 
  1.45, 1.54E-05 
Q9D074 (E3 ubiquitin-protein ligase 
MGRN1) 
  1.45, 1.54E-05 
Q9D074-5 (Isoform 5 of E3 ubiquitin-
protein ligase MGRN1) 
  1.45, 1.53E-05 
Q9D074-3 (Isoform 3 of E3 ubiquitin-
protein ligase MGRN1) 
  1.45, 1.51E-05 
Q8CI32 (BAG family molecular 
chaperone regulator 5) 
  1.45, 1.42E-04 
Q8VEK0 (Cell cycle control protein 50A)   1.44, 1.66E-03 
P28843 (Dipeptidyl peptidase 4)   1.43, 9.36E-03 
Q9DCC8 (Mitochondrial import receptor 
subunit TOM20 homolog) 
  1.43, 4.36E-04 
Q61735 (Leukocyte surface antigen 
CD47) 
  1.42, 3.16E-03 
Q61735-2 (Isoform 2 of Leukocyte 
surface antigen CD47) 
  1.42, 3.16E-03 
Q8BG94 (COMM domain-containing 
protein 7) 
  0.71, 1.52E-03 
Q91ZH7 (Phospholipase ABHD3)   0.71, 7.81E-03 
Q91ZH7-2 (Isoform 2 of Phospholipase 
ABHD3) 
  0.71, 7.81E-03 
O08807 (Peroxiredoxin-4)   0.71, 2.15E-04 
Q9Z0S9 (Prenylated Rab acceptor protein 
1) 
  0.71, 9.50E-03 
O88735 (Ensconsin)   0.70, 1.30E-02 
O88735-2 (Isoform 2 of Ensconsin)   0.70, 1.30E-02 
Q9Z2H1 (Regulator of G-protein 
signaling 11) 
  0.70, 2.42E-02 
Q9Z2H1-2 (Isoform 2 of Regulator of G-
protein signaling 11) 
  0.70, 2.42E-02 
Q8R5M8-6 (Isoform 6 of Cell adhesion 
molecule 1) 




Q8R5M8-7 (Isoform 7 of Cell adhesion 
molecule 1) 
  0.70, 2.26E-03 
Q8BYZ7 (Engulfment and cell motility 
protein 3) 
  0.70, 1.02E-02 
Q60865 (Caprin-1)   0.70, 1.14E-04 
P62911 (60S ribosomal protein L32)   0.70, 2.84E-03 
P53995 (Anaphase-promoting complex 
subunit 1) 
  0.70, 5.89E-03 
A2AWA9-2 (Isoform 2 of Rab GTPase-
activating protein 1) 
  0.70, 9.23E-03 
Q61029-2 (Isoform Delta of Lamina-
associated polypeptide 2) 
  0.70, 1.42E-03 
Q61029-4 (Isoform Gamma of Lamina-
associated polypeptide 2) 
  0.70, 1.42E-03 
Q91WE1 (Sorting nexin-15)   0.70, 3.24E-03 
Q9D7N6 (39S ribosomal protein L30)   0.70, 1.65E-03 
Q9CRG1 (Transmembrane 7 superfamily 
member 3) 
  0.70, 4.04E-02 
Q99M73 (Keratin, type II cuticular Hb4)   0.70, 2.42E-02 
Q148V7-2 (Isoform 2 of LisH domain 
and HEAT repeat-containing protein 
KIAA1468) 
  0.70, 1.56E-02 
Q9JL99 (C-type lectin domain family 1 
member B) 
  0.69, 1.63E-02 
Q9JL99-2 (Isoform 2 of C-type lectin 
domain family 1 member B) 
  0.69, 1.63E-02 
P41105 (60S ribosomal protein L28)   0.69, 6.83E-03 
Q8CBG9-2 (Isoform 2 of E3 ubiquitin-
protein ligase RNF170) 
  0.69, 2.25E-03 
Q8CBG9 (E3 ubiquitin-protein ligase 
RNF170) 
  0.69, 2.25E-03 
Q9WUK2 (Eukaryotic translation 
initiation factor 4H) 
  0.69, 1.89E-03 
Q8BTV2-3 (Isoform 3 of Cleavage and 
polyadenylation specificity factor subunit 
7) 
  0.69, 3.55E-04 
Q923D5(WW domain-binding protein 
11) 
  0.69, 3.47E-03 
Q91V81 (RNA-binding protein 42)   0.69, 8.01E-03 
Q91V81-2 (Isoform 2 of RNA-binding 
protein 42) 
  0.69, 8.01E-03 
Q8CH72 (E3 ubiquitin-protein ligase 
TRIM32) 
  0.69, 2.24E-02 
Q8BJM3 (Coiled-coil domain-containing 
protein R3HCC1L) 
  0.68, 2.17E-03 
Q8BH79-3 (Isoform 3 of Anoctamin-10)   0.68, 9.48E-03 
Q99JW1 (Protein ABHD17A)   0.68, 1.89E-03 
Q99JW1-2 (Isoform 2 of Protein 
ABHD17A) 
  0.68, 1.89E-03 
Q9QXA1 (Cysteine and histidine-rich 
protein 1) 
  0.68, 3.97E-02 
Q9QXA1-2 (Isoform 2 of Cysteine and 
histidine-rich protein 1) 




Q9QXA1-3 (Isoform 3 of Cysteine and 
histidine-rich protein 1) 
  0.68, 3.97E-02 
Q6ZQM8 (UDP-glucuronosyltransferase 
1-7C) 
  0.68, 1.58E-02 
P83882 (60S ribosomal protein L36a)   0.68, 1.79E-02 
P70288 (Histone deacetylase 2)   0.68, 1.13E-02 
P56389 (Cytidine deaminase)   0.68, 2.60E-03 
P61514 (60S ribosomal protein L37a)   0.67, 7.30E-03 
Q3UFF7 (Lysophospholipase-like protein 
1) 
  0.67, 4.11E-02 
P0DOV1-2 (Isoform 2 of Interferon-
activable protein 205-B) 
  0.67, 2.45E-03 
Q8BHN1 (Gamma-taxilin)   0.67, 5.96E-03 
Q8BHN1-3 (Isoform 3 of Gamma-
taxilin) 
  0.67, 5.96E-03 
Q9D0K1 (Peroxisomal membrane protein 
PEX13) 
  0.67, 1.39E-03 
Q07133 (Histone H1t)   0.67, 1.40E-02 
O08716 (Fatty acid-binding protein 9)   0.67, 2.87E-02 
P24526 (Myelin P2 protein)   0.67, 2.87E-02 
Q8K1A5 (Transmembrane protein 41B)   0.67, 4.12E-02 
Q8K1A5-2 (Isoform 2 of Transmembrane 
protein 41B) 
  0.67, 4.12E-02 
Q8K1A5-3 (Isoform 3 of Transmembrane 
protein 41B) 
  0.67, 4.12E-02 
Q9Z2A5 (Arginyl-tRNA--protein 
transferase 1) 
  0.67, 1.69E-02 
Q80YR4 (E3 ubiquitin-protein ligase 
ZNF598) 
  0.67, 2.00E-02 
Q80YR4-2 (Isoform 2 of E3 ubiquitin-
protein ligase ZNF598) 
  0.67, 2.00E-02 
Q80YR4-3 (Isoform 3 of E3 ubiquitin-
protein ligase ZNF598) 
  0.67, 2.00E-02 
P43276 (Histone H1.5)   0.67, 2.45E-02 
Q6IQX8 (Zinc finger protein 219)   0.67, 2.55E-02 
O70443 (Guanine nucleotide-binding 
protein G(z) subunit alpha) 
  0.66, 5.29E-03 
P43274 (Histone H1.4)   0.66, 8.87E-03 
Q924C1 (Exportin-5)   0.66, 2.07E-02 
Q8K1L5 (E3 ubiquitin-protein ligase 
PPP1R11) 
  0.66, 8.06E-04 
Q61704 (Inter-alpha-trypsin inhibitor 
heavy chain H3) 
  0.66, 2.00E-02 
Q8BRT1-5 (Isoform 2 of CLIP-
associating protein 2) 
  0.66, 5.40E-03 
Q8K2H1 (Periphilin-1)   0.66, 4.13E-02 
Q8K2H1-2 (Isoform 2 of Periphilin-1)   0.66, 4.13E-02 
Q8CGE8 (Interferon-activable protein 
205-A) 
  0.66, 2.10E-03 
O35409 (Glutamate carboxypeptidase 2)   0.65, 3.90E-03 
Q8K2D3 (Enhancer of mRNA-decapping 
protein 3) 




Q80SZ7 (Guanine nucleotide-binding 
protein G(I)/G(S)/G(O) subunit gamma-
5) 
  0.64, 6.42E-03 
Q3TXX3 (Protrudin)   0.64, 1.90E-03 
Q3TXX3-2 (Isoform 2 of Protrudin)   0.64, 1.90E-03 
Q6NXY9 (DNA-directed RNA 
polymerase III subunit RPC7) 
  0.63, 1.82E-02 
P15864 (Histone H1.2)   0.63, 5.98E-04 
Q9QZU9 (Ubiquitin/ISG15-conjugating 
enzyme E2 L6) 
  0.63, 9.46E-03 
Q9Z2G6 (Protein sel-1 homolog 1)   0.63, 1.33E-02 
Q9Z2G6-2 (Isoform 2 of Protein sel-1 
homolog 1) 
  0.63, 1.33E-02 
P07744 (Keratin, type II cytoskeletal 4)   0.62, 4.19E-02 
Q9CPV3 (39S ribosomal protein L42)   0.62, 1.16E-02 
P31725 (Protein S100-A9)   0.62, 4.35E-02 
A2AI08 (Taperin)   0.61 2.59E-02 
Q8BFS6-5 (Isoform 5 of 
Serine/threonine-protein phosphatase 
CPPED1) 
  0.61 1.12E-02 
Q9DAS9 (Guanine nucleotide-binding 
protein G(I)/G(S)/G(O) subunit gamma-
12) 
  0.61 1.16E-03 
Q8C570 (mRNA export factor)   0.61 1.32E-03 
Q8BRT1-6 (Isoform 3 of CLIP-
associating protein 2) 
  0.61 4.32E-03 
Q04519 (Sphingomyelin 
phosphodiesterase) 
  0.61, 2.39E-02 
Q09014 (Neutrophil cytosol factor 1)   0.61, 3.80E-02 
Q8BRT1 (CLIP-associating protein 2)   0.61, 1.48E-03 
Q61029-3 (Isoform Epsilon of Lamina-
associated polypeptide 2) 
  0.61, 3.42E-04 
Q9ERN0 (Secretory carrier-associated 
membrane protein 2) 
  0.61, 3.13E-03 
Q62018 (RNA polymerase-associated 
protein CTR9 homolog) 
  0.60, 7.64E-04 
Q62018-2 (Isoform 2 of RNA 
polymerase-associated protein CTR9 
homolog) 
  0.60, 7.64E-04 
Q62018-3 (Isoform 3 of RNA 
polymerase-associated protein CTR9 
homolog) 
  0.60, 7.64E-04 
Q8R003 (Muscleblind-like protein 3)   0.60, 2.41E-02 
Q00651 (Integrin alpha-4)   0.60, 3.63E-05 
O88845 (A-kinase anchor protein 10)   0.59, 1.28E-03 
O88845-2 (Isoform 2 of A-kinase anchor 
protein 10) 
  0.59, 1.28E-03 
O88845-3 (Isoform 3 of A-kinase anchor 
protein 10) 
  0.59, 1.28E-03 
Q99LW6 (YY1-associated factor 2)   0.59, 4.13E-02 
Q9EST4 (Proteasome assembly 
chaperone 2) 
  0.59, 9.02E-03 
Q9EST4-3 (Isoform 3 of Proteasome 
assembly chaperone 2) 




Q9JM52 (Misshapen-like kinase 1)   0.59, 3.29E-02 
Q9JM52-2 (Isoform 1 of Misshapen-like 
kinase 1) 
  0.59, 3.29E-02 
Q9JM52-3 (Isoform 3 of Misshapen-like 
kinase 1) 
  0.59, 3.29E-02 
Q8CD26 (Solute carrier family 35 
member E1) 
  0.59, 2.91E-02 
Q9D159 (Melanocortin-2 receptor 
accessory protein) 
  0.59, 8.81E-03 
O08692 (Neutrophilic granule protein)   0.58, 1.17E-02 
Q3TCJ1 (BRISC complex subunit 
Abraxas 2) 
  0.58, 4.59E-03 
Q66JT0 (Wee1-like protein kinase 2)   0.57, 5.73E-03 
Q8BHN1-2 (Isoform 2 of Gamma-
taxilin) 
  0.57, 5.96E-03 
O54828 (Regulator of G-protein 
signaling 9) 
  0.57, 3.54E-03 
O54828-2 (Isoform 1 of Regulator of G-
protein signaling 9) 
  0.57, 3.54E-03 
O70131 (Ninjurin-1)   0.57, 3.31E-03 
Q5ISE2 (mRNA decay activator protein 
ZFP36L3) 
  0.56, 1.41E-02 
Q6NZF1 (Zinc finger CCCH domain-
containing protein 11A) 
  0.56, 1.12E-03 
P50543 (Protein S100-A11)   0.56, 2.43E-02 
Q9QYI5 (DnaJ homolog subfamily B 
member 2) 
  0.55, 7.80E-03 
Q9QYI5-1 (Isoform 2 of DnaJ homolog 
subfamily B member 2) 
  0.55, 7.80E-03 
Q6P5E6 (ADP-ribosylation factor-
binding protein GGA2) 
  0.55, 2.90E-03 
O70451 (Monocarboxylate transporter 2)   0.55, 1.12E-02 
Q9CYT6 (Adenylyl cyclase-associated 
protein 2) 
  0.55, 1.35E-03 
Q61462 (Cytochrome b-245 light chain)   0.55, 5.27E-03 
Q61462-2 (Isoform 2 of Cytochrome b-
245 light chain) 
  0.55, 5.27E-03 
P17932 (Putative 60S ribosomal protein 
L32') 
  0.54, 6.29E-04 
Q80Y55 (BSD domain-containing protein 
1) 
  0.53, 2.37E-02 
Q9QXP4 (Protein downstream neighbor 
of Son) 
  0.53, 1.69E-02 
Q80YA7 (Dipeptidyl peptidase 8)   0.53, 1.27E-02 
Q8K2X3 (CST complex subunit STN1)   0.53, 1.13E-02 
P11680 (Properdin)   0.52, 1.59E-03 
Q9CQT2 (RNA-binding protein 7)   0.52, 2.57E-03 
Q8VBT1 (Beta-taxilin)   0.51, 2.34E-02 
Q99J23 (GH3 domain-containing protein)   0.51, 1.03E-03 
P97427 (Dihydropyrimidinase-related 
protein 1) 
  0.51, 1.79E-02 
Q922H9 (Zinc finger protein 330)   0.50, 1.70E-03 
Q922H9-2 (Isoform 2 of Zinc finger 
protein 330) 




O70469 (Docking protein 2)   0.49, 3.43E-03 
Q0VGY8 (Protein TANC1)   0.49, 3.03E-03 
Q0VGY8-2 (Isoform 2 of Protein 
TANC1) 
  0.49, 3.03E-03 
Q5SSM3 (Rho GTPase-activating protein 
44) 
  0.48, 7.94E-03 
Q5SSM3-2 (Isoform 2 of Rho GTPase-
activating protein 44) 
  0.48, 7.94E-03 
Q5SSM3-3 (Isoform 3 of Rho GTPase-
activating protein 44) 
  0.48, 7.94E-03 
Q8VIM9 (Immunity-related GTPase 
family Q protein) 
  0.48, 1.02E-03 
Q9D3S3 (Sorting nexin-29)   0.48, 2.37E-02 
P02802 (Metallothionein-1)   0.46, 3.87E-02 
Q3UQS8 (RNA-binding protein 20)   0.46, 1.77E-02 
Q9Z172-2 (Isoform 2 of Small ubiquitin-
related modifier 3) 
  0.46, 7.93E-03 
Q8VCW4 (Protein unc-93 homolog B1)   0.46, 4.27E-02 
Q3U1T9 (DENN domain-containing 
protein 1B) 
  0.44, 7.81E-03 
Q3U1T9-2 (Isoform 2 of DENN domain-
containing protein 1B) 
  0.44, 7.81E-03 
Q3U1T9-4 (Isoform 4 of DENN domain-
containing protein 1B) 
  0.44, 7.81E-03 
P61957 (Small ubiquitin-related modifier 
2) 
  0.44, 1.24E-02 
O35445 (E3 ubiquitin-protein ligase 
RNF5) 
  0.43, 1.44E-02 
Q9Z0F4 (Calcium and integrin-binding 
protein 1) 
  0.43, 4.35E-04 
Q6ZWS8 (Speckle-type POZ protein)   0.41, 3.01E-02 
Q717B4 (TD and POZ domain-
containing protein 3) 
  0.41, 3.01E-02 
Q8CFE5 (BTB/POZ domain-containing 
protein 7) 
  0.41, 3.01E-02 
Q6YCH2 (TD and POZ domain-
containing protein 4) 
  0.41, 3.01E-02 
Q9CQ33 (Leucine-zipper-like 
transcriptional regulator 1) 
  0.41, 3.00E-02 
Q5SWZ9 (Mitochondrial cardiolipin 
hydrolase) 
  0.41, 3.00E-02 
Q6YCH1 (TD and POZ domain-
containing protein 5) 
  0.41, 3.00E-02 
Q8CFE5-3 (Isoform 3 of BTB/POZ 
domain-containing protein 7) 
  0.41, 2.99E-02 
Q717B2 (TD and POZ domain-
containing protein 2) 
  0.41, 2.99E-02 
Q9CQ33-2 (Isoform 2 of Leucine-zipper-
like transcriptional regulator 1) 
  0.41, 2.99E-02 
Q8CFE5-2 (Isoform 2 of BTB/POZ 
domain-containing protein 7) 
  0.41, 2.99E-02 
Q5SWZ9-2 (Isoform 2 of Mitochondrial 
cardiolipin hydrolase) 
  0.41, 2.99E-02 




Q91W67 (Ubiquitin-like protein 7)   0.39, 2.66E-03 
Q62266 (Cornifin-A)   0.33, 4.45E-02 
Q5XKN4 (Protein jagunal homolog 1)   0.33, 1.20E-02 
P11672 (Neutrophil gelatinase-associated 
lipocalin) 
  0.30, 2.41E-02 
P97861 (Keratin, type II cuticular Hb6)   0.30, 3.85E-02 
Q6IMF0 (Keratin, type II cuticular 87)   0.30, 3.85E-02 
Q9ERE2 (Keratin, type II cuticular Hb1)   0.30, 3.85E-02 
Q9Z2T6 (Keratin, type II cuticular Hb5)   0.30, 3.85E-02 
Q9DAF3 (Protein DDI1 homolog 1)   0.28, 2.51E-03 









































Supplemental Table 2: Differentially Hepatic Abundant Proteins Altered by 
PCB126 and Ahr-/- 
 
List of hepatic proteins (Log2 FC, p-value) altered by PCB126, Ahr-/- or both. Log2 
FC≥1 , protein upregulation; Log2 FC≤ -1, protein downregulation. 
Accession Number (Protein Name) 
WT PCB126 
vs WT Vehicle 
Ahr-/-Vehicle vs 




P00184 (Cytochrome P450 1A1) 4.82, 3.19E-04                                  -4.90, 4.66E-06 
P00186 (Cytochrome P450 1A2) 4.36, 7.65E-07 1.91,4.33E-04      -6.43, 1.58E-10 
O55137(Acyl-coenzyme A thioesterase 
1) 
2.05, 1.79E-02 2.97, 2.57E-06  
Q91X77-2 (Isoform 2 of Cytochrome 
P450 2C50) 
1.35, 4.06E-02 -2.13, 9.02E-06 -4.07, 2.74E-09 
P56395 (Cytochrome b5) 1.10, 4.29E-02                                     
P61967 (AP-1 complex subunit sigma-1A) -1.15, 3.55E-02   
Q05816 (Fatty acid-binding protein 5) -1.16, 2.67E-02 -3.80, 9.88E-11 -2.55, 3.15E-08 
O55239 (Nicotinamide N-
methyltransferase) 
-1.19, 3.55E-02                              1.30, 2.84E-04 
P13745 (Glutathione S-transferase A1)                           4.97,9.68E-08           5.13, 8.00E-08 
Q99P91 (Transmembrane 
glycoprotein NMB) 
  4.65, 4.96E-07          4.61, 8.08E-07 
Q62266 (Cornifin-A)   3.90, 3.03E-05          3.53, 1.15E-04 
P19639 (Glutathione S-transferase 
Mu 3) 
  3.76, 7.63E-09          3.21, 8.00E-08 
Q64459 (Cytochrome P450 3A11)   3.61, 2.33E-07          2.38, 4.83E-05 
Q62267 (Cornifin-B)   3.60, 3.70E-05         3.01, 2.05E-04 
Q9JHW9 (Aldehyde dehydrogenase 
family 1 member A3) 
  3.56, 4.50E-09        3.50, 8.05E-09 
Q08857 (Platelet glycoprotein 4)   3.37, 1.53E-04        1.79, 2.54E-02 
Q64481 (Cytochrome P450 3A16)   3.36, 3.64E-07        2.11, 1.24E-04 
Q9CZS1 (Aldehyde dehydrogenase 
X, mitochondrial) 
  3.14, 1.22E-13        3.06, 2.07E-13 
P24472 (Glutathione S-transferase 
A4) 
  3.06, 1.03E-08        2.17, 1.34E-06 
Q9R092 (17-beta-hydroxysteroid 
dehydrogenase type 6) 
  3.02, 3.51E-08        2.24, 2.18E-06 
Q9D379 (Epoxide hydrolase 1)   3.02, 6.18E-10        1.85, 6.83E-07 
Q8VCR2(17-beta-hydroxysteroid 
dehydrogenase 13) 
  3.02, 2.68E-09        2.29, 1.71E-07 
Q8CI94 (Glycogen phosphorylase, 
brain form) 
  3.00, 1.21E-08        2.43, 3.01E-07 
P01756 (Ig heavy chain V region 
MOPC 104E) 
  2.95, 1.24E-06        2.51, 1.14E-05 
P01757 (Ig heavy chain V region 
J558) 
  2.95, 1.24E-06        2.51, 1.14E-05 
Q8VCR2-2 (Isoform 2 of 17-beta-
hydroxysteroid dehydrogenase 13) 
  2.94, 1.86E-09        2.35, 5.83E-08 
P01878 (Ig alpha chain C region)   2.91, 1.32E-09        2.53, 1.57E-08 
Q9QYR9 (Acyl-coenzyme A 
thioesterase 2, mitochondrial) 
  2.90, 7.77E-12        1.99, 2.74E-09 





P43276 (Histone H1.5)   2.72, 4.49E-08        2.49, 1.82E-07 
Q9DBM2 (Peroxisomal bifunctional 
enzyme) 
  2.71, 5.45E-08        1.93, 5.26E-06 
P47740 (Fatty aldehyde 
dehydrogenase) 
  2.63, 1.40E-08        1.06, 8.58E-04 
P06330 (Ig heavy chain V region AC38 
205.12) 
  2.62, 6.45E-07       2.40, 2.38E-06 
P01867 (Ig gamma-2B chain C region)   2.56, 4.33E-04       1.35, 4.49E-02 
P01867-2 (Isoform 2 of Ig gamma-2B 
chain C region) 
 
 2.56, 4.33E-04       1.35, 4.49E-02 
O35728 (Cytochrome P450 4A14)   2.51, 1.03E-03 
Q3TW96-2 (Isoform 2 of UDP-N-
acetylhexosamine pyrophosphorylase-
like protein 1) 
  2.50, 3.13E-07       2.18, 2.10E-06 
P97315 (Cysteine and glycine-rich 
protein 1) 
  2.44, 1.89E-05       1.78, 6.16E-04 
P01837 (Immunoglobulin kappa 
constant) 
  2.42, 5.99E-07       1.84, 2.30E-05 
Q9D8W7 (OCIA domain-containing 
protein 2) 
  2.40, 3.27E-04 
P16045 (Galectin-1)   2.38, 1.35E-05       2.30, 2.38E-05 
P18581 (Cationic amino acid 
transporter 2) 
  2.37, 3.74E-06       1.89, 6.33E-05 
P18581-2 (Isoform 2 of Cationic amino 
acid transporter 2) 
 
 2.37, 3.74E-06       1.89, 6.33E-05 
Q3TW96 (UDP-N-acetylhexosamine 
pyrophosphorylase-like protein 1) 
  2.37, 1.14E-06       2.09, 6.28E-06 
P48036 (Annexin A5)   1.93, 2.05E-07       2.10, 5.83E-08 
Q8VCH0 (3-ketoacyl-CoA thiolase B, 
peroxisomal) 
  2.33, 1.03E-09       1.33, 2.52E-06 
P43275 (Histone H1.1)   2.33, 2.82E-06       2.51, 1.32E-06 
P37804 (Transgelin)   2.30, 2.62E-04       2.00, 1.18E-03 
P50543 (Protein S100-A11)   2.29, 3.13E-07       2.45, 1.70E-07 
P01868 (Ig gamma-1 chain C region 
secreted form) 
  2.29, 2.16E-04 
P01869 (Ig gamma-1 chain C region, 
membrane-bound form) 
  2.29, 2.16E-04 
P11862 (Growth arrest-specific protein 
2) 
  2.28, 2.80E-08      1.84, 6.36E-07 
Q6P549 (Phosphatidylinositol 3,4,5-
trisphosphate 5-phosphatase 2) 
  2.27, 1.23E-04      1.75, 1.67E-03 
Q8R1S9 (Sodium-coupled neutral 
amino acid transporter 4) 
        2.27, 1.36E-04      1.55, 4.69E-03 
P43883 (Perilipin-2)   2.24, 1.18E-03      1.97, 3.88E-03 
P68433 (Histone H3.1)   2.24, 7.34E-06      2.31, 5.82E-06 
P10649 (Glutathione S-transferase Mu 
1) 
  2.23, 5.45E-08      1.66, 3.09E-06 
Q9DCX8(Iodotyrosine deiodinase 1)   2.22,1.33E-03 
Q80WP8 (Acidic amino acid 
decarboxylase GADL1) 
  2.21, 1.53E-04      1.76, 1.56E-03 
Q80WP8-2 (Isoform 2 of Acidic amino 
acid decarboxylase GADL1) 
  2.21,1.53E-04       1.76, 1.56E-03 
O09111 (NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 
11, mitochondrial) 
  2.18, 3.72E-03 
P0DN34 (NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 
1) 
  2.18, 1.03E-03 




P19783 (Cytochrome c oxidase subunit 
4 isoform 1, mitochondrial) 
  2.15, 8.29E-03 
Q8BWN8 (Acyl-coenzyme A 
thioesterase 4) 
  2.14, 9.68E-08      1.21, 1.30E-04 
P46412 (Glutathione peroxidase 3)   2.14, 2.32E-05      2.30, 1.18E-05 
Q80X19 (Collagen alpha-1(XIV) 
chain) 
          2.10, 1.03E-09      1.96, 4.74E-09 
Q80X19-2 (Isoform 2 of Collagen 
alpha-1(XIV) chain) 
  
 2.10, 1.03E-09      1.96, 4.74E-09 
P16110 (Galectin-3)  2.03, 9.83E-07 2.43, 1.24E-07 
Q9CR61 (NADH dehydrogenase                 
[ubiquinone] 1 beta subcomplex  subunit 
7) 
 2.02, 1.04E-02 
Q9CQZ6 (NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex 
subunit 3) 
                    2.01, 8.77E-03  
Q9JK53 (Prolargin)  2.00, 4.77E-06  1.62, 7.05E-05 
P01864 (Ig gamma-2A chain C region             
secreted form) 
    1.98, 2.84E-03 1.62, 1.31E-02 
Q9DCS9 (NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 
10) 
 1.94, 2.18E-03  
P47934(Carnitine O-acetyltransferase)  1.92, 8.51E-06 1.61, 7.55E-05 
Q8R519 (2-amino-3-carboxymuconate-
6-semialdehyde decarboxylase) 
                  1.90, 7.05E-08 2.13, 2.07E-08 
Q9CPQ1 (Cytochrome c oxidase 
subunit 6C) 
                  1.90, 7.16E-03  
Q9JKJ9 (24-hydroxycholesterol 7-
alpha-hydroxylase) 
                  1.89, 1.03E-05  1.87, 1.41E-05 
P17665 (Cytochrome c oxidase subunit 
7C, mitochondrial) 
                  1.89, 6.72E-03  
P13011 (Acyl-CoA desaturase 2)                   1.87, 3.41E-02  
Q99PL7 (Acyl-CoA desaturase 3)                   1.87, 3.41E-02  
Q9QUJ7 (Long-chain-fatty-acid--CoA 
ligase 4) 
                   1.87, 3.20E-05 2.12, 9.24E-06 
Q9QUJ7-2 (Isoform Short of Long-
chain-fatty-acid--CoA ligase 4) 
                   1.87, 3.20E-05 2.12, 9.24E-06 
Q9WUZ9 (Ectonucleoside triphosphate 
diphosphohydrolase 5) 
 1.86, 3.51E-08 1.35, 2.61E-06 
Q8R1L4 (ER lumen protein-retaining 
receptor 3) 
  1.82, 1.17E-02  
Q99JH8 (ER lumen protein-retaining 
receptor 1) 
  1.82, 1.17E-02  
Q9CQM2 (ER lumen protein-retaining 
receptor 2) 
  1.82, 1.17E-02  
Q3UIU2 (NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 
6) 
  1.80, 7.16E-03  
Q60854 (Serpin B6)  1.78, 6.78E-07 1.62, 2.65E-06 
P07356 (Annexin A2)  1.76, 1.07E-05 1.62, 3.32E-05 
Q9EQQ2 (Protein YIPF5)  1.76, 7.18E-04 1.04, 3.40E-02 
P97792 (Coxsackievirus and  
adenovirus receptor homolog) 
  1.76, 7.94E-04  
P97792-2 (Isoform 2 of Coxsackievirus 
and adenovirus receptor homolog) 
  1.76, 7.94E-04  
Q920L1 (Fatty acid desaturase 1)   1.75, 6.73E-05 1.59, 2.10E-04 
O35423 (Serine--pyruvate 
aminotransferase, mitochondrial) 
  1.74, 6.28E-10 1.50, 5.51E-09 
P12787 (Cytochrome c oxidase subunit 
5A, mitochondrial) 






  1.73, 9.30E-09  
Q32MW3 (Acyl-coenzyme A thioesterase 
10, mitochondrial) 
  1.71, 3.67E-07 1.56, 1.59E-06 
Q9R0X4 (Acyl-coenzyme A thioesterase 
9, mitochondrial) 
  
1.71, 3.67E-07 1.56, 1.59E-06 
O35423-2 (Isoform Peroxisomal of 
Serine--pyruvate aminotransferase, 
mitochondrial) 
  1.71, 6.28E-10  
P51885 (Lumican)   1.71, 4.26E-04 1.67, 6.47E-04 
P54071 (Isocitrate dehydrogenase 
[NADP], mitochondrial) 
  1.71, 3.02E-08 1.46, 3.32E-07 
P30681(High mobility group protein B2)   1.71, 1.37E-07 1.52, 8.77E-07 
Q00915 (Retinol-binding protein 1)   1.71, 5.22E-06 2.14, 4.17E-07 
Q9CQU3 (Protein RER1)   1.70, 3.51E-04  
Q60932 (Voltage-dependent anion-
selective channel protein 1) 
  1.69, 3.25E-03  
Q60932-2 (Isoform Mt-VDAC1 of 
Voltage-dependent anion-selective 
channel protein 1) 
 
1.69, 3.25E-03  
P28653 (Biglycan)  1.68, 6.85E-05 1.56, 1.83E-04 
P03888 (NADH-ubiquinone 
oxidoreductase chain 1) 
 1.68, 2.94E-03  
Q8BWU8 (Ethanolamine-phosphate 
phospho-lyase) 
 1.68, 7.56E-07 1.43, 6.95E-06 
P19536 (Cytochrome c oxidase subunit 
5B, mitochondrial) 
 1.66, 3.00E-03  
Q60931 (Voltage-dependent anion-
selective channel protein 3) 
 1.66, 3.51E-04  
Q9Z2G9 (Oxidoreductase HTATIP2)  1.65, 2.01E-05  
Q9DCP2 (Sodium-coupled neutral amino 
acid transporter 3) 
 1.64, 4.58E-05 1.56, 1.09E-04 
Q8R2Q8 (Bone marrow stromal antigen 
2) 
 1.62, 8.32E-04 1.05, 2.26E-02 
P13516 (Acyl-CoA desaturase 1)  1.62, 2.87E-02  
Q3UVK0(Endoplasmic reticulum 
metallopeptidase 1) 
 1.61, 2.97E-04  
P00405(Cytochrome c oxidase subunit 2)  1.60, 1.30E-02  
P55096 (ATP-binding cassette sub-family 
D member 3) 
 1.60, 1.26E-04  
Q9JJ00 (Phospholipid scramblase 1)  1.59, 2.95E-03  
P97792-3 (Isoform 3 of Coxsackievirus 
and adenovirus receptor homolog) 
 1.59, 9.87E-03  
P11930 (Nucleoside diphosphate-linked 
moiety X motif 19) 
 1.58, 1.94E-07 1.04, 4.41E-05 
Q8BIG7 (Catechol O-methyltransferase 
domain-containing protein 1) 
 1.57, 1.43E-04 1.56, 1.86E-04 
Q9JLJ4 (Elongation of very long chain 
fatty acids protein 2) 
 1.57, 8.38E-04 1.34, 3.58E-03 
Q9CWS0(N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1) 
 1.55, 1.35E-05  
Q61070(Etoposide-induced protein 2.4)  1.55, 8.37E-03  
Q80W54 (CAAX prenyl protease 1 
homolog) 
 1.55, 8.63E-05  
P51855 (Glutathione synthetase)  1.55, 8.22E-10 1.42, 4.55E-09 
P01863 (Ig gamma-2A chain C region, A 
allele) 
 1.54, 1.90E-03  
P01865 (Ig gamma-2A chain C region, 
membrane-bound form) 
 1.54, 1.90E-03  




Q9Z0R9 (Fatty acid desaturase 2)  1.53, 3.52E-07 1.29, 3.58E-06 
Q80YX1 (Tenascin)  1.53, 1.80E-04 1.53, 2.03E-04 
Q80YX1-2 (Isoform 2 of Tenascin)  1.53, 1.80E-04 1.53, 2.03E-04 
Q80YX1-3 (Isoform 3 of Tenascin)  1.53, 1.80E-04 1.53, 2.03E-04 
Q80YX1-4 (Isoform 4 of Tenascin)  1.53, 1.80E-04 1.53, 2.03E-04 
Q80YX1-5 (Isoform 5 of Tenascin)  1.53, 1.80E-04 1.53, 2.03E-04 
Q62426 (Cystatin-B)  1.53, 1.37E-07 1.30, 1.44E-06 
Q8VCH6 (Delta(24)-sterol reductase)  1.53, 3.87E-07 1.20, 1.09E-05 
P06728 (Apolipoprotein A-IV)  1.51, 3.65E-06 2.22, 3.15E-08 
P18608 (Non-histone chromosomal 
protein HMG-14) 
 1.50, 3.02E-04 1.26, 1.71E-03 
Q8BH24 (Transmembrane 9 superfamily 
member 4) 
 1.49, 6.72E-03  
O35639 (Annexin A3)  1.48, 3.39E-04 1.21, 2.39E-03 
P48758 (Carbonyl reductase [NADPH] 1)  1.48, 8.26E-08 1.18, 1.70E-06 
Q8R5M8 (Cell adhesion molecule 1)  1.47, 1.03E-05  
Q8R5M8-2 (Isoform 2 of Cell adhesion 
molecule 1) 
 1.47, 1.03E-05  
Q8R5M8-3 (Isoform 3 of Cell adhesion 
molecule 1) 
 1.47, 1.03E-05  
Q8R5M8-4 (Isoform 4 of Cell adhesion 
molecule 1) 
 1.47, 1.03E-05  
Q8R5M8-5 (Isoform 5 of Cell adhesion 
molecule 1) 
 1.47, 1.03E-05  
Q8R5M8-6 (Isoform 6 of Cell adhesion 
molecule 1) 
 1.47, 1.03E-05  
Q8R5M8-7 (Isoform 7 of Cell adhesion 
molecule 1) 
 1.47, 1.03E-05  
Q60930 (Voltage-dependent anion-
selective channel protein 2) 
 1.46, 5.62E-05  
Q03311 (Cholinesterase)  1.44, 3.72E-03 1.38, 6.13E-03 
Q04447 (Creatine kinase B-type)  1.43, 1.05E-04 1.41, 1.56E-04 
P18242 (Cathepsin D)  1.43, 4.08E-07 1.32, 1.44E-06 
Q9Z2G9-2 (Isoform 2 of Oxidoreductase 
HTATIP2) 
 1.43, 1.04E-04  
Q99K41 (EMILIN-1)  1.42, 3.70E-06 1.22, 2.88E-05 
P15626 (Glutathione S-transferase Mu 2)  1.42, 3.02E-08  
Q922Q1 (Mitochondrial amidoxime 
reducing component 2) 
 1.41, 8.27E-04  
Q6WVG3 (BTB/POZ domain-containing 
protein KCTD12) 
 1.39, 1.71E-05 1.16, 1.47E-04 
P01872 (Immunoglobulin heavy constant 
mu) 
 1.39, 2.67E-04 1.51, 1.40E-04 
P01872-2 (Isoform 2 of Immunoglobulin 
heavy constant mu) 
 1.39, 2.67E-04 1.51, 1.40E-04 
Q64310 (Surfeit locus protein 4)  1.39, 5.25E-03  
Q9CQX2 (Cytochrome b5 type B)  1.38, 1.15E-02  
Q9CQJ8 (NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 
9) 
 1.38, 1.88E-02  
Q791V5 (Mitochondrial carrier homolog 
2) 
 1.37, 2.45E-02  
P62897 (Cytochrome c, somatic)  1.37, 8.90E-05  
Q64176 (Carboxylesterase 1E)  1.37, 1.01E-03  
O35405 (Phospholipase D3)  1.37, 1.26E-04 1.30, 2.43E-04 
Q9DC50 (Peroxisomal carnitine O-
octanoyltransferase) 
 1.36, 1.85E-04 1.13, 1.29E-03 
Q91WS0 (CDGSH iron-sulfur domain-
containing protein 1) 
 1.36, 7.54E-03  




Q64505 (Cholesterol 7-alpha- 
monooxygenase) 
 1.34, 1.84E-03  
P17095-1(Isoform HMG-Y of High 
mobility group protein HMG-I/HMG-Y) 
 1.33, 2.85E-03 1.00, 2.26E-02 
Q99M07 (Cytochrome c oxidase 
assembly factor 5) 
 1.33, 1.74E-05 1.12, 1.44E-04 
Q9QXD1 (Peroxisomal acyl-coenzyme A 
oxidase 2) 
 1.33, 9.58E-08 1.09, 1.44E-06 
Q99P72-1 (Isoform 3 of Reticulon-4)  1.33, 2.04E-04 1.37, 1.75E-04 
P97449 (Aminopeptidase N)  1.33, 2.07E-03  
P07309 (Transthyretin)  1.32, 1.53E-04  
Q80XN0 (D-beta-hydroxybutyrate 
dehydrogenase, mitochondrial) 
 1.32, 5.13E-06  
O35143 (ATPase inhibitor, mitochondrial)  1.32, 6.06E-05  
Q6GV12 (3-ketodihydrosphingosine 
reductase) 
 1.32, 3.69E-06  
P00416 (Cytochrome c oxidase subunit 
3) 
 1.31, 2.25E-02  
P20152 (Vimentin)  1.31, 1.71E-05 1.53, 3.01E-06 
Q9CQH3(NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 
5, mitochondrial) 
 1.31, 1.97E-02  
P56393 (Cytochrome c oxidase subunit 
7B, mitochondrial) 
 1.31, 3.60E-02  
P49586 (Choline-phosphate 
cytidylyltransferase A) 
 1.29, 1.61E-06 1.09, 1.70E-05 
P50427 (Steryl-sulfatase)  1.29, 1.23E-06  
O09117 (Synaptophysin-like protein 1)  1.28, 5.11E-03  
O09117-2(Isoform 2 of Synaptophysin-
like protein 1) 
 1.28, 5.11E-03  
Q9DD20 (Methyltransferase-like protein 
7B) 
 1.28, 1.71E-05 1.15, 7.29E-05 
Q99P72 (Reticulon-4)  1.27, 1.29E-05  
Q9D711 (Pirin)  1.27, 9.01E-06 1.10, 5.42E-05 
Q99JF8(PC4 and SFRS1-interacting 
protein) 
 1.27, 6.28E-05  
Q99JF8-2 (Isoform 2 of PC4 and SFRS1-
interacting protein) 
 1.27, 6.28E-05  
O35945 (Aldehyde dehydrogenase, 
cytosolic 1) 
 1.26, 2.77E-06  
Q9WVA4 (Transgelin-2)  1.26, 3.84E-06 1.83, 3.69E-08 
Q9WV68 (Peroxisomal 2,4-dienoyl-CoA 
reductase) 
 1.25, 2.35E-05  
P20065 (Thymosin beta-4)  1.24, 7.13E-03 1.60, 1.16E-03 
P20065-2(Isoform Short of Thymosin 
beta-4) 
 1.24, 7.13E-03 1.60, 1.16E-03 
Q9D7S7 (60S ribosomal protein L22-like 
1) 
 1.23, 3.81E-04 1.50, 6.33E-05 
Q9D7S7-2 (Isoform 2 of 60S ribosomal 
protein L22-like 1) 
 1.23, 3.81E-04 1.50, 6.33E-05 
A2AKK5-2 (Isoform 2 of Acyl-coenzyme 
A amino acid N-acyltransferase 1) 
 1.23, 1.16E-04 1.10, 4.55E-04 
P04117 (Fatty acid-binding protein, 
adipocyte) 
 1.23, 1.84E-02 1.11, 3.69E-02 
Q8BGH2 (Sorting and assembly 
machinery component 50 homolog) 
 1.23, 1.04E-03  
B2RX12 (Canalicular multispecific 
organic anion transporter 2) 
 1.23, 2.65E-03  
B2RX12-2 (Isoform 2 of Canalicular 
multispecific organic anion transporter 2) 




B2RX12-3 (Isoform 3 of Canalicular 
multispecific organic anion transporter 2) 
 1.23, 2.65E-03  
Q8BW75 (Amine oxidase [flavin-
containing] B) 
 1.22, 1.16E-05  
P61022 (Calcineurin B homologous 
protein 1) 
 1.22, 2.22E-04 1.08, 8.45E-04 
Q8VCC2 (Liver carboxylesterase 1)  1.22, 8.49E-05  
Q9D6M3 (Mitochondrial glutamate carrier 
1) 
 1.22, 1.80E-06  
Q99J47 (Dehydrogenase/reductase SDR 
family member 7B) 
 1.21, 1.18E-03  
Q99J47-2 (Isoform 2 of 
Dehydrogenase/reductase SDR family 
member 7B) 
 1.21, 1.18E-03  
Q14DH7-2(Isoform 2 of Acyl-CoA 
synthetase short-chain family member 3, 
mitochondrial) 
 1.21, 6.35E-04  
Q9QYA2(Mitochondrial import receptor 
subunit TOM40 homolog) 
 1.20, 3.39E-02  
Q8VCN5 (Cystathionine gamma-lyase)  1.20, 3.64E-07  
Q9CQ00 (Distal membrane-arm 
assembly complex protein 1) 
 1.20, 3.76E-02  
P97872 (Dimethylaniline mono-
oxygenase [N-oxide-forming] 5) 
 1.20, 1.48E-05  
Q8VDP6 (CDP-diacylglycerol—inositol 3-
phosphatidyltransferase) 
 1.20, 3.19E-05 1.13, 7.61E-05 
Q9Z0J0 (NPC intracellular cholesterol 
transporter 2) 
 1.19, 1.24E-06 1.27, 8.08E-07 
Q6ZWY8 (Thymosin beta-10)  1.19, 6.78E-04 1.54, 6.43E-05 
Q99JI6 (Ras-related protein Rap-1b)  1.18, 2.67E-04  
Q811Q9 (Choline-phosphate 
cytidylyltransferase B) 
 1.18, 1.01E-04  
Q811Q9-2 (Isoform 2 of Choline-
phosphate cytidylyltransferase B) 
 1.18, 1.01E-04  
Q8R5J9 (PRA1 family protein 3)  1.17, 3.36E-05  
Q14DH7 (Acyl-CoA synthetase short-
chain family member 3, mitochondrial) 
 1.16, 9.24E-05  
P68510 (14-3-3 protein eta)  1.15, 3.98E-05 1.21, 3.15E-05 
P13020 (Gelsolin)  1.15, 1.87E-05  
P13020-2 (Isoform 2 of Gelsolin)  1.15, 1.87E-05  
Q07133 (Histone H1t)  1.15, 5.84E-06  
P21981(Protein-glutamine  
gamma-glutamyltransferase 2) 
 1.14, 2.97E-04 1.58, 1.10E-05 
Q921H9 (Cytochrome c oxidase 
assembly factor 7) 
 1.14, 4.15E-04 1.11, 6.37E-04 
Q9D8V0 (Minor histocompatibility antigen 
H13) 
 1.14, 5.45E-03  
Q9D8V0-3 (Isoform 3 of Minor 
histocompatibility antigen H13) 
 1.14, 5.45E-03  
Q9D8V0-4 (Isoform 4 of Minor 
histocompatibility antigen H13) 
 1.14, 5.45E-03  
Q8BFZ9 (Erlin-2)  1.14, 1.62E-02 1.31, 7.93E-03 
Q8R238 (Serine dehydratase-like)  1.14, 1.58E-04 1.06, 3.84E-04 
A2AKK5 (Acyl-coenzyme A amino acid 
N-acyltransferase 1) 
 1.14, 7.34E-05  
P04919 (Band 3 anion transport protein)  1.13, 3.18E-02  
P04919-2 (Isoform 2 of Band 3 anion 
transport protein) 
 1.13, 3.18E-02  
P09803 (Cadherin-1)  1.13, 3.98E-05 1.41, 3.45E-06 




B2RSH2 (Guanine nucleotide-binding 
protein G(i) subunit alpha-1) 
 1.12, 4.29E-05  
Q5XKN4 (Protein jagunal homolog 1)  1.12, 1.36E-03  
P11835 (Integrin beta-2)  1.11, 9.66E-04 1.32, 2.17E-04 
Q4KML4 (Costars family protein 
ABRACL) 
 1.11, 6.07E-05  
Q91XV3 (Brain acid soluble protein 1)  1.11, 5.67E-03 1.74, 1.29E-04 
Q61941 (NAD(P) transhydrogenase, 
mitochondrial) 
 1.10, 3.15E-06  
Q99P72-3 (Isoform 2 of Reticulon-4)  1.10, 8.24E-05  
Q9Z0V7 (Mitochondrial import inner 
membrane translocase subunit Tim17-B) 
 1.09, 5.47E-04  
Q8BZW8 (NHL repeat-containing protein 
2) 
 1.09, 2.56E-03  
Q9DCR2 (AP-3 complex subunit sigma-
1) 
 1.09, 1.97E-02 1.00, 3.49E-02 
Q80XL6 (Acyl-CoA dehydrogenase family 
member 11) 
 1.09, 2.80E-06  
P48771 (Cytochrome c oxidase subunit 
7A2, mitochondrial) 
 1.09, 2.53E-02  
Q2TPA8 (Hydroxysteroid 
dehydrogenase-like protein 2) 
 1.08, 4.78E-08  
Q3UTJ2-6 (Isoform 6 of Sorbin and SH3 
domain-containing protein 2) 
 1.07, 1.01E-04 1.02, 1.91E-04 
Q3UTJ2-7(Isoform 7 of Sorbin and SH3 
domain-containing protein 2) 
 1.07, 1.01E-04 1.02, 1.91E-04 
P58774-2 (Isoform 2 of Tropo-myosin 
beta chain) 
 1.06, 4.51E-02  
P00158 (Cytochrome b)  1.06, 4.39E-03  
P62141(Serine/threonine-protein 
phosphatase PP1-beta catalytic subunit) 
 1.06, 1.44E-03  
Q3UTJ2 (Sorbin and SH3 domain-
containing protein 2) 
 1.06, 3.13E-07  
Q3UTJ2-2(Isoform 2 of Sorbin and SH3 
domain-containing protein 2) 
 1.06, 3.13E-07  
Q3UTJ2-5 (Isoform 5 of Sorbin and SH3 
domain-containing protein 2) 
 1.06, 3.13E-07  
O89053 (Coronin-1A)  1.05, 7.45E-03  
Q9JKF1 (Ras GTPase-activating-like 
protein IQGAP1) 
 1.05, 3.16E-07 1.28, 3.15E-08 
P57746 (V-type proton ATPase subunit 
D) 
 1.05, 6.71E-05  
P51660 (Peroxisomal multifunctional 
enzyme type 2) 
 1.05, 6.52E-05  
Q9WVD5 (Mitochondrial ornithine 
transporter 1) 
 1.04, 2.30E-05  
P37040 (NADPH--cytochrome P450 
reductase) 
 1.04, 1.43E-05  
Q3UTJ2-3 (Isoform 3 of Sorbin and SH3 
domain-containing protein 2) 
 1.04, 4.30E-06  
P27661 (Histone H2AX)  1.04, 2.36E-03 1.59, 5.04E-05 
P43277 (Histone H1.3)  1.03, 1.80E-03 1.00, 2.66E-03 
O88456 (Calpain small subunit 1)  1.03, 5.03E-04  
Q9D7J7 (Calpain small subunit 2)  1.03, 5.03E-04  
Q9DB41 (Mitochondrial glutamate carrier 
2) 
 1.03, 4.56E-03  
Q9DB41-2 (Isoform 2 of Mitochondrial 





Q61879 (Myosin-10)  1.03, 3.72E-03  




containing protein 2) 
P14733 (Lamin-B1)  1.02, 5.25E-08  
P26645 (Myristoylated alanine-rich C-
kinase substrate) 
 1.01, 1.18E-03  
Q8BGG9-2 (Isoform 2 of Acyl-coenzyme 
A amino acid N-acyltransferase 2) 
 1.01, 4.70E-03 1.20, 1.41E-03 
Q8BIW1 (Exopolyphosphatase PRUNE1)  1.01, 1.55E-02  
Q3UTJ2-4 (Isoform 4 of Sorbin and SH3 
domain-containing protein 2) 
 1.01, 2.54E-06  
P45952 (Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial) 
 1.00, 3.52E-07  
Q9DCM2 (Glutathione S-transferase 
kappa 1) 
 1.00, 1.49E-06  
Q8VCM7 (Fibrinogen gamma chain)  -1.01, 2.40E-03  
P11714 (Cytochrome P450 2D9)  -1.02, 2.50E-04 -1.04, 2.43E-04 
Q91WL5 (Cytochrome P450 4A12A)  -1.02, 3.77E-02 -1.83, 8.08E-04 
E9PV24 (Fibrinogen alpha chain)  -1.03, 1.07E-03  
E9PV24-2 (Isoform 2 of Fibrinogen alpha 
chain) 
 -1.03, 1.07E-03  
P70266 (6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase 1) 
 -1.05, 1.80E-05  
P70266-2 (Isoform 2 of 6-phosphofructo-
2-kinase/fructose-2,6-bisphosphatase 1) 
 -1.07, 1.83E-05  
P81117 (Nucleobindin-2)  -1.08, 7.57E-03  
Q9ET01 (Glycogen phosphorylase, liver 
form) 
 -1.09, 7.20E-04 -1.51, 3.11E-05 
Q9D5J6 (Sedoheptulokinase)  -1.10, 7.34E-04  
Q62392 (Pleckstrin homology-like domain 
family A member 1) 
 -1.10, 2.48E-04  




 -1.13, 3.55E-04 -1.47, 2.92E-05 
Q9DBG1 (Sterol 26-hydroxylase, 
mitochondrial) 
 -1.17, 4.04E-06 -1.68, 5.24E-08 
Q9CYW4 (Haloacid dehalogenase-like 
hydrolase domain-containing protein 3) 
 -1.18, 7.22E-04  
P46656 (Adrenodoxin, mitochondrial)  -1.21, 1.25E-04 -1.17, 1.99E-04 
Q9D0S9 (Histidine triad nucleotide-
binding protein 2, mitochondrial) 
 -1.22, 1.74E-05 -1.04, 1.23E-04 
A6X935 (Inter alpha-trypsin inhibitor, 
heavy chain 4) 
 -1.24, 2.44E-02  
A6X935-2 (Isoform 2 of Inter alpha-
trypsin inhibitor, heavy chain 4) 
 -1.25, 2.66E-02  
Q9CYA0 (Cysteine-rich with EGF-like 
domain protein 2) 
 -1.26, 8.93E-04  
P09813 (Apolipoprotein A-II)  -1.30, 4.81E-04 -1.19, 1.27E-03 
Q7TNG8 (Probable D-lactate 
dehydrogenase, mitochondrial) 
 -1.31, 2.61E-06  
P02798 (Metallothionein-2)  -1.32, 4.88E-02  
P97328 (Ketohexokinase)  -1.32, 8.51E-06 -1.15, 5.18E-05 
Q64458 (Cytochrome P450 2C29)  -1.38, 3.58E-04 -2.94, 5.37E-08 
Q91WP6 (Serine protease inhibitor A3N)  -1.40, 2.35E-02  
P19096 (Fatty acid synthase)  -1.40, 2.93E-05 -1.20, 1.84E-04 
Q9D2R0 (Acetoacetyl-CoA synthetase)  -1.42, 2.47E-04 -1.26, 9.54E-04 
Q9QXG4 (Acetyl-coenzyme A 
synthetase, cytoplasmic) 
 -1.46, 4.11E-05 -1.37, 1.09E-04 
P16301 (Phosphatidylcholine-sterol 
acyltransferase) 
 -1.49, 4.26E-03 -2.09, 2.73E-04 




P19157(Glutathione S-transferase P1)  -1.54, 6.82E-07 -1.49, 1.44E-06 
Q8K182 (Complement component C8 
alpha chain) 
 -1.55, 9.71E-05  
P31532 (Serum amyloid A-4 protein)  -1.63, 1.71E-05 -2.04, 1.28E-06 
Q8VCU1 (Carboxylesterase 3B)  -1.67, 1.49E-06 -1.53, 5.08E-06 
Q5F2F2 (Protein ABHD15)  -1.67, 3.74E-02  
P06801 (NADP-dependent malic 
enzyme) 
 -1.68, 3.98E-05 -2.02, 5.46E-06 
Q8VCU1-2 (Isoform 2 of 
Carboxylesterase 3B) 
 -1.69, 1.80E-06 -1.52, 7.94E-06 
Q91X77 (Cytochrome P450 2C50)  -1.71, 1.80E-03 -3.49, 1.10E-06 
Q920E5 (Farnesyl pyrophosphate 
synthase) 
 -1.77, 3.25E-05 -1.49, 2.49E-04 
O88962(7-alpha-hydroxycholest-4-en-3-
one 12-alpha-hydroxylase) 
 -1.78, 1.01E-04 -1.94, 5.04E-05 
P04939 (Major urinary protein 3)  -1.86, 2.21E-06 -2.56, 4.05E-08 
Q9EP96 (Solute carrier organic anion 
transporter family member 1A4) 
 -2.13, 1.81E-02 -3.49, 5.26E-04 
Q63836 (Selenium-binding protein2)  -2.13, 2.16E-06 -2.27, 1.23E-06 
P53657 (Pyruvate kinase PKLR)  -2.23, 1.94E-07 -2.53, 4.66E-08 
Q91YY5(Solute carrier organic anion 
transporter family member 1A5) 
 -2.53, 6.29E-03 -3.26, 9.92E-04 
Q3UY96 (Cilia- and flagella-associated 
protein 74) 
 -2.67, 1.08E-07 -2.19, 1.68E-06 
Q3UY96-2 (Isoform 2 of Cilia- and 
flagella-associated protein 74) 
 -2.67, 1.08E-07 -2.19, 1.68E-06 
P15105 (Glutamine synthetase)  -2.74, 3.04E-10 -2.79, 2.24E-10 
Q60590 (Alpha-1-acid glycoprotein 1)  -2.84, 3.86E-03  
Q9QXZ6 (Solute carrier organic anion 
transporter family member 1A1) 
 -2.85, 1.38E-04 -4.71, 4.76E-07  
Q6XVG2 (Cytochrome P450 2C54)  -2.89, 2.53E-04 -5.03, 5.63E-07 
Q60991(25-hydroxycholesterol 7-alpha-
hydroxylase)  
 -3.77, 1.16E-07 -3.44, 5.88E-07 
P11589 (Major urinary protein 2)  -3.79, 4.73E-07 -4.29, 1.29E-07 
Q61694 (3 beta-hydroxysteroid 
dehydrogenase type 5) 
 -4.28, 9.00E-12 -4.59, 3.47E-12 
Q62264 (Thyroid hormone-inducible 
hepatic protein) 
 -4.45, 3.13E-07 -2.67, 1.68E-04 
B5X0G2 (Major urinary protein 17)  -5.00, 9.68E-08 -6.01, 1.03E-08 
P11588 (Major urinary protein 1)  -5.58, 1.03E-09 -6.46, 1.71E-10 
P48962 (ADP/ATP translocase 1)   2.27, 3.88E-02 
P14602 (Heat shock protein beta-1)   2.06, 2.56E-03 
P14602-2 (Isoform B of Heat shock 
protein beta-1) 
  2.06, 2.56E-03 
P14602-3 (Isoform C of Heat shock 
protein beta-1) 
  2.06, 2.56E-03 
P31001 (Desmin)   1.62, 2.08E-02 
P05064 (Fructose-bisphosphate aldolase 
A) 
  1.54, 4.68E-02 
P14069 (Protein S100-A6)   1.46, 1.35E-02 
Q7TPW1 (Nexilin)   2.13, 4.53E-04 
Q61029 (Lamina-associated polypeptide 
2, isoforms  
beta/delta/epsilon/gamma) 
  1.05, 2.35E-03 
Q61029-3 (Isoform Epsilon of Lamina-
associated polypeptide 2,isoforms 
beta/delta/epsilon/gamma) 
  1.05, 2.35E-03 
P70429 (Ena/VASP-like protein)   1.76, 2.30E-05 
P70429-2 (Isoform 1 of Ena/VASP-like 
protein) 




Q6TEK5 (Vitamin K epoxide reductase 
complex subunit 1-like protein 1) 
  1.01, 3.99E-02 
P52480-2 (Isoform M1 of Pyruvate kinase 
PKM) 
  1.03, 3.62E-02 
P10107 (Annexin A1)   1.28, 8.84E-05 
P63254 (Cysteine-rich protein 1)   1.12, 1.11E-02 
P45376 (Aldose reductase)   1.04, 3.60E-04 
Q9QWG7 (Sulfotransferase family 
cytosolic 1B member 1) 
  -1.45, 2.99E-05 
Q9QWG7-2 (Isoform 2 of 
Sulfotransferase family  
cytosolic 1B member 1) 
  -1.45, 2.99E-05 
Q80ST9 (Lebercilin)   -1.08, 3.56E-03 
Q80ST9-2 (Isoform 2 of Lebercilin)   -1.08, 3.56E-03 
Q9DBT9 (Dimethylglycine  
dehydrogenase, mitochondrial) 
  -1.28, 4.04E-07 
Q91WG0 (Acylcarnitine hydrolase)   -2.45, 2.18E-05 
P07759 (Serine protease inhibitor A3K)   -1.02, 5.08E-06 
Q91VA0-2 (Isoform 2 of Acyl-coenzyme 
A synthetase ACSM1, mitochondrial) 
  -1.06, 1.28E-06 
P43006 (Excitatory amino acid 
transporter 2) 
  -1.78, 1.22E-04 
P43006-2 (Isoform Glt-1A of Excitatory 
amino acid transporter 2) 
  -1.78, 1.22E-04 
P43006-3 (Isoform Glt-1B of Excitatory 
amino acid transporter 2) 
  -1.78, 1.22E-04 
O35400 (Sulfotransferase family cytosolic 
2B member 1) 
  -1.19, 1.88E-04 
O35400-2 (Isoform 2 of Sulfotransferase 
family cytosolic 2B member 1) 
  -1.19, 1.88E-04 
Q91VA0 (Acyl-coenzyme A synthetase 
ACSM1, mitochondrial) 
  -1.07, 1.15E-06 
P50236 (Bile salt sulfotransferase 2)   -2.61, 2.48E-03 
P52843 (Bile salt sulfotransferase 1)   -2.61, 2.48E-03 
P49710 (Hematopoietic lineage cell-
specific protein) 
  2.17, 2.05E-04 
Q8VBT2 (L-serine dehydratase/L-
threonine deaminase) 
  1.36, 1.89E-05 
Q07797 (Galectin-3-binding protein)   1.29, 7.71E-04 
P29699 (Alpha-2-HS-glycoprotein)   1.21, 1.05E-04 
O89086 (RNA-binding protein 3)   1.20, 2.03E-04 
Q6IME9 (Keratin, type II cytoskeletal 72)   1.15, 1.99E-03 
P05201 (Aspartate amino-transferase, 
cytoplasmic) 
  1.14, 2.40E-05 
P28798 (Granulins)   1.13, 2.57E-03 
P11688 (Integrin alpha-5)   1.12, 1.76E-03 
Q64339 (Ubiquitin-like protein ISG15)   1.11, 1.28E-02 
Q9CQU0(Thioredoxin domain-containing 
protein 12) 
  1.11, 1.71E-03 
Q9CR51 (V-type proton ATPase subunit 
G 1) 
  1.11, 6.36E-05 
Q6IRU2 (Tropomyosin alpha-4 chain)   1.10, 3.88E-05 
Q99M73 (Keratin, type II cuticular Hb4)   1.08, 5.47E-04 
Q8BGG9 (Acyl-coenzyme A amino acid 
N acyltransferase 2) 
  1.07, 1.58E-03 
Q8VDD5 (Myosin-9)   1.06, 1.96E-04 
P10605 (Cathepsin B)   1.05, 8.08E-07 
O55111 (Desmoglein-2)   1.04, 6.63E-03 
Q9D020 (Cytosolic 5'-nucleotidase 3A)   1.04, 3.45E-06 





Q6P069 (Sorcin)   1.04, 7.19E-04 
Q6P069-2 (Isoform 2 of Sorcin)   1.04, 7.19E-04 
P15864 (Histone H1.2)   1.03, 3.45E-05 
Q9WTM5 (RuvB-like 2)   1.03, 3.22E-02 
Q7TMM9 (Tubulin beta-2A chain)   1.03, 1.09E-02 
Q8R0W0 (Epiplakin)   1.03, 5.73E-04 
P61226 (Ras-related protein Rap-2b)   1.02, 2.24E-03 
P25688 (Uricase)   1.00, 1.47E-04 
Q9R013 (Cathepsin F)   -1.01, 2.32E-03 
P52430 (Serum 
paraoxonase/arylesterase 1) 
  -1.02, 2.05E-04 
Q8BFP9 ([Pyruvate dehydrogenase 
(acetyl-transferring)] kinase isozyme 1, 
mitochondrial) 
  -1.02, 1.16E-04 
Q64374 (Regucalcin)   -1.03, 5.46E-05 
P50431 (Serine hydroxy-
methyltransferase, cytosolic) 
  -1.04, 4.63E-06 
Q8JZZ0 (UDP-glucurono-syltransferase 
3A2) 
  -1.06, 4.96E-04 
Q3UJU9 (Regulator of microtubule 
dynamics protein 3) 
  -1.07, 2.30E-05 
Q63886 (UDP-glucuronosyltransferase 1-
1) 
  -1.07, 1.40E-04 
O88587 (Catechol O-methyl-transferase)   -1.09, 2.88E-05 
O88587-2 (Isoform Soluble of Catechol 
O-methyltransferase) 
  -1.09, 2.88E-05 
Q9D6Y9 (1,4-alpha-glucan-branching 
enzyme) 
  -1.10, 2.23E-05 
Q8BSE0 (Regulator of microtubule 
dynamics protein 2) 
  -1.11, 8.69E-05 
Q91W52 (Transmembrane protein 19)   -1.12, 4.70E-03 
Q91W52-2(Isoform 2 of Transmembrane 
protein 19) 
  -1.12, 4.70E-03 
O08756 (3-hydroxyacyl-CoA 
dehydrogenase type-2) 
  -1.12, 2.77E-07 
Q05421 (Cytochrome P450 2E1)   -1.26, 1.25E-04 
P20852 (Cytochrome P450 2A5)   -1.36, 9.97E-03 
E9Q816 (Cytochrome P450 2W1)   -1.37, 7.17E-04 







Supplemental Table 3: Summary of effects of PCB exposures on liver, 
and blood biomarkers in chronic PCB exposure study. 




Cyp 1a2         ↔       ↑          ↑* 
 Cyp 2b10        ↑↑      ↔          ↑ 
Cyp 3a11        ↑      ↔ ↑ 
Steatosis        ↑↑       ↑          ↑ 
           Injury         ↑ ↔          ↔ 
Lipid uptake gene             
      mRNA levels                          
       ↑       ↑          ↑ 
Fatty acid β-oxidation 
gene mRNA levels 
       ↔       ?          ? 
Fatty acid synthesis 
gene mRNA levels 
       ↔       ↓          ↓ 
Inflammation         ↑↑      ↔         ↔ 
Blood Insulin        ↔ ↔  ↔ 
Triglycerides        ↔ ↓ ↓ 
 
Notes: 
1. ↔ indicates no change; ↑ indicates increase; ↓ indicates decrease versus 
vehicle control; 













Supplemental Table 4: Summary of  effects of PCB exposure and Ahr-/- on 
liver, and blood biomarkers in acute AhR knockout study   






         ↑        ↓          ↓* 
 Cyp 
1a2 
         ↑        ↓          ↓* 
Cyp 
2b10 
        ↔        ↑          ↑ 
Cyp 
3a11 
        ↔        ↑ ↑ 
Steatosis          ↑       ↑↑↑          ↑↑↑ 
           Injury         ↔ ↑↑          ↑↑ 
Lipid uptake gene             
      mRNA levels                          
        ↔         ↑          ↑ 
 Lipolytic gene mRNA 
levels 
        ↔         ↓          ↓ 
Hepatic triglycerides         ↔         ↑          ↑ 
Hepatic FFA         ↔         ↑          ↑ 
Blood Glucose        ↔ ↓ ↓ 
Triglycerides        ↔ ↔ ↔ 
Cholesterol        ↔ ↓ ↓ 
 
Notes: 
1. ↔ indicates no change; ↑ indicates increase; ↓ indicates decrease versus 
vehicle control; 
















ACHS Anniston Community Health  Survey                             
AhR Aryl hydrocarbon receptor 
AK3L1 Adenylate kinase isoenzyme  
Alb Albumin 
ALT Alanine aminotransferase  
AML1 Acute myeloid leukemia 1 
ANOVA Analysis variation  
ASL Angiosarcoma of the liver  
AST Aspartate aminotransferase 
ATF4 Activating transcription factor 4 
BMI Body mass index 
 
BW Body weight  
CAR Constitutive androstane receptor 
Cd68 Cluster of differentiation 68 
 




CREB CAMP responsive element binding protein 1 




EPA Environment Protection Agency 
ER Endoplasmic reticulum 
FASN Fatty acid synthase  
FFA Free fatty acid 
GCK Glucokinase 
 
GLUT4 Glucose transporter 4 
GSK3b Glycogen synthase kinase 3b  
H&E Hematoxylin and eosin  
HCC Hepatocellular carcinoma 
HFD High-fat diet  
 
IHC Immunohistochemistry 
KEAP1 Kelch-like ECH-associated protein 1 
LC3 Light chain 3 
LFD Low-fat control  
 






NAFLD Non-alcoholic fatty liver disease 
NASH Non-alcoholic steatohepatitis 
NEFA Non-essential fatty acid 
Nrf2 Nuclear factor-like 2 
OCRs Oxygen consumption rates  
OGTT Glucose tolerance test  
ORO Oil Red-O  
 
OSHA Occupational Safety and Health Association  
p62 Sequestosome 1 
 
PAI-1  Plasminogen activator inhibitor 1 
PAS Periodic Acid-Schiff  
PCK1 Phosphoenolpyruvate carboxykinase 1 
PINK1 PTEN-induced kinase 1 
PPARγ Peroxisome proliferated-activated receptor γ  
Ppm Parts per million 
ROS Reactive oxygen species  
SREBP-1c Sterol regulatory element-binding protein-1c 
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